U.S. patent application number 10/216373 was filed with the patent office on 2007-12-06 for retinal pigmented epithelium derived neurotrophic factor.
Invention is credited to Sofia Patricia Becerra, Gerald J. Chader, Lincoln V. Johnson, Ignacio R. Rodriguez, Fintan R. Steele, Joyce Tombran-Tink.
Application Number | 20070281886 10/216373 |
Document ID | / |
Family ID | 27501264 |
Filed Date | 2007-12-06 |
United States Patent
Application |
20070281886 |
Kind Code |
A9 |
Tombran-Tink; Joyce ; et
al. |
December 6, 2007 |
Retinal pigmented epithelium derived neurotrophic factor
Abstract
The present invention relates to a purified retinal pigmented
epithelium derived neurotrophic factor composition and a method for
purifying such a retinal pigmented epithelium neurotrophic factor.
The present invention also relates to a recombinant DNA molecule
comprising a gene encoding a retinal pigmented epithelium derived
neurotrophic factor having the DNA sequence or the amino acid
sequence in SEQ ID NO:1 and to an organism transformed with the
recombinant DNA molecule. In addition, the present invention
relates to a method of treating tumors, ocular diseases, nerve
injuries, and conditions resulting from the activity of serine
proteases, which comprises administering PEDF.
Inventors: |
Tombran-Tink; Joyce;
(Derwood, MD) ; Steele; Fintan R.; (Washington,
DC) ; Chader; Gerald J.; (Bethesda, MD) ;
Becerra; Sofia Patricia; (Bethesda, MD) ; Johnson;
Lincoln V.; (Pasadena, CA) ; Rodriguez; Ignacio
R.; (Rockville, MD) |
Correspondence
Address: |
WOODCOCK WASHBURN LLP
CIRA CENTRE, 12TH FLOOR
2929 ARCH STREET
PHILADELPHIA
PA
19104-2891
US
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20030096750 A1 |
May 22, 2003 |
|
|
Family ID: |
27501264 |
Appl. No.: |
10/216373 |
Filed: |
August 9, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
08520373 |
Aug 29, 1995 |
6451763 |
|
|
10216373 |
Aug 9, 2002 |
|
|
|
08377710 |
Jan 25, 1995 |
|
|
|
08520373 |
Aug 29, 1995 |
|
|
|
08279979 |
Jul 25, 1994 |
|
|
|
08377710 |
Jan 25, 1995 |
|
|
|
07952796 |
Sep 24, 1992 |
|
|
|
08279979 |
Jul 25, 1994 |
|
|
|
07894215 |
Jun 4, 1992 |
|
|
|
08279979 |
Jul 25, 1994 |
|
|
|
Current U.S.
Class: |
514/1.1 ;
530/399 |
Current CPC
Class: |
C07K 14/811 20130101;
C07K 14/475 20130101; A61K 38/00 20130101 |
Class at
Publication: |
514/012 ;
530/399 |
International
Class: |
A61K 38/18 20060101
A61K038/18; C07K 14/475 20060101 C07K014/475 |
Goverment Interests
[0002] This invention was made with government support under grant
EY04741, awarded by The National Institutes of Health. The United
States government has certain rights in this invention.
Claims
1. A composition comprising purified retinal pigmented epithelium
derived neurotrophic factor.
2. A composition as recited in claim 1 wherein the composition
comprises at least 50% by weight, with respect to the total
protein, epithelium derived neurotrophic factor.
3. A composition as recited in claim 1 wherein the epithelium
derived neurotrophic factor has an amino acid sequence selected
from the group consisting of ID SEQ NO. 2, ID SEQ NO. 3 and
equivalents thereof.
4. A protein which comprises an amino acid sequence that is
equivalent but not identical to the amino acid sequence of SEQ ID
NO. 2.
5. A protein selected from the group consisting of proteins
comprising the amino acid sequence of SEQ ID NO. 3 and equivalent
proteins.
6. A method for purifying a retinal pigmented epithelium
neurotrophic factor comprising: providing an impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor; applying the impure protein fraction
containing retinal pigmented epithelium derived neurotrophic factor
to a cation-exchange chromatography medium; washing the
cation-exchange chromatography medium to elute any unbound
proteins; eluting retinal pigmented epithelium derived neurotrophic
factor from the cation-exchange chromatography medium; and
collecting the PEDF containing fractions to provide a
cation-exchange chromatography-purified PEDF protein fraction.
7. A method as recited in claim 6 wherein the impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor comprises RPE conditioned media.
8. A method as recited in claim 6 wherein the impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor comprises a tissue extract.
9. A method as recited in claim 6 wherein the impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor comprises an extract of an organism transformed
with a recombinant DNA molecule comprising the retinal pigmented
epithelium derived neurotrophic factor gene in a form capable of
expression of the retinal pigmented epithelium derived neurotrophic
factor gene.
10. A method as recited in claim 6 wherein the impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor comprises a medium in which an organism,
transformed with a recombinant DNA molecule comprising the retinal
pigmented epithelium derived neurotrophic factor gene in a form
capable of expression of the retinal pigmented epithelium derived
neurotrophic factor gene, is grown.
11. A method as recited in claim 6 further comprising ammonium
sulfate precipitation of the impure protein fraction containing
PEDF.
12. A method as recited in claim 11 wherein contaminating proteins
are precipitated from the impure protein fraction containing PEDF
by bringing the impure protein fraction containing PEDF to 50%
saturation with ammonium sulfate to provide a 50% ammonium sulfate
protein fraction.
13. A method as recited in claim 11 wherein PEDF is precipitated
from the impure protein fraction containing PEDF by bringing the
impure protein fraction containing PEDF to 70% saturation with
ammonium sulfate to provide a 70% ammonium sulfate protein
fraction.
14. A method as recited in claim 6 further comprising: applying the
cation-exchange chromatography purified PEDF protein fraction to a
size-exclusion chromatography medium; eluting the proteins from the
size-exclusion chromatography medium; and collecting the
PEDF-containing fractions.
15. A method for purifying a retinal pigmented epithelium
neurotrophic factor comprising: providing an impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor; and purifying the PEDF further by a method
selected from the group consisting of ammonium sulfate
precipitation, cation-exchange chromatography, size-exclusion
chromatography, and combinations thereof.
16. A method of producing the protein encoded by a nucleic acid
molecule which comprises the sequence of SEQ ID NO:1 comprising
expressing the DNA sequence encoding the gene in a host cell.
17. A method of producing a protein which comprises an sequence
that is equivalent but not identical to the sequence of SEQ ID
NO:2, comprising expressing the DNA sequence encoding the gene in a
host cell.
18. A method of producing a protein which comprises the sequence of
SEQ ID NO:3 or an equivalent protein, comprising expressing the DNA
sequence encoding the gene in a host cell.
19. A recombinant DNA molecule comprising a gene encoding a retinal
pigmented epithelium derived neurotrophic factor having a DNA
sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID
NO. 4, SEQ ID NO: 5, SEQ ID NO. 6.
20. A recombinant DNA molecule as recited in claim 19 further
comprising a promoter region to direct the transcription of the
retinal pigmented epithelium derived neurotrophic factor gene to
form a PEDF mRNA.
21. A recombinant DNA molecule as recited in claim 19 further
comprising a polyadenylation region to direct the processing of the
retinal pigmented epithelium derived neurotrophic factor mRNA.
22. A recombinant DNA molecule as recited in claim 19 further
comprising ribosomal binding sites for directing the translation of
the PEDF mRNA.
23. A purified nucleic acid molecule selected from the group
consisting of nucleic acids which comprises the sequence of SEQ ID
NO:1 and equivalents thereof.
24. A purified nucleic acid which encodes a protein selected from
the group consisting of proteins which comprise the sequence of SEQ
ID NO:2 and equivalent proteins.
25. A purified nucleic acid molecule which encodes a protein
selected from the group consisting of proteins which comprise the
sequence of SEQ ID NO:3 and equivalent proteins.
26. A vector which comprises a nucleic acid molecule with the DNA
sequence of SEQ ID NO:1.
27. A vector which comprises a nucleic acid molecule which encodes
the amino acid sequence of SEQ ID NO:2.
28. A vector which comprises a nucleic acid molecule which encodes
the amino acid sequence of SEQ ID NO:3.
29. An organism transformed with a recombinant DNA molecule
comprising a retinal pigmented epithelium derived neurotrophic
factor gene having a DNA sequence selected from the group
consisting of SEQ ID NO:1.
30. An organism as recited in claim 29 wherein the recombinant DNA
molecule further comprises a promoter region, suitable for
recognition by the organism transformed with the recombinant DNA
molecule to direct the transcription of the retinal pigmented
epithelium derived neurotrophic factor gene, to form a PEDF
mRNA.
31. An organism as recited in claim 29 wherein the recombinant DNA
molecule further comprises a polyadenylation region, suitable for
recognition by the organism transformed with the recombinant DNA
molecule to direct the processing of the retinal pigmented
epithelium derived neurotrophic factor gene, to form a PEDF
mRNA.
32. An organism as recited in claim 29 wherein the recombinant DNA
molecule further comprises a ribosomal binding site, suitable for
recognition by the organism transformed with the recombinant DNA
molecule, to direct the translation of the PEDF mRNA.
33. A host cell containing the vector of claim 26.
34. A host cell containing the vector of claim 27.
35. A host cell containing the vector of claim 28.
36. A recombinantly produced PEDF protein, which has been produced
in accordance with the method of claim 16 and which is free from
those risks normally associated with proteins isolated or purified
from a naturally occurring source organism.
37. A purified human genomic DNA molecule which encodes a protein
having an amino acid sequence of SEQ ID NO:2.
38. A purified human genomic DNA molecule which encodes a protein
having an amino acid sequence of SEQ ID NO:3.
39. A method of treating tumors which comprises administering
PEDF.
40. A method as recited in claim 39 wherein the retinal pigmented
epithelium derived neurotrophic factor is formulated with a
time-release compound.
41. A method as recited in claim 39 wherein the time-release
compound comprises poly-lactic acid.
42. A method as recited in claim 39 wherein the treated tumor is a
retinal tumor.
43. A method as recited in claim 39 wherein the PEDF is
administered by a method selected from the group consisting of
intravitreal injection, subretinal injection, intravenous
injection, subcutaneous injection, intra-peritoneal injection and
injection into the site of the tumor.
44. A method as recited in claim 39 wherein the PEDF is
administered at a concentration of 1 to 100 .mu.g/ml 1 to 10 times
per day.
45. A method of treating ocular disease which comprises
administering PEDF.
46. A method as recited in claim 45 wherein the retinal pigmented
epithelium derived neurotrophic factor is formulated with a
time-release compound.
47. A method as recited in claim 45 wherein the time-release
compound comprises poly-lactic acid.
48. A method as recited in claim 45 wherein the PEDF is
administered by a method selected from the group consisting of
intravitreal injection, subretinal injection, intravenous
injection, subcutaneous injection and intra-peritoneal
injection.
49. A method as recited in claim 45 wherein the PEDF is
administered at a concentration of 1 to 100 .mu.g/ml 1 to 10 times
per day.
50. A method of treating neuronal cell pathologies which comprises
administering PEDF.
51. A method as recited in claim 50 wherein the retinal pigmented
epithelium derived neurotrophic factor is formulated with a
time-release compound.
52. A method as recited in claim 50 wherein the time-release
compound comprises poly-lactic acid.
53. A method as recited in claim 50 wherein the PEDF is
administered by a method selected from the group consisting of
intravitreal injection, subretinal injection, intravenous
injection, subcutaneous injection, intra-peritoneal injection and
injection into the site of the nerve damage.
54. A method as recited in claim 50 wherein the PEDF is
administered at a concentration of 1 to 100 .mu.g/ml 1 to 10 times
per day.
55. A method of treating conditions resulting from the activity of
serine proteases which comprises administering PEDF wherein the
conditions are selected from the group consisting of excessive of
unwanted blood coagulation, thrombosis, bacterial infection,
parasitic infection, elastosis, vascular disorders involving
fibrinoid formation, coagulation disorders, arteriosclerosis,
ischemia, arthroses diabetes, emphysema, arthritis, septic shock,
lung diseases, excessive complement activation, ulcers, ulcerative
colitis, pancreatitis, psoriasis, fibrinolytic disease,
arthropathy, bone resorption, hypertension, congestive heart
failure, cirrhosis, or allergy caused by proteases.
56. A method as recited in claim 55 wherein the retinal pigmented
epithelium derived neurotrophic factor is formulated with a
time-release compound.
57. A method as recited in claim 55 wherein the time-release
compound comprises poly-lactic acid.
58. A method as recited in claim 55 wherein the PEDF is
administered by a method selected from the group consisting of
intravitreal injection, subretinal injection, intravenous
injection, subcutaneous injection, intra-peritoneal injection and
injection into the site of the condition to be treated.
59. A method as recited in claim 55 wherein the PEDF is
administered at a concentration of 1 to 100 .mu.g/ml 1 to 10 times
per day.
Description
RELATED APPLICATIONS
[0001] This application is a continuation in part of U.S. patent
application Ser. No. 07/894,215, filed Jun. 4, 1992 and U.S. patent
application Ser. No. 07/952,796, filed Sep. 24, 1992, which are
incorporated herein by reference.
FIELD OF THE INVENTION
[0003] This invention relates to the purification and use of a
retinal pigmented epithelium derived neurotrophic factor (PEDF).
This invention also relates to a truncated version of PEDF that is
referred to as PEDF-BH. In addition to PEDF and PEDF-BH and
functionally equivalent proteins, this invention relates to nucleic
acids that encode PEDF, PEDF-BH and functionally equivalent
proteins, to vectors comprising such nucleic acids, to host cells
into which such vectors have been introduced, and to the use of
these host cells to produce such proteins.
BACKGROUND OF THE INVENTION
[0004] Many types of neurons depend upon the availability of
special regulatory molecules, known as neurotrophic factors, for
their survival and well-being. The best characterized of the
neurotrophic factors is nerve growth factor (NGF). NGF regulates
the survival and specialized function of sympathetic and dorsal
root ganglion neurons in the peripheral nervous system and of some
cholinergic neurons in the central nervous system. Trophic factors,
which act on other neurons, have also been identified, and two such
factors, ciliary neurotrophic factor (CNTF) and brain-derived
neurotrophic factor (BDNF) have been purified. Moreover, it has
recently been shown that some growth factors, such as fibroblast
growth factor (FGF)and epidermal growth factor (EGF), which
initially were identified based on their mitogenic effects upon
cells, also function as survival-promoting agents for some neurons.
Post-synaptic target cells and satellite cells, such as glial
cells, appear to be major sources of neurotrophic factors.
[0005] It has been proposed that the survival of retinal
photoreceptor cells may also be regulated by specific neurotrophic
factors. Evidence supporting this concept includes the observation
that photoreceptors undergo developmental neuronal death in some
species, a phenomenon which is generally considered to reflect the
limited availability of neurotrophic factors. Photoreceptor
development, as well as maintenance of normal function, has also
been shown to require interactions with the retinal pigment
epithelium (RPE), suggesting that RPE-derived molecules or factors
could be necessary for photoreceptor function and survival.
[0006] The RPE develops in advance of and lies adjacent to the
neural retina. A closed compartment between the two cell layers
contains the interphotoreceptor matrix, and many soluble secretory
products of RPE and neural retina cells are contained in the
interphotoreceptor matrix. Nutrients, metabolites or trophic
factors exchanged between the RPE and neural retina, must pass
through the interphotoreceptor matrix. RPE cells, for example, are
thought to synthesize and secrete a photoreceptor
survival-promoting factor (PSPA).
[0007] Cultured RPE cells synthesize a number of well known trophic
factors, including platelet derived growth factor (PDGF), FGF,
transforming growth factor-.alpha. (TGF-.alpha.), and transforming
growth factor-.beta. (TGF-.beta.). It is possible that these or
other unknown factors derived from RPE could influence the
development of the neural retina.
[0008] The neural-derived RPE forms a monolayer of cells interposed
between the neural retina and circulating blood within the choroid.
In this strategic location, the RPE forms a part of the
blood-retina barrier, performs functions essential to retinal
integrity and functions, and plays important roles in vascular,
inflammatory, degenerative, and dystrophic diseases of the retina
and choroid. The functions of the RPE in relation to the visual
process are several-fold and include light-dark adaption,
phagocytosis of shed photoreceptor outer segment membrane and
nutrition. On the other hand, the close interdependence of the RPE
and the neural retina during normal development has been known for
a long time, but functionally is not well understood, although it
is known that the RPE is important for retinal regeneration. It has
been consistently observed that loss of contact of the neural
retina with the RPE of many vertebrates (retinal detachment)
results in degeneration of the retina. As a side effect of the
retinal detachment, strong cell proliferation, originating from the
RPE which underlies the areas of detachment, has often been
observed.
[0009] Thus, identification of hypothetical survival-promoting
factors for photoreceptor cells would potentially be of great
importance for the treatment of pathological conditions which
result in blindness due to photoreceptor degeneration of unknown
etiology. While these types of selective photoreceptor
degenerations could be due to a variety of different mechanisms,
analogies with neuronal degenerations in other regions of the
nervous system suggest the possible involvement of a neurotrophic
activity in the retina.
SUMMARY OF THE INVENTION
[0010] The present invention relates to a purified retinal
pigmented epithelium derived neurotrophic factor composition and a
method for purifying such a retinal pigmented epithelium
neurotrophic factor. The purification procedure comprises providing
an impure protein fraction containing retinal pigmented epithelium
derived neurotrophic factor and applying the impure protein
fraction containing retinal pigmented epithelium derived
neurotrophic factor to a cation-exchange chromatography medium. The
cation-exchange chromatography medium is then washed to elute any
unbound proteins and the retinal pigmented epithelium derived
neurotrophic factor is eluted from the cation-exchange
chromatography medium and collected.
[0011] The present invention also relates to a recombinant DNA
molecule comprising a gene encoding a retinal pigmented epithelium
derived neurotrophic factor having the DNA sequence or the amino
acid sequence in SEQ ID NO:1 and to an organism transformed with a
recombinant DNA molecule comprising a retinal pigmented epithelium
derived neurotrophic factor gene having a DNA sequence identified
in SEQ ID NO:1.
[0012] The present invention also relates to a method of treating
tumors, ocular diseases and conditions resulting from the activity
of serine proteases which comprises administering PEDF.
DETAILED DESCRIPTION
[0013] Cells of the retinal pigmented epithelium are closely
associated with differentiating retinoblasts in vivo and contribute
to an environment essential to their development and normal
function, both in vivo and in vitro. Retinoblastoma cells exhibit a
multi-potential differentiative nature paralleling that of their
precursor, the primitive retinoblast, as evidenced by the fact that
agents, such as laminin, sodium butyrate and dibutyryl cAMP, can
induce the expression of neuronal, glial, and pigmented epithelial
characteristics in vitro.
[0014] A human retinoblastoma cultured cell line, Y79 cells, when
exposed to RPE-conditioned medium (RPE-CM), exhibits a high degree
of neuronal-like differentiation. The differentiation is observed
in both the morphological and biochemical characteristics of the
cells. The exposed cells extend arborizing neuritic processes from
their cell bodies and express elevated levels of neuron-specific
enolase (NSE) and neurofilament proteins. In addition, RPE-CM
extends the life of the attached, differentiated cells for more
than 30 days as compared to 10 to 15 days for non-treated
cells.
[0015] RPE-secreted proteins have been fractionated from RPE-CM,
and a protein doublet, with an apparent molecular weight of about
50,000 to about 55,000, that is unique to RPE-CM has been
identified. This pigment epithelium derived neurotrophic factor
(PEDF), which is a major secretory product of human fetal RPE
cells, has been isolated and shown to have neurotrophic effects on
Y79 retinoblastoma cells. Additionally, a smaller 36,000 molecular
weight, form of PEDF has also been identified.
[0016] PEDF has uses in the treatment of retinal diseases
including, but not limited to, retinoblastoma and other ocular
tumors, retinitis pigmentosa, various forms of retinal detachment,
macular degeneration, diabetic retinopathy, and other inherited and
age-related pathologies of retinal cells.
[0017] In the case of retinal tumors, PEDF induces the tumor cells
to display biochemical and phenotypic characteristics of mature
neuronal cells. Such changes are identified by a cessation or
reduction in the rate of cell division, which leads to tumor
regression or a slowing in the rate of tumor growth. In the case of
non-tumorous retinal diseases, the neurotrophic properties of PEDF
enhance survival and well-being of photoreceptor or other retinal
cells, prolonging their functional life span and delaying the rate
of the onset of impaired vision and ultimate blindness. In the case
of retinal detachment, PEDF prolongs the life span of photoreceptor
cells sufficiently to allow standard reattachment procedures to be
effective in re-establishing the retina-RPE interface, thereby
restoring normal vision.
1. Preparation of an Impure Protein Fraction Containing Retinal
Pigmented Epithelium Derived Neurotrophic Factor
[0018] Retinal pigmented epithelium derived neurotrophic factor
(PEDF) may be isolated from any tissue or cell producing PEDF.
[0019] Naturally-occurring cells that produce PEDF are retinal
pigmented epithelium cells. Such cells may be grown in culture to
secrete PEDF into the medium in which they are growing. The medium
may be harvested periodically, and the PEDF isolated from the
media. Suitable cell cultures may be established from retinal
pigmented epithelium cells derived from humans, monkeys, and other
primates or other animals, such as chickens, mice, rats, cows and
pigs. PDEF may also be isolated from the vitreous humor of human,
bovine, monkey and other primates. The vitreous contains an
abundance of PEDF and is very easy to remove from the eye cup. This
is probably the easiest source from which to isolate PEDF
[0020] PEDF may also be isolated by extraction of the
interphotoreceptor matrix (IPM) or from the retina of humans,
monkeys, and other primates or other animals, such as chickens,
mice, rats, cows and pigs.
[0021] Alternatively PEDF may be derived from sources in which it
is not naturally-occurring, such as organisms transfected with a
recombinant DNA molecule constructed to result in the expression of
PEDF or a PEDF equivalent protein in the host cells chosen for the
expression of the gene. It is well known in the art that proteins
can be modified by deletion, addition or substitution of amino
acids without changing the function of the protein. Such proteins
which retain the specificity of PEDF are considered to be
equivalent.
A. Culturing of Human Retinal Pigmented Epithelium (RPE) Cells
[0022] Cultures of RPE cells are established by harvesting
post-mortem eyes by aseptically opening the eyes and removing the
vitreous body and retina. The exposed RPE is washed with a buffered
solution such as modified Earle's balanced salt solution (MEBS:
115.5 mM NaCl, 3.5 mM KCl, 1 mM NaH.sub.2PO.sub.4, 0.5 mM
CaCl.sub.2, 0.27 mM MgCl.sub.2, 0.37 MgSO.sub.4, 15 mM HEPES, 14 mM
NaHCO.sub.3, 12 mM glucose, pH 7.2). RPE cells are scraped from
Bruch's membrane or are dislodged by a stream of fluid such as MEBS
or cell culture medium, applied using a Pasteur or similar pipette.
This step may be preceded by exposure to proteolytic or other
enzyme(s), such as Dispase (Boehringer-Mannheim, Indianapolis, Ind.
Catalog #295 825). Alternatively, RPE cells may be isolated by
detaching sections of sclera from an intact eye to expose choroidal
tissue and treating this choroidal surface with proteolytic or
other enzymes such as Dispase prior to removal of the vitreous and
retina and dislodging RPE cells by the spraying of cell culture
medium as described by Pfeffer et al., J. Cell. Physiol. 117
333-341 (1983). Tissue fragments are transferred to tissue culture
dishes in a medium such as "low Ca.sup.++" or "high Ca.sup.++"
complete RPE-47 medium, as described by Pfeffer et al., J. Cell.
Physiol. 117 333-341 (1983), or Eagles's minimal essential medium
(MEM, supplied by GIBCO of Grand Island, N.Y.) supplemented with
about 0.5% to about 20% v/v fetal calf serum. At concentrations
below about 0.5% v/v fetal calf serum, the serum concentrations are
too low to effectively support the growth of the cells. At
concentrations above about 20% v/v serum, no additional benefit,
with respect to cell growth, is conferred on the cells.
[0023] The medium may also be supplemented with antibiotics and/or
fungicides to prevent the growth of bacteria and/or fungi in the
cultures. Antibiotics and fungicides suitable for use in the
present invention are about 1,000 units/ml penicillin, about 100
.mu.g/ml streptomycin, about 0.25 .mu.g amphotericin, and about 50
.mu.g/ml gentamicin, or other suitable such agents known in the
art. These antibiotics may be used individually or in combination,
as desired.
[0024] The cells are incubated at about 37.degree. C. in an
atmosphere of about 5% v/v CO.sub.2. Retinal pigmented epithelium
(RPE) cells attach to the surface of the dishes, proliferate, and
eventually form confluent monolayers.
[0025] When the cells have grown to confluence, about 3-7 days from
the initial culturing of the cells, they are harvested, for
example, by trypsinizing the cell monolayer, or by other methods
known to those skilled in the art, and resuspending the cells in a
medium such as MEM, supplied by GIBCO, supplemented with about 5%
v/v to about 20% v/v fetal calf serum. A portion of the cells are
reseeded into sterile tissue culture flasks, after which time the
cells are again grown in an atmosphere of about 5% v/v CO.sub.2 at
about 37.degree. C.
[0026] Alternatively, RPE cells may be isolated by removing the
cornea, the 2 mm scleral ring, and the vitreous and neural retina
from the eyes. The eyes are washed with calcium and magnesium-free
Hanks Balanced Salt Solution (HBSS: 1.3 mM CaCl.sub.2, 5 mM KCl,
0.3 mM KH.sub.2PO.sub.4, 0.5 mM MgCl.sub.2, 0.4 mM MgSO.sub.4, 138
mM NaCl, 4 mM NaHCO.sub.3, 0.3 mM Na.sub.2HPO.sub.4, 5.6 mM
D-glucose and 0.03 mM Phenol Red, supplied by GIBCO/BRL of
Gaithersburg, Md.). The eye cup is filled with a solution
comprising about 0.1% w/v trypsin, about 0.1% w/v hyaluronidase in
calcium and magnesium-free Hanks balanced salt solution, and the
eye is incubated at about 37.degree. C. for about 15 to about 30
minutes.
[0027] The loose RPE cells are collected by gentle aspiration, and
the procedure is repeated until the RPE cells are released. The
trypsin is inactivated by adding about 5% v/v to about 20% v/v
fetal calf serum to the cell sample. The cells are collected by
centrifugation at about 1,200 rpm for about 7 minutes.
[0028] The RPE cells are then plated onto sterile tissue culture
plates at a density of about 1.times.10.sup.5 cells for a 35 mm
plate. (Proportionally more or less cells are plated if larger or
smaller plates or containers are used.) The cells are grown in
DulBecco's Modified Eagles Medium (DMEM), supplied by GIBCO, or
other suitable medium. The medium may be supplemented with an equal
volume of HAM's F12 medium (supplied by GIBCO), --about 1 mM sodium
pyruvate, about 0.625 mM Hepes, about 6 mM L-glutamine, about 1%
w/v non-essential amino acids, about 5 .mu.g/ml insulin, about 5
.mu.g/ml transferrin, about 5 ng/ml selenium, antibiotics as
described above, and about 0.5% v/v to about 20% v/v fetal calf
serum, as described above. The insulin, transferrin, and selenium
are supplied by Collaborative Research of Lexington, Mass. Other
reagents suitable for use in the present invention, unless
otherwise specified, are supplied by Sigma Chemical Co. of St
Louis, Mo.
[0029] When the cells have grown to confluence (about 3-7 days from
the initial culturing of the cells), they are harvested, for
example, by trypsinizing the cell monolayer or by other methods
known to those skilled in the art, and resuspending the cells in a
medium such as MEM supplemented with about 0.5% v/v to about 20%
v/v fetal calf serum. A portion of the cells are reseeded into
sterile tissue culture flasks, after which time the cells are again
grown in an atmosphere of about 5% v/v CO.sub.2 at about 37.degree.
C.
[0030] While only two methods for the culturing of RPE cells are
described, other suitable methods for culturing RPE cells are known
in the art. Such methods are also suitable for use in the practice
of the present invention.
B. Preparation of Retinal Pigmented Epithelium Conditioned Medium
(RPE-CM)
[0031] PEDF is a secreted protein, and RPE cells secrete PEDF into
the medium in which they are grown. Therefore, a convenient method
of producing PEDF is to grow RPE cells in culture and to
periodically harvest the media from the cultures.
[0032] A method suitable for use in the present invention for
isolating PEDF from medium is to allow RPE cells to grow to
confluence in a medium such as DMEM supplemented with about 1 mM
sodium pyruvate, about 0.625 mM Hepes, about 6 mM L-glutamine,
about 1% w/v non-essential amino acids, about 5 .mu.g/ml insulin,
about 5 .mu.g/ml transferrin, about 5 ng/ml selenium, antibiotics
and/or fungicides as described above, and about 0.5% v/v to about
20% v/v fetal calf serum, as described above. The confluent
cultures of RPE cells are washed extensively with Hank's balanced
salt solution, or other suitable wash solutions, to remove serum
proteins derived from the fetal calf serum present in the media
used to culture the RPE cells. About 1 ml, per cm.sup.2 of cell
surface area, of serum-free medium such as DMEM supplemented with
about 1 mM sodium pyruvate, about 0.625 mM Hepes, about 6 mM
L-glutamine about 1% w/v non-essential amino acids, about 5
.mu.g/ml insulin, about 5 .mu.g/ml transferrin, about 5 ng/ml
selenium, and antibiotics and/or fungicides as described above, is
added to the cultures, and they are incubated in an atmosphere of
about 5% v/v CO.sub.2 at about 37.degree. C. for about 1 to about
10 days. Alternatively, PEDF can be isolated from serum-containing
medium such as DMEM supplemented with about 1 mM sodium pyruvate,
about 0.625 mM Hepes, about 6 mM L-glutamine, about 1% w/v
non-essential amino acids, about 5 .mu.g/ml insulin, about 5
.mu.g/ml transferring about 5 ng/ml selenium, antibiotics and/or
fungicides as described above, and about 0.5% v/v to about 20% v/v
fetal calf serum as described above.
[0033] The medium is then collected by pouring the medium into
plastic centrifuge tubes, and the medium is centrifuged at about
3,000 rpm for about 10 minutes to remove any free cells and other
particulate matter from the medium, and filtered to provide an
impure PEDF protein solution. The medium may be used directly for
the purification or testing of PEDF or it may be stored at
-20.degree. C. until required.
C. Isolation of PEDF from Tissue Samples
[0034] PEDF may be isolated directly from eyes by opening the eyes
and removing the vitreous body and retina. The retinal pigmented
epithelium is scraped off the Bruch's membrane using a disposable
cell scraper. Tissue fragments are transferred to a Teflon or glass
homogenizer in a solution such as 10 mM phosphate-buffered saline
(PBS) and homogenized to break the cells. The solution is then
centrifuged at about 10,000 rpm for about 10 minutes and filtered
to remove cell debris. The supernatant, which contains PEDF, is
collected to provide an impure PEDF protein solution. The medium
may be used directly for the purification or testing of PEDF or it
may be stored at -20.degree. C. until required.
D. Isolation of PEDF from Bovine Vitreous
[0035] The vitreous is a gel like substance which fills the eye
cup. The vitreaous is removed from the eye and solubilized by
freezing and thawing. About 20 ml of solubilized vitreous are
obtained per bovine eye cup and this volume contains about 16 g/100
.mu.l of vitreous.
F. Isolation of PEDF from Recombinant Cells
[0036] PEDF may also be isolated from recombinant cells which have
been constructed to express the PEDF gene. The PEDF may be
expressed as an intracellular or an extracellular protein.
[0037] Intracellular PEDF is isolated by homogenizing the cells in
a Dounce or other suitable homogenizer in a buffer, such as PBS,
that may contain detergents or other solubilizing agents such as
urea or guanidine hydrochloride, and centrifuging at about 10,000
rpm for about 20 minutes to remove cellular debris, to provide an
impure PEDF protein fraction.
[0038] Extracellular PEDF is isolated by collecting the medium in
which cells expressing PEDF are grown. This is most conveniently
performed in a continuous centrifugation process, such as with a
Sharples centrifuge. The supernatant is collected to provide an
impure PEDF protein fraction. The medium may be used directly for
the purification or testing of PEDF or it may be stored at
-20.degree. C. until required.
2. Purification of PEDF
A. Small Scale Purification of PEDF
i. Ammonium Sulfate Precipitation
[0039] An impure PEDF protein fraction may be partially purified by
ammonium sulfate precipitation to provide an ammonium sulfate
purified PEDF protein fraction. Percent ammonium sulfate refers to
% saturation of ammonium sulfate at 20.degree. C. and is based on a
100% saturation of 767 g/l.
[0040] An impure PEDF protein fraction is brought to about 50%
saturation with ammonium sulfate by the addition of about 313 g of
solid ammonium sulfate per liter of impure protein fraction at
about 20.degree. C. The ammonium sulfate is preferably added slowly
to the impure protein fraction while the solution is stirred, such
as with a stir bar on a mechanical stirrer. The ammonium sulfate is
added slowly to prevent localized high concentrations of ammonium
sulfate that may result in rapid precipitation and denaturation of
proteins present in the impure protein fraction. After all the
ammonium sulfate is added, the about-50% ammonium sulfate solution
is stirred for about 30 minutes at about 20.degree. C. The
about-50% ammonium sulfate solution is then centrifuged at about
10,000 g, at about 20.degree. C. for about 20 minutes. The
supernatant is collected for further processing. Alternatively, the
about-50% ammonium sulfate solution may be filtered through filter
paper such as Whatman #1, to remove the precipitate. In this case,
the filtrate is collected for further processing.
[0041] The about-50% ammonium sulfate solution is then brought to
about 70% saturation by the addition of about 137 g/l of ammonium
sulfate. The ammonium sulfate is added slowly, and after all the
ammonium sulfate is added, the about-70% ammonium sulfate solution
is stirred for about 30 minutes at about 20.degree. C. The
about-70% ammonium sulfate solution is centrifuged or filtered, as
described above, and the precipitate is collected.
[0042] The ammonium sulfate precipitate is then redissolved in a
buffer such as about 10 mM phosphate, pH 7, to form a 50-70%
ammonium sulfate fraction. The solution is then diafiltered using
an Amicon Diaflo ultrafiltration unit, or dialyzed against a buffer
such as about 10 mM phosphate, pH 7, to remove the residual
ammonium sulfate from the redissolved 50%-70% ammonium sulfate
fraction.
ii. Purification of PEDF by SDS Gel Electrophoresis
[0043] A small-scale isolation of PEDF is conducted by
SDS-polyacrylamide slab gels. Such polyacrylamide gels are well
known in the art, and the preparation of such gels has been
described by Weber and Osborn, J. Biol. Chem. 244 4406 (1969), as
modified by Laemmli, Nature 277 680 (1970).
[0044] Samples of an impure PEDF protein fraction or ammonium
sulfate purified PEDF protein fraction are dialyzed against a
buffer such as about 10 mM sodium phosphate buffer, pH 7.5,
lyophilized and resuspended in 62.5 mM Tris, pH 6.8, 2% w/v SDS,
10% v/v glycerol, 0.001% w/v bromophenol blue, and 0.1 M
2-mercaptoethanol, wherein the bromophenol blue is a migration
marker. Additional samples to be loaded on the gel include
molecular-weight standards such as phosphorylase B, bovine serum
albumin, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor
and lysozyme (such as supplied by Bio-Rad, catalog #161-0304), and
controls as may be necessary. In cases where conditioned media are
used as samples, media which have not been exposed to RPE cells
(unconditioned media) are included as controls.
[0045] The samples are then incubated in a boiling-water bath for
about 5 minutes and loaded onto SDS-polyacrylamide slab gels. The
markers and unconditioned media are loaded into wells on the
outside of the gel, and the impure PEDF protein fractions or the
ammonium sulfate purified PEDF protein fraction are loaded on the
remaining inside wells. The samples are then subjected to
electrophoresis. The electrophoresis is continued until the
bromphenol blue marker has reached the bottom of the gel. At the
completion of electrophoresis, strips from each outside edge of the
gels, which included the markers and a lane each of an impure PEDF
protein fraction and an unconditioned media control, are stained
with Coomassie blue. The stained protein bands which develop on the
stained strips are aligned with the unstained portion of the gel to
locate the position of the proteins present in the impure PEDF
protein fraction or the ammonium sulfate purified PEDF protein
fraction but absent from control media.
[0046] A PEDF protein doublet, with an apparent molecular weight of
about 50,000 to about 55,000, unique to the impure PEDF protein
fraction, is excised and the proteins electro-eluted, by methods
known in the art, from the unstained portion of the gel. The eluant
is centrifuged to remove gel fragments and the supernatant dialyzed
against 10 mM phosphate-buffered saline (145 mM NaCl, 8.1 mM
Na.sub.2HPO.sub.4, and 1.9 mM NAH.sub.2PO.sub.4.H.sub.2O) to
provide an SDS-polyacrylamide purified PEDF protein fraction.
iii. Purification of PEDF Using BioRad PREP CELL
[0047] Large quantities of PEDF can be purified by using BioRad
PREP CELL which is an electrophoresis unit containing a tube gel.
Samples are loaded onto the top of the tube gel and fractions are
collected from the bottom. Individual fractions are examined by SDS
gel electrophoresis for a 50,000 molecular weight protein.
Fractions containing a 50,000 molecular weight protein are
collected and pooled.
iv. Purification of PEDF by Cation-Exchange HPLC
[0048] An impure PEDF protein fraction or an ammonium sulfate
purified PEDF protein fraction is dialyzed against water or a
buffer such as about 10 mM phosphate buffer, pH 7.2, or other
suitable buffer, to remove media and salts from the impure protein
sample. PEDF may be purified by cation-exchange HPLC using a column
chromatography medium, such as that supplied under the trade name
"Brownlee Aquapore CX-300", by Western Analytical, Temecula,
Calif., packed into a column, such as a 4.6.times.30 mm column, or
other suitable cation-exchange HPLC chromatography medium.
[0049] The chromatography medium is equilibrated with a buffer such
as about 10 mM phosphate, pH 7.2. The dialyzed impure PEDF protein
fraction or ammonium sulfate purified PEDF protein fraction is
loaded onto the chromatography medium, and the chromatography
medium with PEDF bound to it is washed with a buffer such as about
10 mM phosphate, pH 7.2, until all unbound proteins are washed from
the chromatography medium. PEDF is eluted from the chromatograph
medium with a linear salt gradient from about 0.0 to about 0.5 M
NaCl. PEDF elutes as a single peak with a NaCl concentration of
about 0.25 M.
[0050] The eluted PEDF is concentrated by lyophilization and
resolubilized in water or a buffer such as about 10 mM phosphate
buffer, pH 7.2, or other suitable buffer, to form a cation-exchange
HPLC purified PEDF protein fraction.
iv. Purification of PEDF by Reverse-Phase HPLC
[0051] An impure PEDF protein fraction or ammonium sulfate purified
PEDF protein fraction is dialyzed against a buffer such as about 10
mM phosphate buffer, pH 7.2, or other suitable buffer, to remove
media and salts from the impure protein sample. PEDF may be
purified by reverse-phase HPLC using a column chromatography medium
such as a chromatography medium supplied under the trade name
"Vydac C8" by The Separation Group of Hesperia, Calif., packed into
a column such as a 4.6.times.250 mm column or other suitable
reverse-phase HPLC chromatography medium.
[0052] The chromatography medium is equilibrated with a solution
such as about 0.1% v/v trifluoroacetic acid (TFA). The dialyzed
impure PEDF protein fraction or ammonium sulfate purified PEDF
protein fraction is loaded onto the chromatography medium, and the
chromatography medium with PEDF bound to it is washed with an
eluant such as 0.1% v/v TFA, until all unbound proteins are washed
from the chromatography medium. PEDF is eluted from the
chromatograph medium with a linear gradient from about 0.1% v/v TFA
in water to about 95% v/v acetonitrile (CH.sub.3CN), 0.1% v/v TFA,
5% v/v H.sub.2O. PEDF elutes as a single peak with a CH.sub.3CN
concentration of about 70% v/v.
[0053] The eluted PEDF is concentrated by lyophilization and
resolubilized in water or a buffer such as about 10 mM phosphate
buffer, pH 7.2, or other suitable buffer, to form a reverse-phase
HPLC purified PEDF protein fraction.
V. Size-Exclusion HPLC
[0054] An impure PEDF protein fraction, an ammonium sulfate
purified PEDF protein fraction, a cation-exchange HPLC purified
PEDF protein fraction, or a reverse-phase HPLC purified PEDF
protein fraction may be purified by size-exclusion chromatograph
using a chromatography medium, such as that supplied under the
trade name "Bio-Rad TSK-250" by Bio-Rad of Richmond, Calif., packed
into a column such as a 7.5.times.300 mm column. The impure PEDF
protein fraction, the ammonium sulfate purified PEDF protein
fraction, the cation-exchange HPLC purified PEDF protein fraction,
or the reverse-phase HPLC purified PEDF protein fraction is loaded
onto the size-exclusion chromatography medium, which has been
equilibrated with a buffer such as 0.02 M Tris-HCl, pH 7.0, 0.6 M
NaCl. PEDF-containing fractions are collected and dialyzed against
a buffer such as about 10 mM phosphate buffer, pH 7.2 to provide a
size-exclusion purified PEDF protein fraction.
vi. Heparin Chromatography
[0055] An impure PEDF protein fraction or an ammonium sulfate
purified PEDF protein fraction may also be purified by heparin
chromatography. A heparin chromatography medium such as heparin
agarose, supplied by Sigma Chemical Co. of St Louis, Mo. (Cat. No.
H-5380), is equilibrated with a buffer such as about 10 mM
Tris-HCl, pH 7.5.
[0056] An impure PEDF protein fraction or an ammonium sulfate
purified PEDF protein fraction is dialyzed against a buffer such as
about 10 mM Tris, pH 7.5, to remove any salts or media from the
samples, and the dialyzed PEDF solution is applied to the
equilibrated heparin agarose. After the PEDF solution has been
applied to the heparin agarose, the heparin agarose is washed with
a buffer such as about 10 mM Tris-HCl, pH 7.5, until all unbound
proteins are eluted from the heparin agarose. PEDF is then eluted
from the heparin agarose with a buffer such as about 10 mM
Tris-HCl, pH 7.5, 0.5 M NaCl.
[0057] The eluate containing PEDF is then diafiltered in an Amicon
Diaflo ultrafiltration unit, or is dialyzed against a buffer such
as about 10 mM Tris-HCl, pH 7.5, to remove NaCl present in the
eluate, thereby providing a heparin purified PEDF protein
fraction.
[0058] The above-described purification procedures may use an
impure PEDF protein fraction or an ammonium sulfate purified PEDF
protein fraction as the starting material for the subsequent column
purification. Alternatively, a protein fraction which has already
been purified by one or more of the described chromatography steps
could also be used. Therefore, the purification procedures may be
used alone or in combination with each other or with other
purification techniques known in the art to produce a PEDF protein
fraction of the desired purity.
B. Large-Scale Preparation of PEDF
i. Ammonium Sulfate Precipitation
[0059] Large-scale purification of PEDF may be prepared by ammonium
sulfate precipitation to provide an ammonium sulfate purified PEDF
protein fraction.
[0060] An impure PEDF protein fraction is brought to about 50%
saturation with ammonium sulfate by the addition of about 313 g of
solid ammonium sulfate per liter of impure PEDF protein fraction.
The ammonium sulfate is preferably added slowly to the impure
protein fraction while the solution is stirred, such as with a stir
bar on a mechanical stirrer. The ammonium sulfate is added slowly
to prevent localized high concentrations of ammonium sulfate which
may result in rapid precipitation, and denaturation of proteins
present in the impure protein fraction. After all the ammonium
sulfate is added, the 50% ammonium sulfate solution is stirred for
about 30 minutes at 20.degree. C. The 50% ammonium sulfate solution
is then centrifuged at about 10,000 g, at 20.degree. C. for about
20 minutes. The supernatant is collected for further processing.
Alternatively, the 50% ammonium sulfate solution may be filtered
through filter paper, such as Whatman #1, to remove the
precipitate. The filtrate is collected for further processing.
[0061] The 50% ammonium sulfate solution is then brought to about
70% saturation by the addition of about 137 g/l of ammonium
sulfate. The ammonium sulfate is added slowly, and after all the
ammonium sulfate is added, the 70% ammonium sulfate solution is
stirred for about 30 minutes at 20.degree. C. The 70% ammonium
sulfate solution is centrifuged or filtered, as described above,
and the precipitate is collected.
[0062] The ammonium sulfate precipitate is then redissolved in a
buffer such as about 10 mM phosphate, pH 7, to form a 50-70%
ammonium sulphate fraction, then diafiltered using an Amicon Diaflo
ultrafiltration unit, or dialyzed against about 10 mM sodium
phosphate, pH 7, to remove the ammonium sulfate from the
redissolved 50-70% fraction to provide an ammonium sulfate purified
PEDF protein fraction.
ii. Anion-Exchange Chromatography
[0063] The pI of the PEDF protein is about 3.9 to about 7.2.
Therefore, at a pH of about 7.5, the protein has a net negative
charge and binds to an anion-exchange chromatography medium such as
DEAE (diethylaminoethyl) cellulose.
[0064] For use, an anion-exchange chromatography medium such as
DEAE cellulose is equilibrated with a buffer such as about 10 mM
Tris, pH 7.5. The PEDF is applied to the anion-exchange
chromatography medium, and the medium is washed with a buffer such
as about 10 mM Tris, pH 7.5, until all unbound proteins are eluted
from the column. After all the unbound proteins are eluted, PEDF is
eluted with a linear salt gradient from about 0 to about 1 M NaCl
in a buffer such as about 10 mM Tris-HCl, pH 7.5. The fractions
containing PEDF are collected and pooled. These fractions are then
diafiltered or dialyzed against a buffer such as about 10 mM
Tris-HCl, pH 7.5, to remove NaCl, thereby providing an
anion-exchange chromatography purified PEDF protein fraction.
[0065] Anion-exchange chromatography may be conducted by either
batch or column chromatography techniques.
iii. Heparin Chromatography
[0066] Heparin chromatography may also be used for the large-scale
purification of PEDF. A heparin chromatography medium such as
heparin agarose, supplied by Sigma Chemical Co. (Cat. No. H-5380),
is equilibrated with a buffer such as about 10 mM Tris-HCl, pH
7.5.
[0067] An impure PEDF protein fraction or an ammonium sulfate
purified PEDF protein fraction is dialyzed against a buffer such as
about 10 mM Tris-HCl, pH 7.5, and then applied to the heparin
agarose. After the PEDF solution has been applied to the heparin
agarose, the heparin agarose is washed with a buffer such as about
10 mM Tris-HCl, pH 7.5, until all unbound proteins are eluted from
the heparin agarose. PEDF is then eluted from the heparin agarose
with a buffer such as about 10 mM Tris-HCl, pH 7.5, 0.5 M NaCl.
[0068] The eluant containing PEDF is collected and diafiltered in
an Amicon Diaflo ultrafiltration unit, or dialyzed against a buffer
such as about 10 mM Tris-HCl, pH 7.5, to remove the NaCl present in
the eluate, to provide a heparin purified PEDF protein
fraction.
[0069] The above-described purification procedures may use an
impure PEDF protein fraction or an ammonium sulfate purified PEDF
protein fraction as the starting material for the subsequent column
purification. Alternatively, a protein fraction which has already
been purified by one or more of the described chromatography steps
could also be used. Therefore, the purification procedures may be
used alone or in combination with each other or with other
purification techniques known in the art to produce a PEDF protein
fraction of the desired purity.
3. PEDF Assays
A. SDS Gel Electrophoresis
[0070] PEDF may be identified by SDS-polyacrylamide gel
electrophoresis on, for example, 7.5%, 10%, 12.5% w/v
SDS-polyacrylamide gels. The preparation of such gels has been
described by Weber and Osborn J. Biol. Chem. 244 4406 (1969), as
modified by Laemmli, Nature 277 680 (1970), and the preparation and
use of such gels are well known in the art.
[0071] The PEDF protein samples are mixed with about 5 .mu.l of
62.5 mM Tris, pH 6.8, 12% w/v SDS, 0.001% w/v bromophenol blue, 10%
v/v glycerol, and 0.1 M 2-mercaptoethanol, wherein the bromophenol
blue is a marker. Molecular-weight marker samples which include
molecular-weight standards such as phosphorylase B, bovine serum
albumin, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor
and lysozyme (such as supplied by Bio-Rad, catalog #161-0304) are
included on the gels as controls. The PEDF protein samples and the
molecular-weight standards are boiled for about 5 minutes and
loaded onto separate wells on the SDS-polyacrylamide slab gels. The
samples are then subjected to electrophoresis until the bromphenol
blue has migrated to the bottom of the gel. At the completion of
electrophoresis, the gel is silver-stained, stained with Coomassie
blue, or stained by other suitable protein staining methods. The
molecular weight of proteins in the PEDF sample is then compared to
the molecular-weight standards.
[0072] Alternatively, larger quantities of PEDF can be collected
from SDS-PAGE tube gels using BioRad PREP CELL equipment and a
fraction collector.
[0073] PEDF migrates as a protein doublet, with an apparent
molecular weight of from about 50,000 to about 55,000 on SDS
polyacrylamide gels.
B. Neuronal Inductivity
[0074] PEDF activity in protein samples may be assayed by its
neuronal inductivity. Various concentrations of PEDF are added to
cultures of cells such as Y79 retinoblastoma (RB) cells, supplied
by the American Type Culture Collection, Access No. HTB 18, of
Rockville, Md.
[0075] The Y79 RB cells are grown in suspension culture. The cells
are harvested by centrifugation for about 5 minutes at about 900
rpm at room temperature and resuspended in a serum-free medium such
as Dulbecco's modified Eagle's medium supplemented with 5 ug/ml
insulin, 5 ug/ml transferrin, 5 ng/ml selenous acid, and 876.6
ug/ml L-glutamine (serum-free medium), which has previously been
warmed to about 37.degree. C. The collected cells are resuspended
at a concentration of about 10.sup.6 cells/ml in serum-free medium.
About 50 to about 500 ng/ml of PEDF is added to about 25 ml
aliquots of the cells. The cells are incubated for about 7 days at
about 37.degree. C., then attached to poly-D-lysine-coated flasks
or glass coverslips. The poly-D-lysine-coated flasks are prepared
by coating with a solution containing about 200 ug/ml poly-D-lysine
(such as that supplied by Sigma, Catalog #P7405) for about 1-24
hours, followed by rinsing with water and serum-free medium. Other
cells may be used and it will be clear to one skilled in the art
that testing other cells is a routine matter of following the
methods set out above with the desired cell line.
i. Cell Analyses
[0076] Morphology of attached cells is monitored daily by phase
contrast microscopy of living cells using a microscope such as an
inverted Diaphot TMD microscope, supplied by Nikon of Tokyo, Japan,
or by differential interference contrast microscopy of cells, fixed
with a fixative such as about 4% v/v paraformaldehyde in 0.1 M
sodium cacodylate buffer, using a microscope, such as a BHS-BH2
microscope, supplied by Olympus of Tokyo, Japan.
[0077] Differentiation is assessed by calculating the percentage of
cellular aggregates (more than 90% of Y79 cells plated from
suspension culture attach to poly-D-lysine-coated flasks as
aggregates containing more than 5 cells) in which cells extend
processes at day 1, 3, 7 and 11 after attachment. Experiments are
performed in replicates of 3 and are repeated twice.
[0078] Expression of neuron-specific enolase (NSE) and
neurofilament 200,000 molecular weight protein subunit (NF 200) is
monitored by immunofluorescence and viewed by either
epifluorescence microscopy (Olympus BHS-BH2 microscope) or
microspectrofluorometry (MSA, Farrand Microscope Spectrum
Analyzer). Quantification is by 1) visual scoring of intensity of
fluorescence at 485 nm excitation as +=weak; ++=moderate;
+++=strong; ++++=very intense, and 2) microspectrofluorometric
analysis (MSA) readings (.mu.A.times.100, time constant of about
0.3 seconds; specimen size of approximately 2 mm or about 100
cells/aggregate; target size of about 15 .mu.m or approximately
that of 1 cell).
[0079] The presence of PEDF in the protein sample results in the
Y79 RB cells, extending neurite-like processes. At a concentration
of about 500 ng/ml, about 70% of the cells extend neurite-like
processes.
ii. Differentiation
[0080] Cells were cultured as described above. The cells were then
monitored daily by phase-contrast microscopy of living cells
(Olympus IMT-2) and by differential interference contrast
microscopy (Olympus BHS) of cells fixed with a fixative such as
about 4% v/v paraformaldehyde. The percentage of differentiating
cells is estimated by calculating the number of cellular aggregates
containing five or more cells exhibiting neurite outgrowths
following 8-10 days of culture on a poly-D-lysine substratum.
[0081] With about 50 to about 500 ng/ml PEDF, approximately 80% of
the cells undergo morphological differentiation within about 3
days.
4. Characterization of the PEDF Protein
A. Isolation of PEDF Peptides
[0082] Purified PEDF, about 500 .mu.g, is concentrated using
Centricon 10 microconcentrators (Amicon, Danvers, Mass.), and then
diluted in a suitable digestion buffer such as about 25 mM Tris, pH
8.5, 1 mM EDTA. To the protein sample is added a proteolytic
enzyme, such as endoproteinase Lys-C, supplied by
Boehringer-Mannheim of Indianapolis, Ind. The PEDF/proteinase
mixture is incubated for about 18 hours at about 30.degree. C., or
until the reaction has gone to completion, i.e., until all the PEDF
is completely digested by the proteinase. Alternatively, the
protein may be digested with trypsin in a buffer comprising about
10 mM PBS or by using other proteinases known in the art.
[0083] The resulting PEDF polypeptide fragments are separated by
using a separation system such as HPLC on a Vydac C8 reverse-phase
column. A 4.6.times.250 mm column is suitable for use in the
present invention. The column is equilibrated with about 0.1% v/v
TFA in water. The polypeptides are eluted with about 90% v/v
CH.sub.3CN, 0.1% v/v TFA and 5% v/v H.sub.2O.
[0084] Polypeptides eluted from the column which are well separated
from other polypeptides are collected and subjected to protein
sequencing analysis.
B. Protein Sequencing Analysis
[0085] The purified polypeptide fragments are subjected to
amino-acid sequence analysis by methods known in the art.
Alternatively, the amino-acid sequence analysis is conveniently
performed under contract at an amino-acid sequencing facility, such
as the Microsequencing Facility of Beckman Research Institute at
the City of Hope in Duarte, Calif.
5. Characterization of the PEDF Gene
[0086] The present invention provides, among other things, a
nucleic acid which encodes PEDF. In particular, a cDNA sequence is
provided for human PEDF as set forth in SEQ ID NO:1, for mouse PEDF
as set forth in SEQ ID NO:7 and for human PEDF as set forth in SEQ
ID NO:8. This cDNA sequence codes for PEDF, which has the amino
acid sequence set forth in SEQ ID NO:2. The cDNA and amino acid
sequences are listed in the GenBank.RTM. Data Bank under accession
number M76979.
[0087] The term "nucleic acid" refers to a polymer of
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), which can be
derived from any source, can be single- or double-stranded, and can
optionally contain synthetic, non-natural, or altered nucleotides
which are capable of being incorporated into DNA or RNA polymers.
The nucleic acid of the present invention is preferably a segment
of DNA.
[0088] The present invention further provides a truncated version
of PEDF, which is referred to as PEDF-BH. PEDF-BH comprises the
amino acid sequence Met-Asn-Arg-Ile fused to Asp.sup.44 . . .
Pro.sup.418 of PEDF, the amino terminus of which has been deleted.
The truncated protein comprises the amino acid sequence of SEQ ID
NO:3. The present invention also provides a nucleic acid which
encodes a protein comprising the amino acid sequence of PEDF-BH,
i.e., the amino acid sequence of SEQ ID NO:3.
[0089] One who is skilled in the art will appreciate that more than
one nucleic acid may encode any given protein in view of the
degeneracy of the genetic code and the allowance of exceptions to
classical base pairing in the third position of the codon, as given
by the so-called "Wobble rules." Moreover, nucleic acids that
include more or less nucleotides can result in the same or
equivalent proteins. Accordingly, it is intended that the present
invention encompass all nucleic acids that encode the amino acid
sequences of SEQ ID NO:2 and SEQ ID NO:3, as well as equivalent
proteins. The phrase "equivalent nucleic acids" is intended to
encompass all of these nucleic acids.
[0090] It also will be appreciated by one skilled in the art that
amino acid sequences may be altered without adversely affecting the
function of a particular protein. In fact, some alterations in
amino acid sequence may result in a protein with improved
characteristics. The determination of which amino acids may be
altered without adversely affecting the function of a protein is
well within the ordinary skill in the art. Moreover, proteins that
include more or less amino acids can result in proteins that are
functionally equivalent. Accordingly, it is intended that the
present invention encompass all amino acid sequences that result in
the PEDF and PEDF-BH proteins, proteins that are functionally
equivalent to PEDF and PEDF-BH, and proteins derived therefrom. The
phrase "equivalent proteins" is intended to encompass all of these
amino acid sequences.
[0091] Some examples of possible equivalent nucleic acids and
equivalent proteins include nucleic acids with substitutions,
additions, or deletions which direct the synthesis of the PEDF and
PEDF-BH proteins and equivalent proteins; nucleic acids with
different regulatory sequences that direct the production of the
PEDF and PEDF-BH proteins; variants of PEDF-BH which possess
different amino acids and/or a number of amino acids other than
four fused to the amino terminal end of the protein; and PEDF and
PEDF-BH proteins with amino acid substitutions, additions,
deletions, modifications, and/or posttranslational modifications,
such as glycosylations, that do not adversely affect activity.
[0092] The present invention also provides a vector which comprises
a nucleic acid of SEQ ID NO:1, a nucleic acid which encodes a
protein comprising the amino acid sequence of SEQ ID NO:2 or an
equivalent protein, a nucleic acid which encodes a protein
comprising the amino acid sequence of SEQ ID NO:3 or an equivalent
protein, and equivalent nucleic acids thereof.
A. Cloning of the PEDF cDNA
[0093] Oligonucleotides are constructed from the sequence derived
for the isolated polypeptide of PEDF on an ABI 392 DNA/RNA
Synthesizer or by methods well known in the art.
[0094] The oligonucleotides are used as primers for a polymerase
chain reaction (PCR) by using a Techne thermal cycler and standard
reagents and methodologies, supplied under the trade name "GeneAMP"
by Perkin-Elmer/Cetus of Emeryville, Calif.
[0095] A human fetal eye Charon BS cDNA library is screened by PCR
techniques using a Techne thermal cycler and standard reagents and
methodologies. The cDNA fragment generated by the reaction is
isolated on a 3% w/v NuSieve 3:1 gel (FMC Biochemicals) using NA-45
DEAE-cellulose paper (Schleicher and Schull) as described by
Sambrook et al., 1989 In: Molecular Cloning: A Laboratory Manual
2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y. Briefly,
the screening procedure is performed by taking about 1, 5 and 50
.mu.l aliquots of the library and placing them in 600 .mu.l
siliconized reaction tubes and then bringing them to a final volume
of about 74 .mu.l with double-distilled sterile water. The phage
particles are disrupted by incubation at about 70.degree. C. for
about 5 minutes and then cooling on wet ice.
[0096] PCR master mix is made up in a 600 .mu.l reaction tube for 3
reaction tubes as follows: [0097] 30 .mu.l of 10.times.Taq
polymerase buffer; [0098] 24 .mu.l of dNTP mix; and an appropriate
volume of double-distilled water is added to bring the master mix
to a final volume of about 78 .mu.l.
[0099] The final solution, therefore, comprises about 192 mM KCl,
38.5 mM Tris-HCl, pH 8.3, 51.8 mM MgCl.sub.2, 0.038% w/v gelatin,
0.77 mM of each dNTP, and 3.8 .mu.l of each oligonucleotide primer.
About 26 .mu.l of master mix is added to each reaction tube. The
library aliquots and the master mix solutions are overlayed with
about 100 .mu.l of mineral oil and heated to about 94.degree. C.
for about 5 minutes. The solutions are then equilibrated to the
desired primer annealing temperature.
[0100] After the solutions have been equilibrated to the desired
primer annealing temperature, about 1.5 .mu.l of Tag polymerase is
added to the solution and incubated for about 20 minutes.
[0101] Thermal cycling is continued by incubating: at about
72.degree. C. for about 3 minutes for primer extension, however,
this primer extension time may be varied if desired; at about
94.degree. C. for about 1 minutes about 20 seconds to denature the
extension product from the template; at about 37.degree. C. for
about 2 minutes to anneal the primers to a template; and at about
72.degree. C. for about 3 minutes for primer extension. The "cycle"
is the repeated for a total of about 25 to about 30 cycles. At the
end of the last cycle, a final primer extension step, of about 7
minutes at 72.degree. C. is added.
[0102] The fragment is labelled with .sup.32P by random priming
using a kit supplied under the trade name "Prime-It Random Primer
Labeling Kit" supplied by Stratagene Inc., La Jolla, Calif. The
labelled probe is used to screen about 200,000 plaque-forming units
of the Charon BS cDNA library by methods well known in the art.
[0103] Positive clones are isolated, and the DNA purified, with
reagents supplied under the trade name "Qiagen Maxi" by Qiagen Inc.
of Studio City, Calif.
[0104] The inserts within the phage vector are excised with an
appropriate restriction enzyme, circularized with T4 DNA ligase
supplied by New England Biolabs of Beverly, Mass. and transformed
into competent E. coli Sure cells supplied by Stratagene. The cells
are then plated on
ampicillin/5-bromo-4-chloro-3-indolyl-.beta.-D-galactoside (X-gal)
plates.
[0105] White colonies are selected and mini-prepped using a plasmid
miniprep reagent supplied by Qiagen. Purified plasmids are digested
to excise the insert, and the fragments are separated by gel
electrophoresis to determine the size of the inserts. A clone with
an appropriately-sized insert is then chosen for further
investigation.
[0106] The cDNA's for mouse and bovine PEDF were obtained following
similar procedures.
B. Cloning of the Genomic DNA Sequence
[0107] The cDNA insert is labeled ith .alpha.-.sup.32P dCTP and
used to screen two genomic DNA libraries: a cosmid library
constructed from MboI partial digests of human placental DNA
(Clonetech) and a human placental genomic library constructed in
.lamda. DASH II (Stratagene). Positively hybridizing clones are
analyzed by Southern blot analysis. Two strongly hybridizing
fragments: a 7.1 kb BamHI fragment from the cosmid clone and a 7.2
kb Not1 fragment from the .lamda. DASH II clone are selected for
subcloning and DNA sequencing.
[0108] In an alternative embodiment of the present invention,
primers, designed from the internal coding region of the PEDF cDNA
sequence are synthesized using an ABI 392 DNA/RNA synthesizer and
used as primers in polymerase chain reaction (PCR) experiments. The
primer sequences are as follows: primer 603: [0109] 5'-ACAAGCTGGC
AGCGGCTGTC-3' is located in SEQ ID NO:1 at 271-290; primer 604:
[0110] 5'-CAGAGGTGCC ACAAAGCTGG-3' is located on the antisense
strand in SEQ ID NO:1 at 570-590; primer 605: [0111] 5'-CCAGCTTTGT
GGCACCTCTG-3' is located in SEQ ID NO:1 at 570-590; primer 606:
[0112] 5'-CATCATGGGG ACCCTCACGG-3' is located on the antisense
strand in SEQ ID NO:1 at 829-848; primer 2213: [0113] 5'-AGGATGCAGG
CCCTGGTGCT-3' is located in SEQ ID NO:1 at 114-133; primer 2744:
[0114] 5'-CCTCCTCCAC CAGCGCCCCT-3' is located on the antisense
strand in SEQ ID NO:1 at 224-244; primer 2238: [0115] 5'-ATGTCGGACC
CTAAGGCTGT T-3' is located in SEQ ID NO:1 at 846-866; primer 354:
[0116] 5'-TGGGGACAGT GAGGACCGCC-3' is located on the antisense
strand in SEQ ID NO:1 at 1043-1062. The primer pairs 603:604
amplified a single 2 kb PCR product (jt108); 605:606 amplified a
single 3.3 kb PCR product (jt109); 2213:2744 amplified a single 2.3
kb PCR product (jt115) and 2238:354 amplified a single 1.5 kb PCR
product (jt116).
[0117] In an alternative embodiment of the present invention, two
sets of primers JT10-UP01:JT10-DP01 corresponding to bases
6536-6559 of jt106 genomic sequence and 1590:1591 corresponding to
bases 1-89 of SEQ ID NO:1 are used in PCR reactions to isolate P1
clones (Genome Systems). The primer sequences are as follows:
primer JT10-UP01: [0118] 5'-GGTGTGCAAA TGTGTGCGCC TTAG-3' is
located in SEQ ID NO: 4 at 6536; primer JT10-DP01: [0119]
5'-GGGAGCTGCT TTACCTGTGG ATAC-3' is located in SEQ ID NO: 4 at
7175; primer 1590: [0120] 5'-GGACGCTGGA TTAGAAGGCA GCAAA-3' is
located in SEQ ID NO:1 at 1-25; and primer 1591: [0121]
5'-CCACACCCAG CCTAGTCCC-3' is located in SEQ ID NO:1 at 71-89.
[0122] Positive clones are screened by PCR and Southern blot
analysis and isolated.
C. DNA Sequence Analysis
[0123] Sequence analysis is performed with an automated sequencer
or by other techniques well known in the art.
6. Expression of the PEDF Gene in Recombinant Cells
[0124] Commercial or large-scale production of PEDF may be achieved
by expression of the gene, after cloning into an appropriate
vector, in a suitable host cell. One such suitable vector/host
system is the baculovirus/insect cell systems.
[0125] In one embodiment of the present invention, the PEDF gene is
cloned into a baculovirus transfer vector such as pAC373, described
by Lithgow et al., DNA and Cell Biology 10 443-449 (1991); pVL941,
described by Ghiasi et al., Virology 185 187-194 (1991); or other
such baculovirus transfer vectors that are well known by those
skilled in the art.
[0126] Generally, such vectors comprise the polyhedron promoter of
the Autographa californica nuclear polyhedrosis virus (AcNPV),
inserted into a transfer vector such as pAc373, described by
Summers and Smith (A manual for baculovirus vector and insect cell
culture procedures, Texas Agric. Exp. Station Bull. No. 1555).
Recombinant plasmids are prepared by methods well known in the art,
such as those described by Maniatis et al. In: Molecular Cloning: A
Laboratory Manual 2nd ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y. (1982).
[0127] The host cells, such as S. frugiperda (Sf9), are grown in
TC100 medium supplied by GIBCO, supplemented with 10% v/v fetal
calf serum. The Sf9 cells are co-transfected with purified
infectious AcNPV DNA, about 1 .mu.g, and about 50 .mu.l of the
recombinant DNA. Culture supernatants are harvested about 4 days
after transfection. Recombinant viruses are identified by plaque
hybridization or radiolabelling of the proteins produced.
[0128] The above description provides an example of the expression
of the PEDF gene in a vector/host expression system. Other
expression systems are known in the art; for example, Saccharomyces
cerevisiae has been used in conjunction with a number of vectors
such as those described by Silar et al., Gene 104 99-102 (1991),
Dietrich et al., Eur. J. Biochem. 201 399-407 (1991), or
Akiyoshi-Shibata et al., DNA and Cell Biology 10 613-612 (1991);
recombinant vaccinia virus vectors in HeLa host cells such as those
described by Nakano et al., Gene 105 173-178 (1991). Any such
methods or other methods known in the art are suitable for use in
the present invention for expression of the PEDF gene.
[0129] The PEDF gene may be expressed as a transported protein
where the PEDF is isolated from the medium in which the recombinant
expression host is grown, or may be expressed as an intracellular
protein by deleting the leader or other peptides, in which case the
PEDF is isolated from the host cells. The PEDF so isolated is then
purified by the methods described above.
[0130] In another embodiment of the present invention the vector
.pi.FS17, ATCC Deposit No. ______, which comprises the nucleic acid
of SEQ ID NO:1, and the vector pEV-BH, ATCC Deposit No. ______,
which comprises a nucleic acid which encodes a protein comprising
the amino acid sequence of SEQ ID NO:3. It will be appreciated by
those skilled in the art that the cDNA inserts described can be
present in alternative vectors. For example, inserts can be in
vectors of different nature, such as phages, viral capsids,
plasmids, cosmids, phagemids, YACs, or even attached to the outside
of a phage or viral capsid. The vectors can differ in host range,
stability, replication, and maintenance. Moreover, the vectors can
differ in the types of control exerted over cloned inserts. For
example, vectors can place cloned inserts under the control of a
different promoter, enhancer, or ribosome binding site, or even
organize it as part of a transposon or mobile genetic element.
[0131] The present invention also provides a host cell into which a
vector, which comprises a nucleic acid of SEQ ID NO:1, a nucleic
acid which encodes a protein comprising the amino acid sequence of
SEQ ID NO:2 or an equivalent protein, a nucleic acid which encodes
a protein comprising the amino acid of SEQ ID NO:3 or an equivalent
protein, or an equivalent nucleic acid thereof, has been
introduced. In particular, the host cell may have the vector
.pi.FS17, which comprises the nucleic acid of SEQ ID NO:1, or the
vector pEV-BH, which comprises a nucleic acid which encodes a
protein comprising the amino acid sequence of SEQ ID NO:3.
[0132] The vectors of the present invention can be introduced into
any suitable host cell, whether eukaryotic or prokaryotic. These
host cells may differ in their preferred conditions for growth,
their nutritive requirements, and their sensitivity to
environmental agents. Any appropriate means of introducing the
vectors into the host cells may be employed. In the case of
prokaryotic cells, vector introduction may be accomplished, for
example, by electroporation, transformation, transduction,
conjugation, or mobilization. For eukaryotic cells, vectors may be
introduced through the use of, for example, electroporation,
transfection, infection, DNA coated microprojectiles, or protoplast
fusion.
[0133] The form of the introduced nucleic acid may vary with the
method used to introduce the vector into a host cell. For example,
the nucleic acid may be closed circular, nicked, or linearized,
depending upon whether the vector is to be maintained as an
autonomously replicating element, integrated as provirus or
prophage, transiently transfected, transiently infected as with a
replication-disabled virus or phage, or stably introduced through
single or double crossover recombination events.
[0134] The present invention also provides a method of producing
PEDF, PEDF-BH, and equivalent proteins, which method comprises
expressing the protein in a host cell. For example, a host cell
into which has been introduced a vector which comprises a nucleic
acid of SEQ ID NO:1, a nucleic acid which encodes a protein
comprising the amino acid sequence of SEQ ID NO:2 or an equivalent
protein, a nucleic acid which encodes a protein comprising the
amino acid of SEQ ID NO:3 or an equivalent protein, or an
equivalent nucleic acid thereof, may be cultured under suitable
conditions to produce the desired protein. In particular, a host
cell into which has been introduced the vector .pi.FS17, which
comprises the nucleic acid of SEQ ID NO:1, or the vector pEV-BH,
which comprises a nucleic acid which encodes a protein comprising
the amino acid sequence of SEQ ID NO:3, may be cultured under
suitable conditions to produce the proteins comprising the amino
acid sequences of SEQ ID NO:2 and SEQ ID NO:3, respectively.
[0135] The present invention also provides recombinantly produced
PEDF, PEDF-BH, and equivalent proteins, which have been produced in
accordance with the aforementioned present inventive method of
culturing an appropriate host cell to produce the desired protein.
The production of a protein such as PEDF by recombinant means
enables the obtention of large quantities of the protein in a
highly purified state, free from any disease-causing agents which
may accompany the protein isolated or purified from a naturally
occurring source organism, and obviates the need to use, for
example, fetal tissue as a source for such a protein.
[0136] The provision of cDNA sequences in the present invention
also enables the obtention of human genomic DNA sequences that
encode PEDF or that have substantial sequence homology to
PEDF-BH.
[0137] The obtention of genomic DNA sequences from cDNA sequences
can be accomplished using standard techniques.
[0138] Recombinant PEDF, PEDF-BH, and equivalent proteins may be
supplied as active agents to cells by a variety of means,
including, for example, the introduction of nucleic acids, such as
DNA or RNA, which encode the protein and may be accordingly
transcribed and/or translated within the host cell, the addition of
exogenous protein, and other suitable means of administration as
are known to those skilled in the art. In whatever form in which
supplied, the active agent can be used either alone or in
combination with other active agents, using pharmaceutical
compositions and formulations of the active agent which are
appropriate to the method of administration. Pharmaceutically
acceptable excipients, i.e., vehicles, adjuvants, carriers or
diluents, are well-known to those who are skilled in the art, and
are readily available. The choice of excipient will be determined
in part by the particular compound, as well as by the particular
method used to administer the compound. Accordingly, there is a
wide variety of suitable formulations which can be prepared in the
context of the present invention. However, pharmaceutically
acceptable excipients not altering the neurotrophic activity of the
recombinant protein are preferred.
7. Treatment with PEDF
A. Treatment of Tumors
[0139] PEDF is administered, alone or in conjunction with other
clinical (such as surgical) procedures. PEDF is administered by
intravitreal, subretinal, intravenous or intramuscular injection or
injected or applied at sites of tumor growth. The PEDF may be
administered alone or in conjunction with compounds, such as
polylactic acid, which facilitate a slow, "time release" of the
PEDF. Typically, about 0.01 to about 10 .mu.g of PEDF at a
concentration of about 1 to about 100 .mu.g/ml in a physiologic
saline solution or other buffered solution is administered per
dose, and about 0 to about 10 doses are administered per day. When
time-release compounds are included in the composition, they are
used at a concentration of about 1 to about 100 .mu.g/ml. Treatment
is continued until cessation of tumor growth and/or tumor
regression is observed.
[0140] Treatment with PEDF is effective for retinal tumors such as
retinoblastoma, other neuronal tumors such as neuroblastoma, or
tumors of non-neuronal origin. The treatment results in a cessation
or reduction in the rate of cell division and a concomitant
reduction in the rate of tumor growth, which in turn results in
tumor regression.
B. Neurotrophic Treatment of Ocular Disease
[0141] PEDF is administered, alone or in conjunction with other
clinical (such as surgical) procedures. PEDF is administered by
intravitreal or subretinal injection. The PEDF may be administered
alone or in conjunction with compounds such as polylactic acid
which facilitate a slow, "time release" of the PEDF. Typically,
about 0.01 to about 10 .mu.g of PEDF at a concentration of about 1
to about 100 .mu.g/ml in a physiologic saline solution or other
buffered solution is administered per dose, and about 0 to about 10
doses are administered per day. When time-release compounds are
included in the composition, they are used at a concentration of
about 1 to about 100 .mu.g/ml. Treatment is continued until the
progress of the pathology is halted and/or reversed.
[0142] Treatment with PEDF is directed at diseases of the neural
retina, retinal pigmented epithelium, and other ocular tissue.
Treatment results in enhanced survival and well-being of the
photoreceptors and other ocular cells, prolonging their functional
life span and delaying the onset of impaired vision and ultimate
blindness.
C. Neurotrophic Treatment of Neuronal Cell Pathology
[0143] PEDF is administered, alone or in conjunction with other
clinical (such as surgical) procedures. PEDF is administered by
intravenous or intramuscular injection or application or injection
at the site of neuronal cell pathology. The PEDF may be
administered alone or in conjunction with compounds such as
polylactic acid which facilitate a slow, "time release" of the
PEDF. Typically, about 0.01 to about 10 .mu.g of PEDF at a
concentration of about 1 to about 100 .mu.g/ml in a physiologic
saline solution or other buffered solution is administered per
dose, and about 0 to about 10 doses are administered per day. When
time-release compounds are included in the composition, they are
used at a concentration of about 1 to about 100 .mu.g/ml. Treatment
is continued until nerve regeneration is completed.
[0144] Treatment with PEDF is directed at injuries to nerves and
pathologies of cells. Treatment results in enhanced survival of
nerve cells and promotion of neurite outgrowth and nerve
regeneration.
D. Treatment of Conditions Related to Serine Proteinases
[0145] PEDF is a serine proteinase inhibitor. As such, it is
effective in the treatment of conditions caused by serine
proteinases or where a serine proteinase inhibitor would be
advantageous. Serine proteinases include, but are not limited to,
chymotrypsin, trypsin, subtilisin, elastin, thrombin, and plasmin.
Therefore, PEDF is useful as: an anti-coagulant, an
anti-thrombotic, an anti-microbial, an anti-fungal, an
anti-parasitic, and a contraceptive; in cosmetic preparations as a
proteinase inhibitor; as a weight-gain promoter; in treatments for
elastosis, vascular disorders involving fibrinoid formation,
coagulation disorders, arteriosclerosis, ischemia, arthroses
diabetes, emphysema, arthritis, septic shock, lung diseases,
excessive complement activation, ulcers, ulcerative colitis,
pancreatitis, psoriasis, fibrinolytic disease, arthropathy, bone
resorption, hypertension, congestive heart failure, cirrhosis, or
allergy caused by proteases, as a dermatological agent for skin
discoloration and age-related wrinkling.
[0146] For use as an anti-coagulant, an anti-thrombotic, an
anti-microbial, an anti-parasitic, or a contraceptive, or in
treatment of elastosis, vascular disorders involving fibrinoid
formation, coagulation disorders, arteriosclerosis, ischemia,
arthroses diabetes, emphysema, arthritis, septic shock, lung
diseases, excessive complement activation, pancreatitis, psoriasis,
fibrinolytic disease, arthropathy, bone resorption, hypertension,
congestive heart failure, cirrhosis, or allergy caused by
proteases, PEDF is administered by intravenous or intramuscular
injection or site-directed injection or application. The PEDF may
be administered alone or in conjunction with compounds such as
polylactic acid which facilitate a slow "time release" of the PEDF.
Typically, about 0.01 to about 10 .mu.g of PEDF at a concentration
of about 1 to about 100 .mu.g/ml in a physiologic saline solution
or other buffered solution are administered per dose, and about 0
to about 10 doses are administered per day. When time-release
compounds are included in the composition, they are used at a
concentration of about 1 to about 100 .mu.g/ml. Treatment is
continued until progress of the pathology is halted and/or
reversed.
[0147] Treatment with PEDF is directed at injuries to nerves.
Treatment results in promotion of neurite outgrowth and nerve
regeneration.
[0148] For use in cosmetic preparations as a proteinase inhibitor,
arthritis or elastosis PEDF is added to the preparations to a
concentration of about 0.01 to about 100 .mu.g/ml.
[0149] For use in treatment as a weight-gain promoter, ulcers,
ulcerative colitis, or pancreatitis, PEDF may be administered
orally at a concentration of about 0.01 to about 10 .mu.g per kg of
body weight per day.
[0150] For use as a treatment for conditions such as psoriasis,
PEDF may be administered topically at a concentration of about 0.01
to about 100 .mu.g/ml, formulated in a suitable carrier.
EXAMPLE 1
Establishment of RPE Cell Cultures
[0151] RPE cells were harvested from post-mortem human eyes, as
described by Pfeffer et al., J. Cell. Physiol. 117 333-341 (1983).
The cells were grown in 75 cm flasks with Eagles's minimal
essential medium supplemented with 15% v/v fetal calf serum and 5%
v/v CO.sub.2 at 37.degree. C. Cells were grown to confluence,
harvested by trypsinizing the cell monolayer, and resuspended in
MEM supplemented with 15% v/v fetal calf serum. A portion of the
cells (about 5%) were reseeded into new 75 cm, where the cells were
again grown in 5% v/v CO.sub.2 at 37.degree. C.
EXAMPLE 2
Preparation of RPE-Conditioned Medium
[0152] Confluent cultures of RPE cells were washed extensively with
HBSS, before conditioning, to remove serum proteins. Twenty-five ml
of serum-free MEM was added, and the cultures were incubated with
5% v/v CO.sub.2 at 37.degree. C. for about 48 hours. The
conditioned medium was then collected and centrifuged at 1,000 rpm
at room temperature, to remove any free cells and other particulate
matter, to provide an impure PEDF protein fraction.
EXAMPLE 3
Purification of PEDF by SDS Gel Electrophoresis
[0153] Proteins contained in human fetal RPE-conditioned medium,
prepared as described in Example 2, and in control non-conditioned
medium were analyzed on an SDS-polyacrylamide slab gel.
[0154] The conditioned and non-conditioned media samples were mixed
with an electrophoresis sample buffer (62.5 mM Tris, pH 6.8, 2% w/v
SDS, 10% v/v glycerol, 0.001% w/v bromophenol blue, and 0.1 M
2-mercaptoethanol). Molecular-weight markers, such as phosphorylase
B, bovine serum albumin, ovalbumin, carbonic anhydrase, soybean
trypsin inhibitor and lysozyme (such as that supplied by Bio-Rad),
were also mixed with an electrophoresis sample buffer. All the
samples were denatured at 100.degree. C., in a boiling water bath,
for 5 minutes and loaded onto a SDS containing 7.5% w/v
polyacrylamide gel. The electrophoresis was conducted at 20 mA
until the bromphenol blue marker dye migrated to the bottom of the
gel.
[0155] At the completion of electrophoresis, strips from each
outside edge of the gels, which included the markers and a lane
each of conditioned and non-conditioned media, were stained with
Coomassie blue. The stained protein bands which developed on the
stained strips were used to align with the unstained portion of the
gel, to locate the proteins present in conditioned medium but
absent from non-conditioned medium.
[0156] The about 50,000 to about 55,000 molecular-weight PEDF
protein doublet, unique to RPE-CM, were excised, and the proteins
were electro-eluted from the unstained portion of the gel. A strip
of the same gel excised from the region containing bovine serum
albumin was treated similarly to serve as a control. The eluant was
centrifuged to remove gel fragments, and the supernatant was
dialyzed and analyzed by gel electrophoresis to assess its
purity.
[0157] The electrophoretic patterns of human fetal RPE-CM and
non-conditioned control medium show the presence of the prominent
about 50,000 to about 55,000 molecular-weight PEDF doublet unique
to the conditioned medium.
EXAMPLE 4
Small Scale Ammonium Sulfate Precipitation
[0158] An impure PEDF protein fraction, prepared as described in
Example 2, was divided into six 10 ml aliquots. One of the aliquots
was brought to 40% saturation, at 20.degree. C., by the addition of
2.42 g of ammonium sulfate; another aliquot was brought to 50%
saturation, at 20.degree. C., by the addition of 3.14 g of ammonium
sulfate; another aliquot was brought to 60% saturation, at
20.degree. C., by the addition of 3.90 g of ammonium sulfate;
another aliquot was brought to 70% saturation, at 20.degree. C., by
the addition of 4.72 g of ammonium sulfate; another aliquot was
brought to 80% saturation, at 20.degree. C., by the addition of
5.61 g of ammonium sulfate; and the final aliquot was brought to
90% saturation, at 20.degree. C., by the addition of 6.57 g of
ammonium sulfate. The aliquots were mixed until the ammonium
sulfate was completely dissolved. The precipitates which formed in
each of the tubes were collected by centrifugation at 10,000 rpm
for 20 minutes. The precipitates were each resuspended in 10 mM
sodium phosphate buffer, pH 7.5, and dialyzed against 2 l of 10 mM
sodium phosphate buffer, pH 7.5, for 24 hours.
[0159] The samples were then collected and subjected to
SDS-polyacrylamide gel electrophoresis on a 10% w/v
SDS-polyacrylamide gel, as described in Example 3.
[0160] The results are summarized in Table I. TABLE-US-00001 TABLE
I % Saturation Relative concentration Ammonium Sulfate of PEDF 40 -
50 - 60 + 70 +++ 80 - 90 -
[0161] The results indicate that the PEDF precipitates with an
ammonium sulfate saturation of 60% to 70%. The small amount of PEDF
in the 50% to 60% sample indicates that some PEDF is present, and
that a suitable ammonium sulfate "cut" is from 50% to 70%
saturation. The samples were subjected to SDS-polyacrylamide gel
electrophoresis, as described in Example 3. It was estimated that
the purity of the PEDF in the 60% to 70% ammonium sulfate fraction
was about 50%.
EXAMPLE 5
Ammonium Sulfate Precipitation
[0162] An impure protein fraction, prepared as described in Example
2, was brought to 50% saturation with ammonium sulfate by the
addition of 313 g/l of solid ammonium sulfate. The ammonium sulfate
was added slowly to the impure protein fraction while the solution
was stirred with a stir bar on a mechanical stirrer. After all the
ammonium sulfate was added, the 50% ammonium sulfate solution was
stirred for 30 minutes at 20.degree. C. The 50% ammonium sulfate
solution was then centrifuged at 10,000 g, at 20.degree. C. for 20
minutes. The supernatant was collected.
[0163] The 50% ammonium sulfate solution was then brought to 70%
saturation by the addition of 137 g/l of ammonium sulfate. The
ammonium sulfate was added slowly, and after all the ammonium
sulfate was added, the 70% ammonium sulfate solution was stirred
for 30 minutes at 20.degree. C. The 70% ammonium sulfate solution
was centrifuged or filtered, as described above, and the
precipitate was collected.
[0164] The ammonium sulfate precipitate was then redissolved in 10
mM sodium phosphate, pH 7, to form a 50%-70% ammonium sulphate
fraction, then diafiltered using an Amicon Diaflo ultrafiltration
unit, or dialyzed against 10 mM sodium phosphate, pH 7, to remove
the ammonium sulfate from the redissolved 50-70% fraction.
[0165] The samples were subjected to SDS-polyacrylamide gel
electrophoresis, as described in Example 3. It was estimated that
the purity of the PEDF in the 50% to 70% ammonium sulfate fraction
was about 50%.
EXAMPLE 6
Purification of PEDF by Cation Exchange HPLC
[0166] RPE-CM, prepared as described in Example 2, was dialyzed
against 10 mM sodium phosphate buffer, pH 6.5, to remove media and
salts from the impure protein sample. The dialyzed PEDF sample was
then loaded onto a Brownlee Aquapore CX-300 HPLC chromatography
medium, packed into a 4.6.times.30 mm column. The chromatography
medium was previously equilibrated with 10 mM phosphate, pH 6.5.
The dialyzed RPE-CM was loaded onto the chromatography medium, and
the chromatography medium, with PEDF, was washed with 10 mM
phosphate, pH 6.5, until all unbound proteins were washed from the
chromatography medium. PEDF was eluted from the chromatography
medium with a linear salt gradient from 0.0 to 0.5 M NaCl in 10 mM
phosphate, pH 6.5. PEDF, eluted with a NaCl concentration of 0.25
M.
[0167] The eluted PEDF was concentrated by lyophilization and
resolubilized in 10 mM phosphate, pH 6.5. The eluted PEDF was
analyzed by SDS gel electrophoresis, as described in Example 3. The
eluted PEDF was estimated to be approximately 70% pure.
EXAMPLE 7
Purification of PEDF by Cation-Exchange HPLC
[0168] Ammonium sulfate-precipitated RPE-CM, prepared as described
in Example 5, was dialyzed against 10 mM sodium phosphate buffer,
pH 6.5, to remove ammonium sulfate. An 80 .mu.l sample of the
dialyzed ammonium sulfate-purified PEDF protein fraction was loaded
onto a Brownlee Aquapore CX-300 chromatography medium, packed into
a 4.6.times.30 mm column. The chromatography medium was previously
equilibrated with 10 mM phosphate, pH 7.2. The PEDF/chromatography
medium was washed with 10 mM sodium phosphate buffer, pH 7.2, until
all unbound proteins were washed from the chromatography medium.
PEDF was eluted from the chromatography medium with a linear salt
gradient from 0.0 to 0.5 M NaCl in 10 mM sodium phosphate buffer,
pH 7.2. PEDF eluted as a single peak with a NaCl concentration of
about 0.25 M.
[0169] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0170] The eluted PEDF was estimated to be about 70% pure.
EXAMPLE 8
Purification of PEDF by Reverse-Phase HPLC
[0171] Ammonium sulfate-precipitated RPE-CM, prepared as described
in Example 5, was dialyzed against 10 mM sodium phosphate buffer,
pH 6.5, to remove ammonium sulfate. An 80 .mu.l PEDF-containing
sample was then loaded onto a Vydac C8 chromatography medium,
packed into a 4.6.times.250 mm column. The chromatography medium
was previously equilibrated with 0.1 v/v TFA in water. The
PEDF/chromatography medium was washed with 0.1% v/v TFA in water
until all unbound proteins were washed from the chromatography
medium. PEDF was eluted from the chromatography medium with a
linear gradient from 0.0 to 95% v/v CH.sub.3CN, 0.1% v/v TFA in
water, and 5% v/v H.sub.2O.
[0172] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0173] The PEDF eluted from the column was estimated to be about
80% pure.
EXAMPLE 9
Purification of PEDF by Reverse-Phase HPLC
[0174] A PEDF-containing sample, partially purified as described in
Example 2, was then loaded onto a Vydac C8 chromatography medium,
packed into a 4.6.times.250 mm column. The chromatography medium
was previously equilibrated with 0.1% v/v TFA in water. The
PEDF/chromatography medium was washed with 0.1% v/v TFA in water
until all unbound proteins were washed from the chromatography
medium. PEDF was eluted from the chromatography medium with a
linear gradient from 0.0 to 95% v/v CH.sub.3CN in 0.1% v/v TFA and
5% v/v H.sub.2O.
[0175] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0176] The PEDF eluted from the column was estimated to be about
60% pure.
EXAMPLE 10
Purification of PEDF by Reverse-Phase HPLC
[0177] A PEDF-containing sample, partially purified as described in
Example 6, was then loaded onto a Vydac C8 chromatography medium,
packed into a 4.6.times.250 mm column. The chromatography medium
was previously equilibrated with 0.1% v/v TFA in water. The
PEDF/chromatography medium was washed with 0.1% v/v TFA in water
until all unbound proteins were washed from the chromatography
medium. PEDF was eluted from the chromatography medium with a
linear gradient from 0.0 to 95% v/v CH.sub.3CN in 0.1% v/v TFA and
5% v/v H.sub.2O.
[0178] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0179] The PEDF eluted from the column was estimated to be about
80% pure.
EXAMPLE 11
Purification of PEDF by Reverse-Phase HPLC
[0180] A PEDF-containing sample, prepared as described in Example
6, was loaded onto Brownlee RP-300 chromatography medium, packed
into a 4.6.times.250 mm column. The chromatography medium was
previously equilibrated with 0.1% v/v TFA in water. The
PEDF/chromatography medium was washed with 0.1% v/v TFA in water
until all unbound proteins were washed from the chromatography
medium. PEDF was eluted from the chromatography medium with a
linear gradient from 0.0 to 95% v/v CH.sub.3CN in 0.1% v/v TFA and
5% v/v H.sub.2O.
[0181] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0182] The PEDF eluted from the column was estimated to be about
90% pure.
EXAMPLE 12
Purification of PEDF by Size-Exclusion Chromatography
[0183] Partially-purified PEDF, prepared as described in Example 5
or 6, was purified further by chromatography on Bio-Rad TSK-250
chromatography medium, packed into a 7.5.times.300 mm column. A 40
.mu.l sample of resolubilized PEDF was loaded onto the
size-exclusion chromatography medium, which had been previously
equilibrated with 20 mM Tris, pH 7.0, 0.6 M NaCl. PEDF was eluted
with 20 mM Tris, pH 7.0, 0.6 M NaCl.
[0184] The eluted PEDF was dialyzed against 10 mM sodium phosphate
buffer, pH 7.2, lyophilized, and resolubilized in water. The sample
was then subjected to SDS-polyacrylamide gel electrophoresis, as
described in Example 3.
[0185] The PEDF eluted from the column was estimated to be about
75% pure.
EXAMPLE 13
Anion-Exchange Chromatography
[0186] DEAE cellulose is equilibrated with 10 mM Tris, pH 7.5.
PEDF, prepared as described in Example 5, is applied to the column,
and the column is washed with 10 mM Tris, pH 7.5, until all unbound
proteins are eluted from the column. After all the unbound proteins
are eluted, the PEDF is eluted with a linear gradient from 0 to 1 M
NaCl in 10 mM Tris-HCl, pH 7.5. The fractions containing PEDF are
collected and pooled. These fractions are then diafiltered against
10 mM Tris-HCl, pH 7.5 to remove NaCl.
EXAMPLE 14
Anion-Exchange Chromatography
[0187] DEAE cellulose is equilibrated with 10 mM Tris, pH 7.5.
PEDF, prepared as described in Example 2, is applied to the column,
and the column is washed with 10 mM Tris, pH 7.5, until all unbound
proteins are eluted from the column. After all the unbound proteins
are eluted, the PEDF is eluted with a linear gradient from 0 to 1 M
NaCl in 10 mM Tris-HCl, pH 7.5. The fractions containing PEDF are
collected and pooled. These fractions are then diafiltered against
10 mM Tris-HCl, pH 7.5 to remove NaCl.
EXAMPLE 15
Cation-Exchange Chromatography
[0188] Bio-Rex 70 resin (Bio-Rad) cellulose is equilibrated with 10
mM PBS, pH 7.2. PEDF, prepared as described in Example 2, is
applied to the column, and the column is washed with 10 mM PBS, pH
7.2, until all unbound proteins are eluted from the column. After
all the unbound proteins are eluted, the PEDF is eluted with a
linear gradient from 0 to 1 M NaCl in 10 mM PBS, pH 7.2. The
fractions containing PEDF are collected and pooled. These fractions
are then diafiltered against 10 mM Tris-HCl, pH 7.5 to remove
NaCl.
EXAMPLE 16
Cation-Exchange Chromatography
[0189] Bio-Rex 70 resin (Bio-Rad) cellulose is equilibrated with 10
mM PBS, pH 7.2. PEDF, prepared as described in Example 5, is
applied to the column, and the column is washed with 10 mM PBS, pH
7.2, until all unbound proteins are eluted from the column. After
all the unbound proteins are eluted, the PEDF is eluted with a
linear gradient from 0 to 1 M NaCl in 10 mM PBS, pH 7.2. The
fractions containing PEDF are collected and pooled. These fractions
are then diafiltered against 10 mM Tris-HCl, pH 7.5 to remove
NaCl.
EXAMPLE 17
Heparin Chromatography
[0190] Two ml of heparin agarose was packed into a 0.7.times.10 cm
column, washed with 20 ml of 10 mM Tris-HCl, pH 7.5, 3 M NaCl, then
equilibrated with 20 ml of 10 mM Tris-HCl, pH 7.5. Twelve ml of a
PEDF solution, prepared as described in Example 2, from a
17-year-old human donor, was-dialyzed against 4 l of 10 mM sodium
phosphate buffer, pH 7.5, at 4.degree. C. for 19 hours. The volume
after dialysis was 19 ml. The dialysate was applied to the heparin
agarose at a flow rate of 0.4 ml/minutes. After the PEDF solution
had been applied to the heparin agarose, the heparin agarose was
washed with 20 ml of 10 mM Tris-HCl, pH 7.5, to remove unbound
proteins from the heparin agarose. PEDF was then eluted from the
heparin agarose with 12 ml of 10 mM Tris-HCl, pH 7.5, 3 M NaCl.
[0191] The eluate containing PEDF was dialyzed against 10 mM
Tris-HCl, pH 7.5, to remove the NaCl present in the eluate. The
dialyzed eluate was then lyophilized, redissolved in 10 mM sodium
phosphate buffer, pH 7.5, and a sample was subjected to 12.5% w/v
SDS-polyacrylamide gel electrophoresis, as described in Example
3.
[0192] The PEDF eluate was estimated to be about 60% pure.
EXAMPLE 18
Heparin Chromatography
[0193] Two ml of heparin agarose was packed into a 0.7.times.10 cm
column, washed with 20 ml of 10 mM Tris-HCl, pH 7.5, 3 M NaCl, then
equilibrated with 20 ml of 10 mM Tris-HCl, pH 7.5. One ml of a PEDF
solution, prepared as described in Example 5, was dialyzed against
4 l of 10 mM sodium phosphate buffer, pH 7.5, at 4.degree. C. for
19 hours. The volume of the dialysate was 1.3 ml. The dialysate was
applied to the heparin agarose at a flow rate of 0.4 ml/minutes.
After the PEDF solution had been applied to the heparin agarose,
the heparin agarose was washed with 20 ml of 10 mM Tris-HCl, pH
7.5, to remove unbound proteins from the heparin agarose. The
heparin agarose was then successively eluted with 12 ml of 10 mM
Tris-HCl, pH 7.5, 0.5 M NaCl; 12 ml of 10 mM Tris-HCl, pH 7.5, 1 M
NaCl; 12 ml of 10 mM Tris-HCl, pH 7.5, 2 M NaCl; and 12 ml of 10 mM
Tris-HCl, pH 7.5, 3 M NaCl.
[0194] Each of the eluates was dialyzed against 10 mM Tris-HCl, pH
7.5, to remove the NaCl present in the eluate. The dialyzed eluates
were then lyophilized and redissolved in 10 mM sodium phosphate
buffer, pH 7.5, and a sample of each dialyzed eluate was subjected
to 12.5% w/v SDS-polyacrylamide gel electrophoresis, as described
in Example 3.
[0195] The PEDF eluate was estimated to be about 70% pure.
EXAMPLE 19
Neuronal Inductivity and Differentiation Activity of Isolated
PEDF
[0196] Electro-eluted PEDF was prepared as described in Example 3.
To characterize the neuronal inductive activity of the isolated
PEDF, the optimal concentration and pre-seeding stimulatory periods
were determined. Either 1, 2, 4, 6, 8, or 10 .mu.g/ml of
electro-eluted PEDF in serum-free DME, supplemented with 1 mM
sodium pyruvate, 0.625 mM HEPES, 6 mM L-glutamine, 1% w/v
non-essential amino acids, 5 .mu.g/ml insulin, 5 .mu.g/ml
transferrin, and 5 ng/ml selenous acid, was tested. As a control,
RPE-CM, diluted with an equal volume of non-conditioned medium (50%
RPE-CM), was also used.
[0197] The Y79 RB cells were grown in suspension culture. The cells
were harvested by centrifugation for 5 minutes at 900 rpm at room
temperature and resuspended in serum-free DME medium, which had
previously been warmed to 37.degree. C. The cells were collected by
centrifugation and resuspended at a concentration of 10.sup.6
cells/ml in serum-free DME medium. One, 2, 4, 6, 8, or 10 .mu.g/ml
electro-eluted PEDF or 50% RPE-CM was introduced into separate Y79
RB cell cultures. The cells were incubated for 7 days at 37.degree.
C., and were then attached to poly-D-lysine-coated flasks. The
cells were observed daily by phase-contrast microscopy.
[0198] The optimal pre-seeding period required for maximal
inductive activity of PEDF was assessed by treating Y79 RB cell
cultures with 2 .mu.g/ml of electro-eluted PEDF for 2, 4, 8, or 16
days prior to seeding onto a poly-D-lysine substratum. In addition,
1 or 2 .mu.g/ml of electro-eluted PEDF was added to attached
cultures of cells not previously stimulated in suspension
culture.
[0199] Greater than 80% of Y79 cell aggregates treated with 2
.mu.g/ml electro-eluted PEDF extended arborizing processes within
8-10 days after attachment to a poly-D-lysine substratum; untreated
cells showed only minimal signs of neuronal differentiation.
[0200] Y79 cells exhibited maximal differentiative response to
electro-eluted PEDF at a protein concentration of 2 .mu.g/ml; the
response was reduced at concentrations exceeding 4 .mu.g/ml. The
results are shown in Table II. TABLE-US-00002 TABLE II
Pre-Attachment Percent Stimulatory Differentiated PEDF (.mu.g/ml)
Period (days) Cells 0 7 13 .+-. 8.sup.1 1 7 82 .+-. 10 2 7 80 .+-.
10 4 7 33 .+-. 10 6 7 5 .+-. 5 8 7 0 10 7 0 1 .sup. 0.sup.2 20 .+-.
14 2 .sup. 0.sup.2 28 .+-. 11 1 .mu.g/ml BSA.sup.3 7 8 .+-. 6
(control) .sup.1Standard error .sup.2PEDF added to non-stimulated
attached cells, 24 hours post-seeding .sup.3bovine serum
albumin
[0201] A pre-seeding stimulatory period (in suspension culture) of
8 days, in the presence of this factor, results in maximal
differentiation of Y79 cells at day 10 post-attachment. Decreased
frequencies of differentiation (less than 50%) are noted with both
shorter and longer pre-seeding inductive periods. In addition,
cells not previously stimulated with PEDF prior to attachment,
exhibit a low frequency of neuronal differentiation (approximately
20%) if 1-2 .mu.g/ml electro-eluted protein is added
post-attachment. This response, however, is relatively slow, i.e.,
less than 15 days. Control BSA-treated cultures exhibit less than
10% differentiation, comparable to cells exposed only to
non-conditioned media.
[0202] PEDF induced a high degree of neuronal differentiation in
human retinoblastoma cells. Long ramifying neuritic processes were
induced to extend from aggregates of stimulated cells; concomitant
increases in the expression of the neuronal marker molecules,
neuron-specific enolase, and the 200,000 molecular weight
neurofilament protein were also observed. The expression of the
neuronal phenotype in Y79 cells appears to involve three sequential
events: 1) stimulation of cells in suspension culture by PEDF; 2)
attachment of stimulated cells to a substratum; followed by 3)
neurite outgrowth of attached, stimulated cells. Since only 20%
differentiation was observed when non-stimulated, attached cultures
were treated with PEDF, commitment to neuronal differentiation in
Y79 cells appears to precede cell attachment and neurite outgrowth
and may be initiated during the stimulatory period.
EXAMPLE 20
Comparison of the Effects of RPE-CM from Different Species
[0203] Cell cultures were established as described in Example 1,
except the eyes from which the cells were derived were either fetal
humans, adult humans, adult rats, fetal rats, or embryonic
chickens.
[0204] RPE-CM was prepared from each of the cell cultures, as
described in Example 2. Fetal human cell cultures which were newly
established (short-term cultures) and cultures which had been
established for 6 months (long-term cultures) were included.
[0205] The differentiation activity of the conditioned media was
performed as described in Example 19.
[0206] The results of experiments monitoring the effects of RPE-CM
from various species are summarized in Table III. TABLE-US-00003
TABLE III Source of RPE-Conditioned Medium Aggrregates %
Differentiated Human (fetal, short-term cultures) 88 .+-. 3* Human
(fetal, long-term cultures) 50 .+-. 8 Human (adult) 55 .+-. 9 Rat
(adult) 20 .+-. 11 Rat (fetal) 42 .+-. 7 Chicken (embryonic) 86
.+-. 7 *Standard error
[0207] The table summarizes the inductive activity of a variety of
RPE-conditioned media on Y79 cells. Indicated are the percentages
of 10 days attached aggregates (more than 5 cells/aggregate)
exhibiting neurite outgrowth after 7 days' stimulation with 50% v/v
RPE-CM from the various species. One hundred aggregates were
counted from each sample in replicates of three.
[0208] The greatest differentiative response in Y79 cells is
induced by human fetal RPE-CM (short-term cultures) and embryonic
chicken RPE-CM, both of which induce neuronal differentiation in
greater than 80% of cellular aggregates when used at a 50% v/v
concentration. In contrast, decreased frequencies (less than 50%)
of cellular differentiation are noted for conditioned media from
long-term (12-18 months) cultures of human fetal RPE and adult
human RPE. Only 40% neuron-like differentiation is induced by fetal
rat RPE-CM and 20% by adult rat RPE-CM.
[0209] Conditioned media from human fetal and embryonic chicken RPE
cells contain similar neurotrophic activity, while those from adult
cultures (chicken and rat) and long-term cultures of human fetal
RPE-CM are less effective in promoting the neuronal phenotype in
Y79 cells. It is possible that mature RPE cells no longer secrete
this neurotrophic factor, or they secrete reduced quantities which
are less effective in the culture conditions utilized. The fact
that some trophic activity is seen in RPE-conditioned media from
other species suggests that PEDF, or a similar factor, is also
secreted by RPE cells of other species and may be generally
important to normal retinal development and function.
EXAMPLE 21
Two-Dimensional Gel Electrophoresis
[0210] Two-dimensional gel analysis was conducted by the method
described by O=Farrell, J. Biol. Chem. 250 4007-4021 (1975) and
Jones, J. Exp. Med 14b 1251-1279 (1977). Silver-staining was
performed using a Bio-Rad silver-stain plus kit. Twenty .mu.g of
PEDF, purified by cation-exchange and size-exclusion HPLC, was
loaded onto the IEF tube gel.
[0211] Two-dimensional electrophoretic analysis of HPLC-purified
PEDF reveals the presence of four closely-grouped molecular
species. The four species vary slightly in apparent molecular
weight, but all are in the 50,000 molecular-weight region of the
gel, consistent with the previously identified molecular weight of
PEDF. The resolved species also vary slightly in isoelectric point,
suggesting slight variations in post-translational modifications.
Amino-acid sequence analysis (see Example 22), however, indicated
the presence of only a single polypeptide.
EXAMPLE 22
Isolation of PEDF Specific Peptides and Amino-Acid Sequences
[0212] One-hundred-and-eighty .mu.g of purified PEDF (purified as
described in Examples 2, 6, and 12) was concentrated using a
Centricon 10 microconcentrator, supplied by Amicon of Danvers,
Mass., and then diluted in 25 mM Tris, pH 8.5, 1 mM EDTA. To the
protein sample was added endoproteinase Lys-C. The PEDF/proteinase
mixture was incubated for about 18 hours at 30.degree. C. to digest
the PEDF.
[0213] The resulting PEDF polypeptide fragments were separated
using by HPLC on a Vydac C8 reverse-phase HPLC packed into a
4.6.times.250 mm column. The column was equilibrated with 0.1% v/v
TFA in water. The polypeptides were eluted with 90% v/v CH.sub.3CN,
0.1% v/v TFA in water.
[0214] Polypeptides eluted from the column which are well separated
from other polypeptides were collected and subjected to protein
sequencing analysis. The amino-acid sequence analysis was performed
under contract at the Microsequencing Facility of Beckman Research
Institute at the City of Hope.
[0215] The amino-acid sequences for the isolated polypeptides were
determined to be: TABLE-US-00004 PEDF-13 (SEQ ID NO:2, residues
226-244) Thr Ser Leu Glu Asp Phe Tyr Leu Asp Glu 5 10 Glu Arg Thr
Val Arg Val Pro Met Met 15 PEDF-14 (SEQ ID NO:2, residues 161-186)
Ser Tyr Gly Thr Arg Pro Arg Val Leu Thr 5 10 Gly Asn Pro Arg Leu
Asp Leu Gln Glu Ile 15 20 Asn Asn Trp Val Gln Ala 25
[0216] Sequencing of PEDF-13 yielded 19 residues of unequivocal
sequence. PEDF-14 yielded 26 residues, 25 of which were
unequivocal. The identification of residue 23 in PEDF-14 as
tryptophan was not absolutely certain.
EXAMPLE 23
Isolation of PEDF Specific Peptides and Amino Acid Sequence
[0217] PEDF, purified as described in Examples 2, 6, and 12, was
reduced and alkylated. The sample was dried, redissolved in 50
.mu.l of CRA buffer (8 M urea, 0.4 M ammonium bicarbonate, pH 8.0),
and 5 .mu.l of 45 mM DTT (Calbiochem) was added. After heating at
50.degree. C. for 15 minutes, the solution was cooled, and 5 .mu.l
of 100 mM iodoacetic acid (Sigma Chemical Co.) was added. After 15
minutes, the solution was diluted to a concentration of 2 M urea
and subjected to trypsin digestion, supplied by
Boehringer-Mannheim, using an enzyme:substrate ratio of 1:25
(wt/wt), for 22 hours at 37.degree. C.
[0218] Tryptic peptides were separated by narrow-bore reverse-phase
HPLC on a Hewlett-Packard 1090 HPLC, equipped with a 1040 diode
array detector, using a Vydac 2.1 mm.times.150 mm C18 column.
Buffer A was 0.06% v/v trifluoroacetic acid/H.sub.2O, and buffer B
was 0.055% v/v trifluoroacetic acid/acetonitrile, a gradient of 5%
v/v B at 0 minutes, 33% v/v B at 63 minutes, 60% v/v B at 95
minutes, and 80% v/v B at 105 minutes, with a flow rate of 150
.mu.l/minutes, was used. Chromatographic data at 210, 277 nm and UV
spectra from 209 to 321 nm of each peak were obtained.
[0219] Samples for amino terminal sequence analysis were applied to
a polybrene pre-cycled glass fibre filter and subjected to
automated Edman degradation at the Harvard Microchemical Facility
in Boston, Mass., on an ABI model 477A gas-phase protein sequencer
using program NORMAL 1. The resulting phenylthiohydantoin amino
acid fractions were manually identified using an on-line ABI Model
120A HPLC and Shimadzu CR4A integrator.
[0220] The sequences of the isolated peptides were determined to
be: TABLE-US-00005 (SEQ ID NO:2 residues 54-67) Leu Ala Ala Ala Val
Ser Asn Phe Gly Tyr 5 10 Asp Leu Tyr Arg (SEQ ID NO:2 residues
107-135) Ala Leu Tyr Tyr Asp Leu Ile Ser Ser Pro 5 10 Asp Ile His
Gly Thr Tyr Lys Glu Leu Leu 15 20 Asp Thr Val Thr Ala Pro Gln Lys
Asn 25 (SEQ ID NO:2 residues 307-316) Thr Val Gln Ala Val Leu Thr
Val Pro Lys 5 10 (SEQ ID NO:2 residues 317-327) Leu Lys Leu Ser Tyr
Glu Gly Glu Val Thr 5 10 Lys (SEQ ID NO:2 residues 360-389) Ala Gly
Phe Glu Trp Asn Glu Asp Gly Ala 5 10 Gly Thr Thr Pro Ser Pro Gly
Leu Gln Pro 15 20 Ala His Leu Thr Phe Pro Leu Asp Tyr His 25 30
EXAMPLE 24
Comparison of the PEDF Peptides to Rat Serine Proteinase
Sequences
[0221] PEDF-13 shows significant sequence homology with serpin
proteinase molecules. Homologous molecules include rat serine
protease inhibitors 1 and 2, a rat hepatocyte growth
hormone-regulated protein, a rat thyroid hormone-regulated protein,
and mouse contrapsin. Human, monkey, sheep, and mouse alpha-1
antitrypsin, and porcine alpha-1-antichymotrypsin, show significant
but somewhat less homology. PEDF-14 shows homology with different
protease inhibitors, but the degree of homology is less than that
observed for PEDF-13. These include human plasma protease C1
inhibitor and human alpha-2-antiplasmin inhibitor. These results
suggest that PEDF may function as a protease inhibitor, but that it
is molecularly distinct from such inhibitors which have been
described previously.
[0222] PEDF shows significant homology with serpins, the family of
serine protease inhibitors that share a common reactive center near
the C-terminal end, which serves as an exposed binding site that
acts as bait for target serine proteinases. It is of interest that
a number of known members of the serpin family have been shown to
have neurotrophic effects on a variety of neuronal cell types. For
example, glial-derived nexin (GDN) promotes neurite outgrowth in
neuroblastoma cells, as do a number of other protease inhibitors,
such as hirudin and leupeptin. Protease inhibitors also stimulate
neuronal differentiation in cells of dorsal root ganglia,
sympathetic neurons, and hippocampal pyramidal neurons. It is also
of interest that the production of proteinases and protease
inhibitors is stimulated by a number of known growth factors. While
it remains to be determined if PEDF has protease inhibitor
activity, it is likely, since inhibitory activity has been shown to
be necessary for the neurite-promoting activity of glial derived
nexin. It has been suggested that the formation of a stable
protease-GDN complex, and a consequent conformational change in GDN
and/or the associated protease, is necessary for the
neurite-promoting activity of GDN. PEDF may well function
similarly, as there are known proteinases present in the
interphotoreceptor matrix and in the developing neural retina.
EXAMPLE 25
Cloning of the PEDF cDNA
[0223] The following oligonucleotides were constructed: [0224]
5'-AGYAAYTTYT AYGAYCTSTA-3' determined in Example 22, and: [0225]
5'-CTYTCYTCRT CSAGRTARAA-3' determined in Example 23.
[0226] The oligonucleotides were prepared on an ABI 392 DNA/RNA
Synthesizer and used as primers in a polymerase chain reaction
(PCR). A human fetal eye Charon BS cDNA library, donated by Dr. A.
Swaroop, was amplified once by the method described by Sambrook et
al., 1989 In: Molecular Cloning: A Laboratory Manual 2nd ed. Cold
Spring Harbor Press, Cold Spring Harbor, N.Y. and screened by PCR
as described by Friedman et al. (Screening of .lamda.gt 11
libraries In: PCR Protocols: A Guide to Methods and Applications
Innis, Gelfand, Sninsky and White, eds., Academic Press, pp.
253-260, 1990) using a Techne thermal cycler and standard reagents
(GeneAMP, Perkin-Elmer/Cetus), except that MgSO.sub.4 was used at 3
mM.
[0227] The recovered fragment was isolated on a 3% w/v NuSieve 3:1
gel (FMC Biochemicals, Rockland Me.) using NA-45 DEAE-cellulose
paper (Schleicher and Schull) and labelled with .sup.32P-dCTP
(Amersham Corp., Arlington Heights, Ill.) by random priming (Random
Priming kit, Boehringer-Mannheim, Indianapolis, Ind.; Prime-It
Random Primer Labeling Kit, Stratagene).
[0228] This probe was used to screen 200,000 pfu's of the same
library. Positive clones were isolated as described by Sambrook et
al., 1989 In: Molecular Cloning: A Laboratory Manual 2nd ed. Cold
Spring Harbor Press, Cold Spring Harbor, N.Y., and the DNA was
purified with Qiagen Maxi preparation protocols (Qiagen).
[0229] The inserts were cut out with NotI (BRL, Gaithersburg, Md.)
circularized with T4 DNA ligase (New England Biolabs, Beverly,
Mass.), transformed into competent E. coli Epicurian Sure cells
(Stratagene), and plated out on 12.5 .mu.g/ml ampicillin/40
.mu.g/ml X-gal agar plates.
[0230] White colonies were selected and mini-prepped (Qiagen
plasmid mini-prep protocol). Purified plasmids were digested with
EcoRI/HindIII (BRL). These restriction sites were added during
library construction through the ligation of linkers to the 5' and
3' ends of the insert, thus EcoRI-HindIII digestion excises the
insert present in isolated plasmids. These fragments were
electrophoresed on a 0.7% w/v agarose gel to determine insert size.
The plasmid possessing the largest insert, namely .pi.FS17, was
selected for mapping and subsequent sequencing using the Sequenase
2.0 sequencing kit (United States Biochemical Corp., Cleveland,
Ohio) to confirm the identity of the clone. Sequence analysis was
performed using the MacVector software package (International
Biotechnologies, Inc.) and the GenBank.RTM. Sequence Data Bank
(Intelligenetics, Mountain View, Calif.).
EXAMPLE 26
cDNA Sequence Analysis of Human PEDF
[0231] One of the identified clones which contained an insert
corresponding to the PEDF gene was selected for mapping and
subsequent sequencing using a USB Sequenase 2.0 protocol and
reagents.
[0232] Sequence analysis of .pi.FS17 revealed a base sequence
comprising SEQ ID NO:1, with a long, open reading frame (ORF)
encoding the 418 amino acids of SEQ ID NO:2, a typical ATG start
codon, and a polyadenylation signal (not shown in SEQ ID NO:1). The
coding sequence of the clone aligns exactly with all previously
determined PEDF peptide sequences. The deduced amino acid sequence
also contains a stretch of hydrophobic amino acids that could serve
as a signal peptide. A comparison of the coding sequence and
peptide sequence with the GenBank.RTM. Data Bank indicates that
PEDF is a unique protein having significant homology to the serpin
(serine antiprotease) gene family, which includes human
[.alpha.]-1-antitrypsin. Although some of the members of this gene
family exhibit neurotrophic activity (Monard et al., Prog. Brain
Res. 58 359-364, 1983); Monard, TINS 11 541-544, 1988), PEDF lacks
homology to the proposed consensus sequence for the serpin reactive
domain.
EXAMPLE 27
cDNA Sequence Analysis of Mouse PEDF
[0233] An isolated cDNA incorporating the mouse cDNA was sequenced.
The sequence covering the first 376 amino acids is presented in SEQ
ID NO:7.
EXAMPLE 28
cDNA Sequence Analysis of Bovine PEDF
[0234] An isolated cDNA incorporating the bovine cDNA was
sequenced. The sequence is presented in SEQ ID NO:8.
EXAMPLE 29
Construction of an Expression Vector for the Production of
Recombinant PEDF-BH
[0235] An expression vector was constructed using the plasmid
.pi.FS17, which contains the full-length cDNA for human PEDF as
described in Example 25. The PEDF coding sequence was placed under
the control of a bacteriophage .lamda. P.sub.L promoter present in
the plasmid pEV-vrf2 (Crowl et al., Gene 38 31-38, 1985) to obtain
the vector pEV-BH. This was accomplished by obtaining a
BamHI-HindIII fragment of .pi.FS17 comprising a portion of the PEDF
coding region (namely, nucleotides 245 to 1490 of SEQ ID NO:1),
digesting plasmid pEV-vrf2 with EcoRI-HindIII, rendering both
fragments blunt by means of a fill-in reaction at the BamHI and
EcoRI ends with DNA polymerase I (Klenow fragment), and ligating
the resultant blunt-ended/compatible-ended fragments to each other.
The resultant vector pEV-BH places a distance of 8 nucleotides
between the Shine-Dalgarno (SD) sequence and the PEDF coding
region. The construct specifies Met-Asn-Arg-Ile-Asp.sup.44 - - -
Pro.sup.418 such that a protein of 379 amino acids, known as
PEDF-BH, is encoded as indicated in SEQ ID NO:3. The amino acids at
the amino terminus of the PEDF-BH protein do not occur in native
PEDF and result from the fusion of nucleic acids during the
construction of pEV-BH.
[0236] To verify production of the recombinant PEDF-BH protein by
pEV-BH, the plasmid was propagated in E. coli strain RRI (Maniatis
et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y., 1982), bearing the low
copy-number compatible plasmid pRK248cIts that contains a gene for
encoding a temperature-sensitive .lamda.cIAt2 repressor (Bernard et
al., Methods in Enzymology 68 482-492, 1979). Protein induction was
performed as described in Becerra et al., Biochem. 30 11707-11719
(1991), with the following modifications. Bacterial cells
containing pEV-BH were grown in LB medium containing 50 .mu.g/ml
ampicillin at 32.degree. C. to early logarithmic phase, such that
OD.sub.600 nm=0.2. The temperature of the culture was rapidly
increased to 42.degree. C. by incubating the flask in a 65.degree.
C. water bath, and the bacteria were subsequently grown at
42.degree. C. for 2-3 hours in an air-flow incubator at 340 rpm.
Aliquots were taken for absorbance readings at 600 nm.
[0237] Nascent proteins, synthesized following protein induction,
were radiolabeled. After the temperature of the culture had reached
42.degree. C., 150 .mu.Ci of L-[.sup.35S]methionine (1040 Ci/mmol,
Amersham Corp., Arlington Heights, Ill.) were added per ml of
culture, and incubation was continued at 42.degree. C. for 10
minutes and 30 minutes. Cells were harvested by centrifugation and
washed with TEN buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 100
mM NaCl). .sup.35S-labeled peptides from total bacterial extracts
were resolved and analyzed on SDS-12% w/v PAGE followed by
fluorography. A band corresponding to a 42,820 M.sub.T polypeptide
was detected 10 and 30 minutes post-induction. The size obtained
for the recombinant protein expressed by pEV-BH matched the
expected size for the coding sequence subcloned in pEV-BH.
EXAMPLE 30
Construction of Expression Vectors Containing the Full-Length PEDF
cDNA.
[0238] In a manner similar to that described in Example 27 for the
construction of pEV-BH, the PEDF ORF of plasmid .pi.FS17 was placed
under the control of the bacteriophage .lamda. P.sub.L promoter
present in the plasmids pRC23 and pEV-vrf1 (Crowl et al., Gene 38
31-38, 1985). This was accomplished by obtaining the SfaNI-HindIII
fragment of .pi.FS17 comprising a portion of the PEDF cDNA (namely,
nucleotides 107 to 1490 of SEQ ID NO:1), digesting the plasmids
with EcoRI-HindIII, rendering the fragments blunt by means of a
fill-in reaction at the SfaNI and EcoRI ends with DNA polymerase I
(Klenow fragment), and ligating the resultant
blunt-ended/compatible-ended fragments to each other. The resulting
vectors PRC-SH and pEV-SH place a distance of 14 and 8 nucleotides,
respectively, between the SD sequence and the PEDF coding region.
The construct pRC-SH encompasses the full-length PEDF ORF, and
specifies a PEDF protein of 418 amino acids, with its naturally
occurring amino terminus, as set forth in SEQ ID NO:2. The
construct pEV-SH encompasses the full-length PEDF ORF, and
specifies a PEDF amino-terminal fusion protein of 425 amino acids,
with Met-Asn-Glu-Leu-Gly-Pro-Arg (SEQ ID NO:4) preceding the PEDF
sequence of SEQ ID NO:2. These additional amino acids at the amino
terminus do not occur in native PEDF, and the codons in pEV-SH
specifying these additional amino acids result from the fusion of
nucleic acids during the construction of pEV-SH.
[0239] To verify production of the recombinant proteins specified
by the two vectors, the vectors were introduced into E. coli strain
RRI [pRK248cIts], and protein induction was performed and monitored
by metabolic labeling with .sup.35S-methionine during induction in
a manner similar to that set forth in Example 27. The induced
expression of the proteins specified by pRC-SH and pEV-SH had a
negative effect on bacterial cell growth. In comparison with
bacterial cultures containing the parental plasmids, cultures
containing pRC-SH and pEV-SH grew and divided more slowly. This
negative effect on bacterial growth correlated with the distance
between the initiation codon and the SD, which may suggest that a
shorter such distance results in more efficient translation of the
recombinant protein. A 46,000 M.sub.T candidate polypeptide for
PEDF was not detected in the media or cell lysates of bacterial
cultures containing pRC-SH and pEV-SH. However, a 35,000 M.sub.T
protein was observed in extracts of cultures containing PRC-SH and
pEV-SH, but not in extracts of cultures containing parental
plasmids. This may indicate that the amino-terminal end of PEDF is
protease-sensitive and that recombinant full-length PEDF is
metabolized in this particular host. Alternatively, failure to
observe the anticipated-sized recombinant PEDF proteins may reflect
an experimental artifact which could be overcome through the use of
alternative expression vectors, hosts, inducible promoters,
subcloning sites, methods of recombinant protein isolation or
detection, or means of protein induction.
EXAMPLE 31
Method for Producing Large Quantities of Recombinantly Produced
PEDF-BH.
[0240] A total of 1 g of E. coli cells containing PEDF-BH was
resuspended in 50 ml 20 mM Tris-HCl, pH 7.5, 20% w/v sucrose, and 1
mM EDTA. The cells were maintained on ice for 10 minutes,
sedimented by centrifugation at 4,000.times.g, and were resuspended
in 50 ml of ice-cold water for 10 minutes. Lysed outer cell walls
were separated from spheroplasts by centrifugation at
8,000.times.g.
[0241] The pelleted spheroplasts were resuspended in 10 ml of
phosphate buffered saline (PBS) containing 5 mM EDTA, 1 .mu.g/ml
pepstatin and 20 .mu.g/ml aprotinin. The suspension was
probe-sonicated with a sonicator (Ultrasonics, Inc., model W-225)
to lyse the cell membranes. Three bursts at 30 second pulses with a
30 second pause were performed while the sample was immersed in an
ice-water bath. RNase TI (1,300 units, BRL) and DNase I (500 .mu.g,
BRL) were added to the sonicated cell suspension, and the
suspension was incubated at room temperature for 10 minutes. This
suspension was diluted by the addition of 40 ml of phosphate
buffered saline (PBS) containing 5 mM EDTA, 1 .mu.g/ml pepstatin
and 20 .mu.g/ml aprotinin, and the crude inclusion bodies were
sedimented by centrifugation at 13,000.times.g for 30 minutes. The
particulate material consisting of inclusion bodies was resuspended
in 40 ml of PBS containing 25% w/v sucrose, 5 mM EDTA, and 1% v/v
Triton X-100, incubated on ice for 10 minutes, and centrifuged at
24,000.times.g for 10 minutes. The washing step was repeated three
times. Finally, the inclusion bodies were resuspended in 10 ml of
denaturation buffer containing 50 mM Tris-HCl, pH 8.0, 5 M
guanidine-HCl, and 5 mM EDTA. The suspension was probe-sonicated
briefly for 5 seconds in an ice-water bath. The resulting
suspension was incubated on ice for an additional hour. After
centrifugation at 12,000.times.g for 30 minutes, the supernatant
was added to 100 ml of renaturation buffer containing 50 mM
Tris-HCl, pH 8.0, 20% v/v glycerol, 1 mM DTT, 1 .mu.g/ml pepstatin,
and 20 .mu.g/ml aprotinin, and stirred gently at 4.degree. C.
overnight to renature the protein. The soluble and insoluble
fractions were separated by centrifugation at 13,500.times.g for 30
minutes.
[0242] The soluble fraction was further purified by concentrating
it to 1 ml using a Centricon 30 microconcentrator (Amicon Div., W.
R. Grace & Co., Beverly, Mass.), and dialyzing it against
Buffer A (50 mM sodium phosphate, 1 mM DTT, 20% v/v glycerol, 1 mM
EDTA, 1 .mu.g/ml pepstatin, and 1 mM benzamidine) at 4.degree. C.
for 3 hours. The dialyzed extract was centrifuged at 14,000 rpm in
an Eppendorf Centrifuge (Model 5415C) for ten minutes. The
supernatant fraction was layered on a S-Sepharose fast-flow
(Pharmacia, New Market, N.J.) medium packed into a column with a 1
ml bed volume and pre-equilibrated with buffer A. The medium was
washed with two column-volumes of buffer A. Finally, recombinant
PEDF-BH was eluted with a step gradient of 50, 100, 150, 200, 300,
400, 500, and 1,000 mM NaCl in buffer A. Fractions of 1 ml were
collected by gravity flow, and were dialyzed against buffer A. The
300 mM NaCl fraction, containing recombinant PEDF-BH, was stored at
-20.degree. C. The recovery in fraction 300 was 50 .mu.g per gram
of packed cells, which represents 25% of the total protein.
[0243] Most of the PEDF-BH was recovered from the insoluble
fraction by dissolving the fraction in 10 ml of 6M guanidinium-HCl
in buffer B (50 mM Tris-HCl, pH 8.0, 1 mM DTT, 2 mM EDTA). The
solution was centrifuged at 10,000.times.g for 5 minutes. The
supernatant was layered onto a SUPEROSE-12 (Pharmacia, New Market,
N.J.) medium packed into a column attached in tandem to a second
SUPEROSE-12 medium containing column (each column 2.6 cm.times.95
cm) pre-equilibrated with buffer containing 4 M guanidinium-HCl in
buffer B. The flow rate was 3 ml/minute. Recombinant PEDF-BH
containing fractions from the SUPEROSE-12 column were pooled and
dialyzed against buffer C (4 M urea, 50 mM sodium phosphate, pH
6.5, 1 mM benzamidine, 1 .mu.g/ml pepstatin, 4 mM EDTA). The
dialyzed fraction was passed through a 0.22 .mu.m filter
(Miller-GV, Millipore Corp., Bedford, Mass.). The filtered solution
was layered onto a MONO-S (Pharmacia, New Market, N.J.) medium
packed into a column (1 cm.times.10 cm, d.times.h) and
pre-equilibrated with buffer C. The medium was washed with buffer
C, and recombinant PEDF-BH was eluted with a gradient of 0-500 mM
NaCl in buffer C at 0.5 ml/minutes. Two-ml fractions were
collected, and the peak fractions of recombinant PEDF-BH were
pooled. The recovery in the pooled fractions was 0.5 mg of
recombinant PEDF-BH per gram of packed cells.
EXAMPLE 32
Use of Purified Recombinant PEDF-BH as a Differentiation Agent
[0244] Y79 cells (ATCC, HTB18) were grown in Eagle's Minimal
Essential Medium with Earl's salts (MEM) supplemented with 15% v/v
fetal bovine serum and antibiotics (10,000 u/ml penicillin and 10
mg/ml streptomycin) at 37.degree. C. in a humidified incubator
under 5% v/v CO.sub.2. Cells were propagated for two passages after
receipt from the ATCC, and then frozen in the same medium
containing 10% v/v DMSO. A few of the frozen aliquots were used for
each differentiation experiment. All experiments were performed in
duplicate.
[0245] After thawing, the cells were kept, without further
passaging, in the serum-containing medium until the appropriate
number of cells were available. Cells were collected by
centrifugation and washed twofold in PBS, resuspended in PBS, and
counted. At that point, 2.5.times.10.sup.5 cells were plated into
each well of a 6-well plate (Nunc, Inc., Roskilde, Denmark) with 2
ml of serum-free medium (MEM, supplemented with 1 mM sodium
pyruvate, 10 mM HEPES, 1.times.non-essential amino acids, 1 mM
L-glutamine, 0.1% v/v ITS mix (5 .mu.g/ml insulin, 5 .mu.g/ml
transferrin, 5 .mu.ng/ml selenium, Collaborative Research, Bedford,
Mass.), and antibiotics as described above.
[0246] Differentiation effectors and control buffers were added
12-16 hours after plating, and the cultures were incubated and left
undisturbed for 7 days. On the eighth day, cells were transferred
to poly-D-lysine-coated six-well plates (Collaborative Research,
Bedford, Mass.), and the old medium was replaced with 2 ml of fresh
serum-free medium, upon attachment of the cells to the substrate.
The cultures were maintained under these conditions for up to 11
days. Post-attachment cultures were examined daily for
morphological evidence of differentiation as well as quantification
of neurite outgrowth using an Olympus CK2 phase-contrast
microscope.
[0247] In comparison with untreated cells, only Y79 cultures that
were exposed to recombinant PEDF-BH showed any significant evidence
of neuronal differentiation. Some neurite outgrowth (below 10%) was
detectable in control cultures treated with the same buffer used to
solubilize PEDF-BH, and no evidence of differentiation was found in
cultures processed in the same manner without the addition of
PEDF-BH or buffer. Phase contrast microscopy of PEDF-BH treated
cultures showed that between 50-65% of the cell aggregates had
neurite extensions by day 3 post-attachment on poly-D-lysine. These
3-day neurite extensions appeared as short projections from
pear-shaped cells at the edges of the cell aggregates. The number
of differentiating aggregates, the number of differentiating cells
per aggregate, and the length of the neurite-like processes
increased with post-attachment time. By day 5 post-attachment,
about 75-85% of the aggregates showed signs of differentiation with
neurites extending from most of their peripheral cells.
PEDF-BH-treated cultures reached the maximum extent of
differentiation on day 7 post-attachment, when 85-95% of the cells
aggregate. At that time, two types of neuronal processes were
observed, i.e., single neurites 2-3 fold longer than those observed
on day 3 extending from peripheral cells of isolated aggregates,
and much longer and thinner processes forming a branching network
between neighbor cell aggregates. Upon extended incubation, i.e.,
beyond 10 days post-attachment, there was a marked decrease in the
proportion of the network connections, and no further growth of the
single neurites, although the viability of the cell aggregates was
not severely affected, and remained at about 75-80% in different
experiments.
[0248] The PEDF and PEDF-BH cDNA clones not only provide means to
produce large quantities of the PEDF and PEDF-BH proteins but also
serve as sources for probes that can be used to study the
expression and regulation of the PEDF gene. In addition, these
sequences can be used in the antisense technique of translation
arrest to inhibit the translation of endogenous PEDF.
[0249] The recombinantly produced PEDF and PEDF-BH proteins and
equivalent proteins can be used as potent neurotrophic agents in
vitro and in vivo. Additional biochemical activities of these
proteins as neurotrophic agents can be determined through standard
in vitro tests, which will enable the development of other
therapeutic uses for these proteins in the treatment of
inflammatory, vascular, degenerative and dystrophic diseases of the
retina. Given that these proteins are such potent neurotrophic
agents, it can be envisioned that these proteins could be modified
for therapeutic utility in the treatment of tissues other than the
retina, which also respond to neurotrophic factors. These proteins
may even find more generic utility as "differentiation" factors for
non-neural tissues and certain types of cancer.
EXAMPLE 33
Treatment of Retinal Tumors
[0250] PEDF is administered, alone or in conjunction with clinical
(such as surgical) procedures. PEDF is administered by intravitreal
or subretinal injection. The PEDF may be administered alone or in
conjunction with compounds such as poly(lactic acid) which
facilitate a slow, "time release" of the PEDF. Typically, 0.01 to
10 .mu.g of PEDF at a concentration of 1 to 100 .mu.g/ml in a
physiologic saline solution or other buffered solution is
administered per dose, and 0 to 10 doses are administered per day.
When time-release compounds are included in the composition, they
are used at a concentration of 1 to 100 .mu.g/ml. Treatment is
continued until tumor progression is halted or reversed.
[0251] Treatment with PEDF is effective for retinal tumors such as
retinoblastoma, other neuronal tumors such as neuroblastoma, or
tumors of non-neuronal origin. The treatment results in a cessation
or reduction in the rate of cell division and a concomitant
reduction in the rate of tumor growth, which in turn results in
tumor regression.
EXAMPLE 34
Neurotrophic Treatment of Ocular Disease
[0252] PEDF is administered, alone or in conjunction with clinical
(such as surgical) procedures. PEDF is administered by intravitreal
or subretinal injection. The PEDF may be administered alone or in
conjunction with compounds such as poly(lactic acid) which
facilitate a slow, "time release" of the PEDF. Typically, 0.01 to
10 .mu.g of PEDF at a concentration of 1 to 100 .mu.g/ml in a
physiologic saline solution or other buffered solution is
administered per dose, and 0 to 10 doses are administered per day.
When time-release compounds are included in the composition, they
are used at a concentration of 1 to 100 .mu.g/ml. Treatment is
continued until the pathology is halted or reversed.
[0253] Treatment with PEDF is directed at diseases of the neural
retina, retinal pigmented epithelium, and other ocular tissue.
Treatment results in enhanced survival and well-being of the
photoreceptors and other ocular cells, prolonging their functional
life span and delaying the onset of impaired vision and ultimate
blindness.
EXAMPLE 35
Neurotrophic Treatment of Injured Nerves
[0254] PEDF is administered, alone or in conjunction with clinical
(such as surgical) procedures. PEDF is administered by intravitreal
or subretinal injection. The PEDF may be administered alone or in
conjunction with compounds such as poly(lactic acid) which
facilitate a slow, "time release" of the PEDF. Typically, 0.01 to
10 .mu.g of PEDF at a concentration of 1 to 100 .mu.g/ml in a
physiologic saline solution or other buffered solution is
administered per dose, and 0 to 10 doses are administered per day.
When time-release compounds are included in the composition, they
are used at a concentration of 1 to 100 .mu.g/ml. Treatment is
continued until nerve regeneration is completed.
[0255] Treatment with PEDF is directed at injuries to nerves.
Treatment results in promotion of neurite outgrowth and nerve
regeneration.
EXAMPLE 36
Transfection of Bacterial Cells
[0256] Competent E. coli Sure cells are mixed with the ligation
mixture and incubated on ice for 60 minutes. The mixture is then
incubated at 42.degree. C. for 2 minutes, then 800 .mu.l of 2% w/v
BACTO Tryptone, 2% w/v BACTO Yeast Extract (both supplied by DIFCO
LABORATORIES), 10 mM NaCl, 10 mM MgSO.sub.4, 20 mM glucose are
added and the mixture incubated at 37.degree. C. for 60 minutes.
Fifty to 500 .mu.l of the DNA mixtures are then spread on selection
plates containing 12.5 .mu.g/ml ampicillin.
[0257] The recombinant colonies are screened by miniprepping and
digestion of the isolated DNA. Positive colonies containing the
appropriate inserts are then prepared by growing the appropriate
colony in 200 ml of Luria Broth plus 12.5 .mu.g/ml ampicillin with
shaking at 37.degree. C. overnight. After the overnight incubation,
the cultures are transferred to centrifuge bottles and centrifuged
at 2500 rpm for 10 minutes. The supernatant is removed and the
cells are resuspended in 30 ml of STET buffer (0.23 M sucrose, 5%
v/v Triton-X-100, 20 mM EDTA, 50 nM Tris-HCl, pH 8) at room
temperature. Five .mu.l of 10 mg/ml lysozyme is added and the
mixture is swirled and incubated for 5 minutes at room temperature.
Each flask is then gently swirled directly over a flame until the
cells begin to coagulate and turn white. The mixture is then
transferred to a boiling-water bath for about 45 seconds. The
solution is then cooled in an ice-water bath for 2 minutes, and the
mixture is transferred to centrifuge tubes and centrifuged for 15
minutes at 16,000 rpm.
[0258] The supernatant is then transferred to a clean container.
Two volumes of 100% ethanol are added, mixed, and the DNA
precipitated at -70.degree. C. for 20 minutes. The precipitate is
collected by centrifugation at 2,500 g for 15 minutes. The ethanol
supernatant is removed, and the pellet is washed with 10 ml of cold
(-20.degree. C.) 90% v/v ethanol. Two-and-one-half ml of extraction
buffer (0.2 M Tris, pH 7.5, 0.08 M EDTA, and 0.2 M KCl) is added to
the pellet, and it is resuspended, at 4.degree. C. 100 .mu.l of 10
mg/ml RNAse, dissolved in 0.1.times.TE (1 mM Tris-HCl, 0.1 mM EDTA,
pH 7.6) and pretreated by boiling for 10 minutes.
EXAMPLE 37
Insect Cell Cultures
[0259] Sf9 cells are seeded into spinner flasks, containing Grace's
Antheraea medium supplied by GIBCO of Grand Island, N.Y., to an
initial density of 1.times.10.sup.6 cells/ml and incubated at
27.degree. C. with constant stirring at 50 rpm. The cells are
subcultured when they reach a density of 2.5.times.10.sup.6
cells/ml, approximately 2 to 3 times a week, and are diluted 1 in
5.
EXAMPLE 38
Cloning Genes into pAC373
[0260] Two .mu.l of pAC373 are combined with 25 .mu.l of
10.times.BamHI restriction enzyme buffer, 20 units of BamHI and
sterile distilled water to bring the volume to 250 .mu.l, and
incubated at 37.degree. for at least 3 hours. After the plasmid is
digested. It is dephosphorylated by adding one unit of calf
intestinal alkaline phosphatase (CAP)/.mu.g of DNA and incubated
for 30 minutes at 37.degree. C. The CAP is then inactivated by
adding EDTA to 25 mM and SDS to 0.5% w/v and incubated at
65.degree. C. for 15 minutes. The solution is then extracted with
an equal volume of phenol/chloroform/ isoamyl alcohol
(25:24:1).
[0261] The aqueous phase is collected, and 125 .mu.l of 7.5 M
ammonium acetate and 800 .mu.l of 95% v/v ethanol are added and
mixed. The DNA is precipitated at -70.degree. C. for 10 minutes.
The precipitate is then collected by centrifugation by
centrifugation at 12,000 rpm for 10 minutes. The pellet is rinsed
with (-20.degree. C.) 90% v/v ethanol. The ethanol is then removed
and the DNA is resuspended in 50 .mu.l of 10 mM Tris-HCl, 1 mM
EDTA, pH 7.6 (1.times.TE).
EXAMPLE 39
Ligation of PEDF to pAC373
[0262] A purified DNA fragment containing the PEDF gene is ligated
to the transfer vector. Two-hundred ng of digested pAC373 are mixed
with an equal molar concentration of PEDF containing fragment.
Ligation buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl.sub.2, 10 mM
dithiothreitol, 0.5 mM spermidine, 2 mM ATP, 2.5 mM hexamine cobalt
chloride and 20 .mu.g/ml BSA) and 10 units of T4 DNA ligase is
added. Water is added to a total volume of 10 .mu.l. The mixture is
incubated at 14.degree. C. for 3 hours.
EXAMPLE 40
Transferring Genes into the AcMNPV Genome
[0263] Sf9 cells are seeded into 25 cm flasks at a density of
2.0.times.10.sup.6 cells/flask in Grace's Antheraea medium. The
cells are allowed to attach for at least one hour. One .mu.g of
MNPV DNA is added to 2 .mu.g of plasmid DNA, which contains the
PEDF gene. The medium is removed from the flask and replaced with
0.75 ml of Grace's medium plus 10% v/v fetal bovine serum and
antibiotics (50 .mu.g/ml gentamicin sulfate, 2.5 .mu.g/ml
amphotericin). 7.5 ml of transfection buffer (25 mM HEPES, pH 7.1,
140 mM NaCl, 125 mM CaCl.sub.2) is added to the DNA solution and
mixed. The DNA solution is added to the Grace's medium, already in
the cell culture flasks.
[0264] Calcium phosphate precipitates form due to the calcium
chloride in the transfection buffer and the phosphate in the
medium. The flasks are incubated at 27.degree. C. for 4 hours,
after which time the medium is removed from the flasks, and the
cells are rinsed with fresh TNM-FH (Grace's medium plus 3.3 g/l
YEASTOLATE and 3.3 g/l Lactalbumin hydrolysate, both from DIFCO
LABORATORIES) plus 10% v/v fetal bovine serum and antibiotics, as
described previously, and 5 ml of TNM-FH plus 10% v/v fetal bovine
and antibiotics, as described previously, is added to the cells.
The cells are incubated for 4-6 days. When the infection is at an
advanced stage, the virus is plated on fresh monolayers, and the
recombinant viruses are plaque-purified.
EXAMPLE 41
Identification of Recombinant Proteins
[0265] Plaque-purified virus is screened by radiolabelling. The
recombinant proteins are identified on SDS-PAGE gels. Sf9 cells are
seeded at 6.times.10.sup.5 cells/well in a 24-well culture plate.
The cells are allowed to attach for an hour. The medium is then
removed and overlaid with medium containing the viral stock and
incubated for 1 hour at 27.degree. C., after which time the viral
inoculum is removed and replaced with 500 .mu.l of complete medium.
The cells are incubated for 48 hours at 27.degree. C. At the end of
this incubation, the medium is removed. 200 .mu.l of
methionine-free Grace's medium is added to the cells, and the cells
are incubated for 60 minutes, after which time the medium is
replaced with 200 .mu.l of fresh methionine-free Grace's medium to
which 10 .mu.Ci of .sup.35S-methionine is added. Cells are
incubated at 27.degree. C. for 6 hours and then harvested by
centrifugation. The supernatant is collected, and the cells are
resuspended in 62.5 mM Tris, pH 6.8, 2% w/v SDS, 10% v/v glycerol,
0.001% w/v bromophenol blue, and 0.1 M 2-mercaptoethanol. An equal
volume of 126 mM Tris, pH 6.8, 4% w/v SDS, 20% v/v glycerol, 0.002%
w/v bromophenol blue, and 0.2 M 2-mercaptoethanol is added to the
supernatant. Samples are then boiled for 3 minutes and then they
are subjected to electrophoresis and autoradiography of the gel to
identify proteins secreted into the medium and proteins that are
not secreted. Controls of uninfected cells and cells infected with
wild-type virus are included.
EXAMPLE 42
Chromosomal Localization of the PEDF Gene: Southern
Hybridization
[0266] Human-hamster somatic cell hybrid DNAs were used to identify
the chromosomal location of the PEDF gene. Twenty-five hybrids were
characterized by karyotype analysis by the method described by
Carlock et al. (Somatic Cell Mol. Genet. 12 163-174, 1986), and the
chromosome content of current passages of each cell line was
determined by Giemsa banding analysis of 20 metaphases. DNA samples
were subjected to restriction fragment length analysis using a
number of restriction enzymes to establish a polymorphism within
the PEDF gene. RsaI was found to be suitable for such use. DNA
samples were digested with RsaI, and 8 .mu.g of each digested DNA
sample was fractionated by electrophoresis in a 1% w/v agarose gel
and transferred onto neutral nylon membranes (BIODYNE A sold by
Pall Corp.).
[0267] Two 20-mer PCR primers were synthesized from the middle of
the translated region of the PEDF cDNA sequence. The primer pair:
[0268] 5'-CTGGGAGCGG ACGAGCGAAC-3' located at SEQ ID NO:1 396-415
(primer 353) and [0269] 5'-TGGGGACAGT GAGGACCGCC-3' located on the
antisense strand of SEQ ID NO:1 at 1043-1062 (primer 354),
amplifies a 667 bp product from the PEDF cDNA. PCR amplification
was carried out for 30 cycles (each cycle: 94.degree. C., 1 minute;
55.degree. C., 1 minute; and 72.degree. C., 1 minute) by methods
well known to those skilled in the art. Fifty nanograms of the
amplified product was labeled by random priming using a random
PRIME-IT kit purchased from Stratagene. Unincorporated nucleotides
were removed using Stratagene's Cloning Systems NUCTRAP PUSH
columns. The nylon filters were prehybridized for 30 minute at
65.degree. C. in QUIKHYB solution (Stratagene) followed by
hybridization for 1 hour at 65.degree. C. in the same solution
supplemented with 1.times.10.sup.6 cpm/ml radiolabeled PEDF probe,
by methods well known to those skilled in the art.
Posthybridization washes were performed for 30 minutes at
25.degree. C. using 300 mM NaCl, 35 mM sodium citrate, pH 7.0, 0.1%
w/v SDS (2.times.SSC/0.1% SDS) and 30 minute at 65.degree. C. in
2.times.SSC/0.1% SDS. Filters were exposed to Hyperfilm-MP
(Amersham, Ill.) with an intensifying screen.
[0270] Somatic cell hybrid DNAs were scored on Southern blots for
the presence or absence of human-specific hybridization with the
PEDF 667 bp PCR fragment. The PEDF cDNA probe identifies 6.5, 6.0,
5.0, and 4.8 kb human restriction fragments, as can be seen in the
human genomic DNA control lanes in each blot. Of the 25 somatic
cell hybrids examined, only 2 contained a PEDF-specific band of an
approximate 5.0 kb molecular size. These hybrids are the only ones
which contain human chromosome 17. A positive correlation therefore
is observed between the presence of this band and human chromosome
17.
EXAMPLE 43
Chromosomal Localization of the PEDF Gene: PCR Assay
[0271] DNAs from human-rodent somatic cell hybrid panels (1 and 2)
were purchased from the NIGMS Human Genetic Mutant Cell Repository
at the Coriell Institute for Medical Research (Camden, N.J.). PCR
and chromosomal localization studies (Sambrook et al., 1989 In:
Molecular Cloning: A Laboratory Manual 2nd ed. Cold Spring Harbor
Press, Cold Spring Harbor, N.Y.) were performed using primers 3 and
4 and hybrid DNAs from NIGMS panel 1. Primers 3 and 4 were designed
from the 3' translated region of the PEDF cDNA using OLIGO primer
analysis software (National Biosciences, Plymouth, Minn.). Primer 1
sequence: [0272] 5'-CACCTTAACC AGCCTTTATT C-3' is located in SEQ ID
NO:1 at 1281-1304 and primer 2 sequence: [0273] 5'-AACCTTACAG
GGGCAGCCTT CG-3' and is located on the antisense strand in SEQ ID
NO:1 at 1438-1459, amplified a 179-bp product from the PEDF cDNA
and human genomic DNA. The PCR reaction contained 10 mM Tris-HCl,
pH 8.3, 50 mM KCl, 80 .mu.M of each dNTP, 1 mM MgCl.sub.2, 200 ng
of each primer, 100 ng of genomic DNA, and 1.25 units of AMPLITAQ
(Perkin Elmer Cetus). Amplification was carried out for 40 cycles
(each cycle consisting of 94.degree. C., 1 minute; 57.degree. C., 1
minute; and 72.degree. C. for 2 minute).
[0274] For panel 2, two additional 24-mer PCR primers from the
3'-untranslated region of the PEDF cDNA were designed. Partial
purification and desalting of this primer pair were accomplished by
passing the oligonucleotide through SEPHADEX G-25 (Pharmacia,
Upsala Sweden) packed into a column. Primer 498: [0275]
5'-TATCCCAGTT TAATATTCCA ATAC-3' is located at SEQ ID NO:1 at
1374-1397 and primer 499: [0276] 5'-TTGTATGCAT TGAAACCTTA CAGG-3'
is located on the antisense strand of SEQ ID NO:1 at 1448-1472
defines a 99-bp domain in the 3' noncoding region of the human PEDF
cDNA sequence. PCR was performed in a 100-.mu.l reaction containing
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 100 .mu.M of each dNTP, 1.5 mM
MgCl.sub.2, 200 ng of genomic DNA from each hybrid, 200 ng of PEDF
primers 5 and 6, and 1.25 units of AMPLITAQ (Perkin Elmer Cetus).
DNA was subjected to preamplification heating at 94.degree. C. for
10 minute, after which amplification was carried out for 20 cycles.
Each cycle consisted of 1 minute denaturation at 94.degree. C., 1
minute annealing at 47.degree. C., and 2 minute extension at
72.degree. C. A final extension was carried out at 72.degree. C.
for 7 minute. One microliter of the amplified product was
reamplified using the above procedure.
[0277] Using primers 3 and 4, a 179 bp product was amplified from
human genomic DNA which was absent from hamster and mouse genomic
DNA. In a human-rodent somatic cell hybrid panel (NIGMS MAP 1), the
179 bp product was observed in somatic hybrids 1-15, which contain
a number of human chromosomes, including chromosome 17, but not in
hybrids 16-18, which do not contain chromosome 17. A second panel,
NIGMS MAP 2, also was investigated using PEDF primers 498 and 499,
which yield a 99 bp product. Each hybrid of this panel contains
only one human chromosome. Of the 24 hybrids tested, only GM/NA
10498 was positive and was the only one to contain human chromosome
17. Amplification was seen with human genomic DNA but not with
mouse and hamster DNAs.
EXAMPLE 44
Chromosomal Localization of the PEDF Gene: Fluorescence in situ
Hybridization (FISH)
[0278] A 7-kb fragment of the PEDF gene from a cosmid clone was
prepared and purified using Quiagen plasmid protocol (Quiagen Inc.,
Chatsworth, Calif.) and digested with NotI (Gibco BRL,
Gaithersburg, Md.), and the insert size was determined on a 0.5%
w/v agarose gel. FISH was performed at Bios Laboratories after the
PEDF probe was labeled by nick translation with dUTP digoxigenin as
described by Lichter et al. (Science 247 64-69, 1990). A chromosome
17 centromeric-specific probe, D17Z1 (Oncor, Gaithersburg, Md.),
which hybridizes to a 171 bp .alpha.-satellite tandem repeat, was
used as a marker in a cohybridization study. The D17Z1 probe was
nick translated and labeled with biotin-dATP, by methods well known
in the art. The PEDF genomic DNA probe was detected using
antidigoxigenin-fluorescein-conjugated F(ab) fragments; D17Z1 was
detected with avidin-conjugated fluorescein-isothiocyanate (FITC).
Chromosomes were counter-stained with propidium iodide. Eight
separate hybridizations were performed for each probe.
[0279] Fluorescence in situ hybridization analyses of eight
metaphase chromosome spreads using a digoxigenin-labeled PEDF probe
revealed that 50% of the cells demonstrated specific fluorescent
signals on chromosome 17. The identity of the chromosome and its
specificity were confirmed since the PEDF probe clearly
cohybridized with D17Z1, a probe specific to .alpha.-satellite
tandem repeats in the centromere of chromosome 17. Of importance as
well is that, in each case, the genomic probe gave a specific
hybridization signal at the terminal end of the short arm of
chromosome 17 (region 13.1).
EXAMPLE 45
Subchromosomal Localization of the PEDF Gene: PCR Assay
[0280] DNAs from a deletion mapping panel of eight somatic cell
hybrids containing different regions of human chromosome 17 (see
Guzzetta et al., Genomics 13 551-559, 1992) were used to further
sublocalize the PEDF gene. PCR conditions for panel 1 were used in
this assay, including primers 3 and 4. Up to 600 ng of DNA for the
chromosome 17 HO-11 hybrid was used in the PCR assay.
[0281] The use of human-rodent cell hybrids containing defined
regions of chromosome 17 (see Guzzetta et al., Genomics 8 279-285,
1991; Guzzetta et al., Genomics 13 551-559, 1992) allows accurate
subchromosomal localization of the PEDF gene. PCR primers 3 and 4,
which yield a 179 bp product, again were used in this study. The
PCR amplification product was seen with four of these hybrids:
MH22-6 contains the entire chromosome; DHA-4 has a deletion in the
p11.2 region; 88-H5 and 357-2D retain much of the p arm, including
the 13.1 region. Two hybrids are seen to be negative: L(17n)C,
which contains only 17q; and MH41, which has only the distal q arm.
The hybrid 12.3B, however, which retains 17p and the proximal q
region, is positive. Finally and of greatest significance, the
hybrid HO-11, which is missing only the 17p13.1 to 17pter region,
is negative. Together, these data localize the PEDF gene to
17p13.1-pter.
[0282] Additional experiments indicate that PEDF is located on
chromosome 11 in mice. The mouse chromosome 11 is syntenic with
human chromosome 17.
EXAMPLE 46
Expression Analysis: Northern Hybridization
[0283] RNA was extracted from human Y79 retinoblastoma cells. The
cells were grown in suspension culture under the following three
conditions: (A) medium (MEM, Mediatech) containing 15% v/v fetal
bovine serum (Y79-control); (B) serum-free, defined medium (MEM,
Y79-SF); (C) seruma-free, defined medium containing 5% v/v bovine
soluble interphotoreceptor matrix components (Y79-IPM) as
previously described by Tombran-Tink et al., J. Comp. Neurol. 317
175-186, 1992). Under a fourth condition (D), the cells were
stimulated with 5% v/v bovine IPM for 1 week in suspension culture
and then attached and allowed to differentiate for 10 days
(differentiated Y79) as previously described (Tombran-Tink et al.,
J. Comp. Neurol. 317 175-186, 1992). Approximately 95% of these
cells differentiate into a neuronal phenotype under this condition.
Cells maintained under conditions A-C are morphologically
undifferentiated clusters that remain in suspension. Cells under
all four conditions were harvested at a total of 17 days in culture
and poly(A).sup.+ RNA extracted by the method of Sambrook et al.
(1989 In: Molecular Cloning: A Laboratory Manual 2nd ed. Cold
Spring Harbor Press, Cold Spring Harbor, N.Y.).
[0284] Human fetal RPE cells were kindly provided by Dr. Dean Bok
(Jules Stein Institute, Univ of Cal., L.A.) These cells were
obtained from 20- to 21-week-old donors and were cultured in
SF-defined medium for 6 months prior to isolation of poly(A).sup.+
RNA (Sambrook et al., 1989 In: Molecular Cloning: A Laboratory
Manual 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).
Two micrograms of poly(A).sup.+ RNA from each sample was
electrophoresed on a 1% v/v formaldehyde denaturing gel,
transferred onto neutral nylon membrane, UV cross-linked, and
hybridized with the PCR-amplified 667 bp PEDF cDNA probe, by
methods well known to those skilled in the art. Hybridization
procedures were similar to those used for Southern hybridization of
somatic cell hybrid panels.
[0285] PEDF was originally detected as a secreted protein in the
medium of human fetal retinal pigment epithelial (RPE) cells
(Tombran-Tink et al., Inves. Ophthalmol. Vis. Sci. 53 411-414,
1989). These cells demonstrate a single 1.5-kb mRNA on Northern
blots. Surprisingly, undifferentiated Y79 retinoblastoma cells
demonstrate a 1.5-kb message even though little if any PEDF protein
can be detected in the medium. Cells grown in suspension culture
for 17 days with 15% v/v fetal bovine serum, SF-defined medium, and
5% v/v soluble components of the bovine interphotoreceptor matrix
(IPM) all express the PEDF message at substantial but varying
levels and all remain morphologically undifferentiated. In
contrast, induction of a marked neuronal phenotype and total
inhibition of PEDF message are seen in Y79 cells that were treated
with soluble components of the bovine IPM for 1 week and then
maintained in attachment culture for 10 additional days.
[0286] In addition Northern blots were performed using mRNA from a
variety of human adult and fetal tissues, as described above. The
results indicate that PEDF mRNA is present in retina, heart, brain,
placenta, lung, liver, skeletal muscle, kidney, pancreas, thymus,
prostate, testis, ovary, small intestine and colon. No significant
mRNA was detected in adult kidney or spleen, however, PEDF is
expressed in abundance in fetal kidney. The most abundant
expression of PEDF is in liver, skeletal muscle, testis and
ovary.
[0287] In brain tissue PEDF is expressed in the amygdala, caudate
nucleus, corpus callosum, hippocampus, hypothalmus, substantia
nigra, subthalmic nucleus, thalamus and pineal. By Western blots,
PEDF is seen in RPE-CM from a number of species including humans,
cow, monkey and chicken. Large quantities of PEDF can also be
detected int he vitreaous humor of these vertebrates.
EXAMPLE 47
Isolation of Genomic Clones: Screening Genomic Libraries
[0288] Bluescript plasmid containing a 1.5 kb PEDF cDNA insert was
digested with EcoRI and HindIII (BRL). Twenty-five ng of PEDF cDNA
insert, purified by gel electrophoresis was labelled with
.alpha.-.sup.32P dCTP (Amersham) by random priming (RANDOM PRIME IT
kit from Stratagene). Unincorporated nucleotides were removed by
Stratagene's NUC TRAP push columns. The labelled probe was used to
screen two genomic DNA libraries: a cosmid library constructed from
MboI partial digests of human placental DNA (Clonetech) and a human
placental genomic library constructed in .lamda. DASH II
(Stratagene). Positively hybridizing clones were isolated by
standard methods (Troen Methods in Enzymology 151 426, 1987;
Sambrook et al., 1989 In: Molecular Cloning: A Laboratory Manual
2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.) and the
DNA purified with Qiagen maxi preparation protocols (Qiagen).
[0289] Southern blot analysis of the purified clones revealed the
presence of two strongly hybridizing fragments: a 7.1 kb BamHI
fragment from the cosmid clone and a 7.2 kb NotI fragment from the
.lamda. DASH II clone. These were selected for subcloning in
Bluescript and DNA sequencing.
EXAMPLE 48
Isolation of Genomic Clones: Cloning by PCR
[0290] Four sets of primers, designed from the internal coding
region of the PEDF cDNA sequence were synthesized using an ABI 392
DNA/RNA synthesizer for use as primers in polymerase chain reaction
(PCR) experiments. The primer sequences are as follows: primer 603:
[0291] 5'-ACAAGCTGGC AGCGGCTGTC-3' is located in SEQ ID NO:1 at
271-290; primer 604: [0292] 5'-CAGAGGTGCC ACAAAGCTGG-3' is located
on the antisense strand in SEQ ID NO:1 at 570-590; primer 605:
[0293] 5'-CCAGCTTTGT GGCACCTCTG-3' is located in SEQ ID NO:1 at
570-590; primer 606: [0294] 5'-CATCATGGGG ACCCTCACGG-3' is located
on the antisense strand in SEQ ID NO:1 at 829-848; primer 2213:
[0295] 5'-AGGATGCAGG CCCTGGTGCT-3' is located in SEQ ID NO:1 at
114-133; primer 2744: [0296] 5'-CCTCCTCCAC CAGCGCCCCT-3' is located
on the antisense strand in SEQ ID NO:1 at 224-244; primer 2238:
[0297] 5'-ATGTCGGACC CTAAGGCTGT T-3' is located in SEQ ID NO:1 at
846-866; primer 354: [0298] 5'-TGGGGACAGT GAGGACCGCC-3' is located
on the antisense strand in SEQ ID NO:1 at 1043-1062. Standard
reagents (obtained from GeneAMP, Perkin-Elmer/Cetus of Norwalk,
Conn.) and 500 ng of human genomic DNA obtained from peripheral
blood lymphocytes were used. PCR reactions were carried out at a
number of different annealing temperatures until only single
amplified products were obtained. The primer pairs 603:604
amplified a single 2 kb PCR product (jt108); 605:606 amplified a
single 3.3 kb PCR product (jt109); 2213:2744 amplified a single 2.3
kb PCR product (jt115) and 2238:354 amplified a single 1.5 kb PCR
product (jt116).
[0299] Seven clones isolated either from genomic libraries or by
PCR-mediated cloning were sequenced and used to characterize the
exon structure of the PEDF gene and to define the intron/exon
junction sequences. The conventional method of cloning was replaced
by PCR-mediated cloning because of instability and rearrangement of
the gene in both cosmid and .lamda. genomic libraries.
[0300] Two positively hybridizing clones, jt101 (7.1 kb) and jt106
(7.2 kb) were isolated from a cosmid and .lamda. DASHII genomic
libraries respectively. Four clones of jt108 (2 kb), jt109 (3.3
kb), jt115 (2.3 kb) and jt116 (1.5 kb) represented PCR products of
human genomic DNA. Ir117 (6 kb) clone was obtained from an exon
1-labeled positively hybridizing BamHI fragment from human genomic
and P147 DNA. Two P1 clones, P1-11 and P1-47 containing the entire
PEDF gene were also isolated and intron/exon boundaries
sequenced.
EXAMPLE 49
Isolation of Genomic Clones: Identification of P1 Clones
[0301] Two sets of primers JT10-UP01:JT10-DP01 corresponding to
bases 6536-6559 of jt106 genomic sequence and 1590:1591
corresponding to bases 1-89 of SEQ ID NO:1 were used in PCR
reactions to isolate P1 clones (Genome Systems). The primer
sequences are as follows: primer Jt10-UP01: [0302] 5'-GGTGTGCAAA
TGTGTGCGCC TTAG-3' is located in SEQ ID NO: 4 at 6536; primer
JT10-DP01: [0303] 5'-GGGAGCTGCT TTACCTGTGG ATAC-3' is located in
SEQ ID NO: 4 at 7175; primer 1590: [0304] 5'-GGACGCTGGA TTAGAAGGCA
GCAAA-3' is located in SEQ ID NO:1 at 1-25; and primer 1591: [0305]
5'-CCACACCCAG CCTAGTCCC-3' is located in SEQ ID NO:1 at 71-89.
Several positive clones were isolated by PCR and two, designated
P1-11 and P1-47, were subjected to Southern blotting analysis and
PCR assays to confirm the presence of the entire PEDF gene and
splice junctions. Primer pairs encompassing contiguous stretches of
the PEDF cDNA sequence were used to amplify products from P1-11.
The primers were as follows: primers 601 and 1591 (spanning bases
1-89 of SEQ ID NO:1; 601 is the sense strand and includes bases
1-25; 1591 is the antisense strand and includes bases 69-89),
primer 2213 (SEQ ID NO:1 at 114-133) and 2744 (antisense strand in
SEQ ID NO:1 at 224-244); 603 (SEQ ID NO:1 at 271-290) and 604
(antisense strand in SEQ ID NO:1 at 570-590); 605 (SEQ ID NO:1 at
570-590) and 606 (antisense strand in SEQ ID NO:1 at 829-848); 2238
(SEQ ID NO:1 at 846-866) and 354 (antisense strand in SEQ ID NO:1
at 1043-1062) and 356:499 (spanning bases 1034-1472 of SEQ ID NO:1;
356 is the sense strand and includes bases 1043-1043; 499 is the
antisense strand and includes bases 1448-1472). The products
obtained were 89 bp, 2.3 kb, 2 kb, 3.3 kb, 1.5 kb and 900 bp,
respectively. The products were sequenced with an automated
fluorescent sequencer to confirm splice junctions of the PEDF gene
from sequences obtained from non-PI clones.
EXAMPLE 50
Characterization of Genomic Clones DNA Sequencing:Dideoxynucleotide
Termination Method
[0306] jt101 and jt106 were purified by gel electrophoresis and
subcloned into the BamHI and NotI sites respectively, of
pBluescript II SK.sup.+ vectors (Stratagene). These were used to
transform XL-I Blue competent cells (Stratagene). Transformants
were isolated and subcloned. The clones were blunt ended using T4
DNA polymerase, gel purified and subcloned into the EcoRV site of
pBluescript II SK.sup.- (Stratagene) and used to transform XL-I
blue cells. Nested deletions were generated from both the T7 and T3
ends of the subclones using ExoIII and SI nuclease (Lark Sequencing
Co.). Plasmid DNA was prepared using a modified alkaline lysis
procedure and deletions clones size selected for DNA sequencing by
electrophoresis on agarose gels. DNA sequencing (Lark Sequencing
Co.) was performed using standard dideoxynucleotide termination
method and sequencing reactions analyzed on 6% w/v polyacrylamide
wedge gels containing 8 M urea.
[0307] jt108, jt109, jt115 and jt116 (PCR products) were cloned
into the modified EcoRV site of the PT7 Blue vector (Novagen).
These were subsequently used to transform Nova Blue cells (Novagen)
such that both orientations of the insert into the vector were
obtained. Nested deletions were then generated from the reverse end
minilysates using ExoIII and SI nuclease and sequenced as
above.
[0308] The sequence analysis of all the above clones the structure
and size of exons and introns of the human PEDF gene were
determined. Exon/intron junctions were established by comparing
genomic and cDNA sequence of PEDF and by identifying consensus
splicing sites (Senapathy et al., Methods in Enzymology 183 252,
1990). The analysis indicates that the human PEDF gene is
approximately 16 kb in length and is composed of 8 exons ranging in
size from 92 nt to 377 nt and 7 introns ranging from 0.4 kb to 6 kb
(Table 1). The 5' splice donor and 3' splice acceptor sites in all
junctions conform to the GT/AG consensus. Exons are distributed
unevenly throughout the gene and the largest intron of 6 kb long is
located between exon 1 and exon 2. No significant patterns were
seen in the spatial organization of exons, in the distribution of
introns or in the occurrence of certain types of splice junctions
to infer a unique evolutionary relationship among any subset of
exons.
EXAMPLE 51
Characterization of Genomic Clones DNA Sequencing: Fluorescent
Automated DNA Sequencing
[0309] Fluorescent sequencing was performed using an ABI model 370A
instrument connected to an Apple Macintosh ci and ABI's 373 A
sequencing software. The sequencing was performed using ABI's Taq
DyeDeoxy Terminator cycle sequencing kit following the
manufacturer's protocol. In general, 0.5 pmoles of template
obtained from PCR products of the P1-10 clone and 3 pmoles of
primer were used per sequencing reaction. All other details are
provided in the ABI's manual included in the sequencing kit.
[0310] jt101: Sequence analysis of this 7.1 kb BamHI fragment
contained the most 3' end of the PEDF gene. Exon 7 (SEQ ID NO:1 at
903-1113) and exon 8 (SEQ ID NO:1 at 1114-1503) of 211 bp and 377
bp, respectively, were contained in this clone. Intron 6 and intron
7 were also sequenced from jt101. Intron 7 was intact and found to
be 444 bp in length while intron 6 was found to be somewhat
rearranged.
[0311] jt106: Sequence analysis of this 7.2 kb NotI fragment
indicated only sequences present in the most 5' end of the PEDF
gene. This clone contained the promoter of the PEDF gene as well as
exon 1 representing 109 bp (SEQ ID NO:1 at 1-109) and an incomplete
intron 1 of 535 bp. We were unable to obtain specific PCR
amplification products for this intron from either total human
genomic DNA or the PI clones suggesting that the size of the first
intron was rather enormous.
[0312] jt108: The PCR clone jt108 contained a 2 kb PCR product
amplified using primer 603:604 and contained most of exon 3 and
exon 4. Intron 3 and intron 4 of 980 bp and 689 bp, respectively,
were sequenced from this clone.
[0313] jt109: This 3.3 kb clone representing PCR product obtained
with primers 605:606 contains most of exon 5 and exon 6 (bases
555-758 of SEQ ID NO:1). The 3 kb intron 5 is also present in this
clone.
[0314] jt115: The 2.3 kb clone JT115 obtained from the PCR product
amplified using the primer pair 2213:2744 contained exon 2 and
intron 2 which is 2.9 kb in length.
[0315] jt116: Sequence analysis of this PCR clone obtained with
primers 2238 and 354 revealed an intact 1.5 kb intronic sequence
representing intron 6 previously determined from sequence analysis
of jt101.
[0316] P1-11: The intron-exon boundaries of the PEDF gene in the
P1-11 clone using primers designed from exon sequences flanking
each intron have also been sequenced. Approximately 200 bp on
either side of the junctions were sequenced and these align
perfectly with the sequence obtained from the above clones. All
splice junctions sequences were confirmed as well as the sizes of
introns and exons.
[0317] Part of the genomic DNA sequence is presented in SEQ ID NOs:
4 to 6.
EXAMPLE 52
Characterization of Genomic Clones DNA Sequencing: RACE
[0318] For RACE (Rapid amplification of cDNA ends) (Frohman In: PCR
protoclols: A Guide to Methods and Applications pp 28-38, Innis,
Gelfand, Sninsky and White eds., Academic Press, 1990) experiments
1.0 .mu.g of total human retina RNA was dried with 20 nanograms of
primer 1590 (SEQ ID NO:1 at 1-25). Reverse transcriptase, reaction
buffer and dNTP solution (BRL) were added to a final volume of 20
.mu.l. The reaction was carried out at 42.degree. C. for 30 minute
followed by a 5 minute incubation at 55.degree. C. Templates were
tailed with poly (A) using terminal deoxytransferase (BRL).
Sequences corresponding to the 5' end of mRNA were then amplified
by PCR using specific primer 1591. The product obtained from the
PCR reaction was sequenced directly using an ABI automated
fluorescent sequencer.
EXAMPLE 53
Gene Expression Analysis
[0319] Multiple human tissue mRNA Northern blots (Clonetech) with 2
.mu.g poly(A) RNA per lane were hybridized with a radioactively
labeled 667 bp PCR amplified PEDF product (Tombran-Tink et al.,
Genomics 19 266-272, 1994). The blots were prehybridized for 30
minute in Stratagene's QUIKHYB solution at 68.degree. C. The
labeled probe was added to this solution and hybridization
continued at the same temperature for 1 hour. Hybridized blots were
washed twice for 15 minute with 2.times.SSC/0.1% w/v SDS at room
temperature and once for 30 minute with 0.1.times.SSC/0.1% w/v SDS
at 68.degree. C. The blots were exposed for 6 hours at -70.degree.
C. using XAR-5 film (Kodak) and intensifying screens.
EXAMPLE 54
Evolutionary Conservation Analysis
[0320] Eight .mu.g of genomic DNA from lymphocytes of a variety of
species including mammalian and primate species (BIOS laboratories,
New Haven Conn.) was digested with EcoR1 and separated in 1% w/v
agarose gels. The gels were transblotted and membranes containing
the digested DNA hybridized using the same procedure as for the
Northerns.
[0321] These studies indicated that the sequence of the PEDF gene
is highly conserved in avian, mammals and primates, as indicated by
Northern blots which are performed under stringent conditions.
Under weaker hybridization conditions, the PEDF gene from species,
lower on the evolutionary scale also are identified, this includes
Drosophila.
EXAMPLE 55
Expression and Secretion of the PEDF in Retinal Interphotoreceptor
Matrix
[0322] Monkey eyes were obtained through the courtesy of the Office
of Biologics, FDA. The procedures for establishing RPE cells in
culture and describing their differentiated characteristics have
been published previously (Pfeffer, 1990. In Progress in Retinal
Research. N. Osborne and G. J. Chader editors. Pergamon Press,
Oxford UK. 251-291). Conditioned medium and cultured monkey RPE
cells were used from the 1st, 2nd, 5th, 10th and 15th passages of
the cells. The cells were routinely maintained in Minimal Essential
Medium (MEM, Eagle's salts, Mediatech, Hearndon, Va.) containing
0.5% v/v fetal calf serum (FCS, GIBCO, Grand Island, N.Y.). Cells
from confluent monolayer cultures were scraped from flasks,
solubilized in phosphate-buffered saline (PBS, pH, 7.4) containing
0.5% v/v Triton-X (Sigma Chemical Co., St. Louis, Mo.) and stored
at -70.degree. C. for Western blot analysis. For Northern blot
analysis, the following sources of RNA were used: 1) cultured fetal
and adult human RPE cells (Flannery et al., Exp. Eye Res. 51
717-728, 1990), 2) human RPE cell explants from 21 week gestational
donors (obtained from Dr. W. O'Day, Jules Stein Eye institute,
UCLA,) 3) human and monkey retina (Clonetech), 4) 1st and 10th
passaged monkey RPE cell cultures (eyes obtained courtesy of In
Vitro Vaccine Testing Section, FDA, Bethesda, Md.).
[0323] Conditioned medium (CM) from cultured fetal and adult human
RPE cells was obtained from monolayer cell cultures grown as
previously described (Carlson et al., Biochemistry 31 9056-9062,
1992). CM from young adult monkey and primary cultures of 11 day
old chick embryo were kind gifts of Dr. Bruce Pfeffer (NEI) and
Margaret Koh (Univ. of Maryland Medical School), respectively. The
medium was conditioned for 7 days by confluent monolayers of RPE
cells, filter-sterilized and stored at -70.degree. C. until used.
Medium conditioned by confluent monolayer of monkey RPE cells after
the 1st, 2nd, 5th, 10th and 15th passage was used for Western blot
analysis to study the secretion of PEDF with successive cell
passages.
[0324] Soluble IPM preparations were obtained from adult human
(obtained from the Clinical Branch, NEI), fetal bovine (10 weeks
gestation) and adult bovine eyes (obtained from Trueth and Sons,
Baltimore, Md.) as previously described (Tombran-Tink et al., J.
Comp. Neurol. 317 175-186, 1992). Briefly, the anterior segment,
lens and vitreous were removed; the resultant eye cups and retina
were gently rinsed with 0.5 ml of PBS solution. This preparation,
which contained soluble IPM components was centrifuged and the
supernatant stored at -70.degree. C. RPE cells were removed from
the eye cup by vigorous repeated pipetting of a small amount of PBS
against the cells in situ to detach them from the underlying
Bruch's membrane. The retina and the RPE cells were subsequently
solubilized in SDS sample buffer to be used for Western blot
analysis.
[0325] Protein concentrations were determined using the BCA assay
(Pierce Chemical Co., Rockford, Ill.) according to the
manufacturer's specifications. Samples of conditioned medium, IPM
or cell extracts were lyophilized and 15 .mu.g of each
reconstituted in SDS sample buffer and boiled for 5 minutes. The
proteins were fractionated on 10% w/v polyacrylamide gels at 25
mAmps/gel constant current for 3 hours (Laemmli, Nature 227
680-685, 1970). Five .mu.g samples of human .alpha.-1-antitrypsin
and .beta.-actin (Sigma Chem. Co.) were included on the gels. The
resultant gels were either stained with Coomassie Brilliant Blue
(Sigma Chem. Co.) for visualization of the electrophoretic protein
profile or transblotted onto nitrocellulose membranes for Western
blot analvsis.
[0326] Two dimensional gel analysis of 1) purified PEDF protein
from CM of cultured fetal RPE cells as previously described
(Tombran-Tink et al., Exp. Eye Res. 53 411-414, 1991), 2) CM from
cultured human RPE cells (Tombran-Tink et al., Exp. Eye Res. 53
411-414, 1991) and 3) adult bovine IPM prepared as previously
described (Tombran-Tink et al., J. Comp. Neurol. 317 175-186, 1992)
was performed according to the method of O'Farrell (J. Biol. Chem.
250 4007-4021, 1975). Isoelectric focusing was carried out in glass
tubes of inner diameter 2.0 mm, using 2% v/v BDH pH 4-8 ampholines
for 9,600 volt hours. The final tube gel pH gradient extended from
about pH 4.0 to about pH 8.2 as measured by a surface pH electrode.
After equilibration for 10 minutes in buffer 0 (10% v/v glycerol,
50 mM dithiothreitol, 2.3% w/v SDS and 62.5 mM Tris, pH 6.8), the
tube gel was sealed to the top of a 10% w/v acrylamide slab gel
(0.75 mm thick) and electrophoresis was carried out for 4 hours at
12.5 mAmps/gel. The gels were then either stained with Coomassie
blue or transblotted onto nitrocellulose membrane for Western blot
analysis.
[0327] Nitrocellulose membranes containing the transblotted
proteins were pretreated with 0.5% v/v non-fat dried milk in 50 mM
Tris buffer, pH 7.4, followed by incubation for 1 hour with an
anti-PEDF polyclonal antibody (a gift of Dr. Vincent Cristofalo,
Medical College of Pennsylvania) diluted at 1:3,000 in Tris buffer
containing 0.5% v/v milk. After this treatment, the membranes were
washed extensively with Tris buffer and subjected to further
incubation for 30 minutes in an appropriate dilution of alkaline
phosphatase-conjugated goat anti-rabbit IgG. The alkaline
phosphatase color development reagents p-nitro blue tetrazolium
chloride (NBT) and 5-bromo-4-chloro-3'indoyl phosphate p-toluidine
salt (BCIP) (BioRad Laboratories, Richmond, Calif.) were used for
the detection of the PEDF protein.
[0328] First strand cDNA synthesis of human and monkey RPE cell
mRNA was performed using the SuperScript Preamplification System
catalyzed by SuperScript RNase H-Reverse Transcriptase (RT) (Gibco,
BRL, Gaithersburg, Md.) . A 3 .mu.l sample of the resulting first
strand cDNA was then used for each PCR reaction. A pair of primers
from the translated sequences of the PEDF cDNA (Steele et al.,
Proc. Natl. Acad. Sci. (USA) 90 1526-1530, 1993), representing a
1472 bp PCR amplification product, was used in the reactions. The
primers were 601 and 499, which have been described previously. The
PCR reaction contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 80 .mu.M
of each dNTP, 1 mM MgCl.sub.2, 100 ng of each primer and 1.25 units
of Amplitag (Perkin Elmer Cetus). A preamplification denaturation
for 10 minutes at 94.degree. C. was performed and amplification was
then carried out for 30 cycles. Each cycle was: 94.degree. C., 1
minute; 50.degree. C., 1 minute; 72.degree. C., 1 minute. Six .mu.l
of the PCR products were analyzed on a 1% w/v agarose gel in
1.times.TAE buffer and products visualized with ethidium
bromide.
[0329] Total RNA was isolated by the RNAzol B method
(Cinna/Biotecx, Friendswood, Tex.). Ten .mu.g of total RNA was
diluted in RNA-loading dye containing ethidium bromide
(5'Prime-3'Prime, Inc., Boulder, Colo.) and electrophoresed for 3
hour at 75 V in 1% v/v formaldehyde gels. The RNA was subsequently
transferred onto Nytran membranes (Schleicher & Schuell, Keene,
N.H.) using 20.times.SSC and Stratagene's Posiblotter (Stratagene,
La Jolla, Calif.). The membranes were UV crosslinked and baked at
80.degree. C. for 2 hours prior to hybridization. Fifty ng of a 667
bp PCR amplified product of the PEDF cDNA was used as the probe.
This was labelled with .alpha.-.sup.32P-dCTP using a Random Prime
It Kit II (Stratagene). Unincorporated nucleotides were removed
using Stratagene's Nuctrap Push columns. The membranes were
prehybridized for 30 minutes at 68.degree. C. in QuikHyb solution
(Stratagene) followed by hybridization for 1 hour at 68.degree. C.
in the same solution supplemented with 1.times.10.sup.6 cpm/ml
radiolabelled PEDF probe. Post-hybridization washes were as
follows: 2.times.15 minute at 25.degree. C. with 2.times.SSC/0.1%
w/v SDS buffer followed by 1.times.30 minute at 68.degree. C. with
0.1.times.SSC/0.1% w/v SDS. The hybridized membranes were exposed
overnight at -70.degree. using XAR-5 X-Ray films (Eastman Kodak Co.
Rochester N.Y.) and intensifying screens.
[0330] A human fetal eye of estimated 17 weeks gestation and 1.5
hours postmortem was fixed in 4% v/v formaldehyde following the
removal of cornea, iris and lens. Following fixation, the posterior
segment of the eye was cut into 1.times.2 mm pieces, dehydrated in
ethanol and embedded in diethylene glycol distearate (Polysciences,
Warrington, Pa.). Sections one micrometer in thickness were cut and
handled as previously published (Porrello et al., J. Histochem.
Cytochem. 39 171-176, 1991).
[0331] A 233 bp fragment containing residues 246-278 of the coding
region was exceed by BamHI and KpnI digestion of human PEDF cDNA
(Steele et al., Proc. Natl. Acad. Sci. (USA) 90 1526-1530, 1993).
This fragment was then ligated into pBluescript II KS-phagemid
(Stratagene). The phagemid with its 233 bp PEDF insert was then
linearized by digestion within its multiple cloning site with StyI
or with BamHI, neither of which have restriction sites in the PEDF
fragment. T3 and T7 RNA polymerase were incubated with these DNA
templates to generate a sense probe 264 bases and an antisense
probe 300 bases in length. Forty of the bases in the sense probe
and 67 in the antisense probe were transcribed from vector DNA.
[0332] .sup.35S-labeled probes were synthesized with a Riboprobe
kit (Promega, Madison, Wis.) according to the manufacturer's
instructions. Optimal radiolabel incorporation for a 1 AM volume
was typically 1.times.10.sup.6 DPM for the sense and antisense
probes. Hybridization and posthybridiation of the probes with
tissue sections were performed as previously described (Porrello et
al., J. Histochem. Cytochem. 39 171-176, 1991) with the exception
that the salt washes were performed at 65.degree. C.
[0333] Monkey RPE cells, cultured in MEM containing 1% v/v FBS,
were seeded onto glass coverslips in 24 well plates. The cells were
fixed in 4% v/v paraformaldehyde for 15 minutes and non-specific
protein binding sites blocked with 1 mg/ml bovine serum albumin.
The PEDF polyclonal antibody was used at a 1:3,000 dilution and
cells were reacted with the antibody for 1 hour followed by
incubation for 30 minutes in an appropriate dilution of
FITC-conjugated goat anti-rabbit IgG. Double-labelling experiments
were performed similarly using an actin monoclonal antibody and
rhodamine-conjugated goat anti-mouse IgG (Pierce, Rockford, Ill.).
Immunoreactivity was visualized by epifluorescence microscopy using
an Olympus BHS microscope equipped with a 40.times.UV lens.
[0334] Coomassie blue staining of proteins in fetal human RPE-CM
shows a prominent 50 kDa PEDF band that was completely absent from
non-conditioned medium. By Western blot analysis, a comparable band
at 50 kDa was readily detected by anti-PEDF in conditioned medium
from RPE cells and in soluble washes of IPM from a number of
species. The 50 kDa protein was found in RPE-CM from both fetal and
adult human RPE cells. CM from young adult monkey (third passage in
culture) and from primary chick embryo RPE cells also showed 50 kDa
bands with the human PEDF polyclonal antibody. A positive PEDF band
was also detected in soluble washes of adult human IPM and in IPM
from fetal and adult cow. PEDF was often clearly defined as a
doublet in lanes with lower concentration of PEDF. The presence of
PEDF in the IPM indicates that it was secreted in vivo in both
fetal and young adult where it could influence neuronal
differentiation and/or survival of retinal neurons.
[0335] Interestingly, a 50 kDa protein, was not detected in total
cellular extracts of tenth passage RPE cells. To better examine the
effect of cellular ageing, CM from RPE cell up to 15 passages in
culture was examined. PEDF was found to be secreted in abundance by
RPE cells in their 1st and 2nd passages and at the 3rd passage but
only weakly by these cells in the 5th passage. The protein was not
detected in the conditioned medium of RPE cells at the 10th or 15th
passages. Thus, PEDF secretion by RPE cells decreases dramatically
in an age-related manner.
[0336] Surprisingly, the anti-PEDF antibody detects a doublet
migrating at 36 kDa rather than at 50 kDa in both the cultured RPE
cells and tissue extracts. The low level of the 36 kDa species
observed in extracts of the neural retina await confirmation by
immunocytochemistry in situ since it would be expected that small
amounts of RPE contamination would be present in the dissected
retinal tissue. This raises the possibility that some PEDF is
retained intracellularly as a lower molecular weight species at
least in RPE cells. It is also interesting to note here that,
similar to the 50 kDa secreted protein, the 36 kDa species is only
present in early passage cells and absent by the loth passage of
the RPE cells. Thus, both molecular species disappear in parallel
with cell passages and aging.
[0337] By 2-dimensional gel analysis, at least four isoforms of the
HPLC-purified native human PEDF protein are detected by Coomassie
blue staining. The spots vary only slightly in apparent molecular
weights and the four most prominent species have apparent pI's of
6.0, 6.2, 6.4 and 6.6. The PEDF polyclonal antibody recognizes all
four isoforms of this protein and possibly two others in both human
RPE-CM and bovine IPM as shown by Western blot analysis of the
transblotted 2-D gels.
[0338] Using primers 601 and 499 which encompass a 1.47 kb sequence
of the PEDF message, a single product of approximately 1.5 kb is
amplified in both fetal human and adult monkey RPE cells. By
Northern blot analysis, a 1.5 kb band is also detected with the 667
bp PCR-amplified PEDF probe in cultures of fetal and adult human
RPE cells as well as in RPE cell explants. Relatively more PEDF
mRNA is seen in the fetal RPE cell explants as compared to cultured
cells. No difference is seen in the size of the messages under any
of the conditions (fetal vs. adult, human vs. monkey). Thus, by
Western and Northern blot analyses and by PCR, the molecular size
and apparent structure of the 50 kDa protein and its message
appears to be similar in human, monkey and bovine RPE cells, retina
and IPM.
[0339] Five .mu.g of total RNA from monkey retina and from 1st and
10th passage monkey RPE cells were electrophoresed and a weak
hybridization signal was seen from total retina RNA. A more,
prominent 1.5 kb transcript band was present in the early passage
(1st passage) monkey RPE cells while no transcript is detected in
the late (10th) passaged RPE cells. Thus, similar to the secretion
pattern of PEDF protein after successive RPE cell passages, late
passage monkey RPE cells do not transcribe the PEDF mRNA.
[0340] The effect of PEDF on Y79 retinoblastoma cell line
differentiation was first demonstrated with conditioned media from
human fetal RPE cells. Thus, we performed in situ hybridization of
a fetal human retina of a developmental age similar to that of the
cells used for fetal human RPE culture (17 weeks gestation).
Retinas hybridized with antisense probes under high stringency
(65.degree. C.) showed specific binding of the probe to the RPE
cell layer. The retinal neuroblastic layer which contains
incompletely differentiated neurons and glia and the ganglion cell
layer, which was well differentiated at this developmental stage,
were not labeled above background.
[0341] In well attached cells (3rd passage, 5-10 days
postattachment), immunofluorescence was seen in association with
cytoskeletal strands within the cells and within the nucleus. At 2
days of attachment, the protein was concentrated around the nucleus
and was of a granular nature. Staining was also associated with a
fibrous cytoskeletal-like network. When monkey RPE cells are
examined soon after seeding (1-2 hours), discrete localization of
the PEDF protein is seen at the tips of many processes of the RPE
cell. Similar to the dramatic decrease seen in PEDF secretion and
transcription with successive cell passages, no immunoreactivity
with the PEDF polyclonal antibody is seen in cultured monkey RPE
cells after the tenth passage.
[0342] To further examine the association of PEDF immunoreactivity
with cytoskeletal elements within the cytoplasm, we analyzed the
structures by double-labelling using anti-PEDF as described above
and an actin antibody detected by rodamine-conjugated goat
anti-mouse IgG. Both antibodies localized to structures around the
nucleus and to cytoskeletal strands in the cytoplasm. Concentration
of both antibodies is also seen at the tip of a pseudopod. Because
of PEDF's apparent association with cytoskeletal structures,
possibly actin microfilaments, we addressed the possibility of
antibody cross reactivity with actin. Anti-PEDF did not bind to
purified actin on a Western blot. Only a positive PEDF band at 50
kDa is observed in RPE conditioned medium. The antibody also does
not recognize human .alpha.-1-antitrypsin, a homologous member of
the serpin supergene family. It thus seems that the PEDF antibody
specifically recognizes and binds to PEDF (50 and/or 36 kDa forms)
associated with the intracellular actin cytoskeletal network of the
RPE cells but does not bind directly to purified actin on a Western
blot.
EXAMPLE 56
PEDF as a Survival Factor for Cerebellar Granule Cells in
Culture
[0343] Cerebellar granule cells (CGC) were prepared from 5 or
8-day-old Sprague Dawley rat pups (Taconic Farms) as previously
described (Novelli et al., Brain Res. 451 205-212, 1988; Levi et
al., In: A Dissection and Tissue Culture Manual of the Nervous
System (Shahar, de Vellis, Vernadakis and Haber, eds), pp. 211-214.
Alan R. Liss, Inc. New York. 1989). In brief, tissue free of
meninges was minced in a buffer containing 124 mM NaCl, 1 mM
NaH.sub.2PO.sub.4, 1.2 mM MgSO.sub.4, 3 mg/ml bovine serum albumin
(BSA), 27 .mu.M phenol red, and 25 mM HEPES, pH 7.4, and
centrifuged at 550.times.g for 3 minutes. The tissue pellet from
10-20 animals was resuspended and trypsinized for 15 minutes at
37.degree. C. in 30 ml of the same buffer containing 250 .mu.g/ml
trypsin; a further 15 ml of buffer, containing 26 .mu.g/ml DNase I
(from Sigma Chemical Co.), 166 .mu.g/ml soybean trypsin inhibitor
(from Sigma Chemical Co.) and 0.5 mM additional MgSO.sub.4, were
added and the tissue was centrifuged again as described above. The
pellet was resuspended in 1 ml of buffer supplemented with 80
.mu.g/ml DNase, 0.52 mg/ml of trypsin inhibitor, and 1.6 mM
additional MgSO.sub.4, and triturated 60 times with a Pasteur
pipette. The suspension was diluted with 2 ml of buffer containing
0.1 mM CaCl.sub.2 and 1.3 mM additional MgSO.sub.4, and
undissociated material was allowed to settle for 5 minutes. The
supernatant was transferred to another tube, cells were recovered
by brief centrifugation and resuspended in serum-containing medium
(Eagle's basal medium, from GIBCO, with 25 mM KCl, 2 mM glutamine,
from GIBCO, 100 .mu.g/ml gentamicin, and 10% v/v heat-inactivated
fetal calf serum, from GIBCO) or chemically defined medium
(DMEM:F12 (1:1, from GIBCO) with 5 .mu.g/ml insulin (from
Boehringer Mannheim), 30 nM selenium (from Boehringer Mannheim),
100 .mu.g/ml transferrin (from GIBCO), 100 nM putrescine (from
Sigma Chemical Co.), 20 nM progesterone (from Sigma Chemical Co.),
50 U/ml penicillin, 50 .mu.g/ml streptomycin, and 2 mM glutamine;
Bottenstein, In: Cell Culture in the Neurosciences, Bottenstein and
Sato, eds., pp. 3-43. Plenum Publishing Corp, New York, 1985).
Cells were plated in poly-L-lysine-coated 96-well plates (for MTS
assay, MTS assay kit were obtained from Promega Corp., and
neurofilament ELISA assay) or 8-well chamber slides (for
immunocytochemistry and 5-bromo-2'-deoxyuridine, BrdU, labelling)
at 2.5.times.10.sup.5 cells/cm.sup.2and grown at 37.degree. C. in a
humidified atmosphere comprising 5% v/v CO.sub.2 in air. After 1
day in culture, cytosine arabinoside (Ara-C) was added only to
cells in serum-containing medium to a final concentration of 10
.mu.M.
[0344] Cerebellar granule cells in 96-well plates were incubated in
a CO.sub.2 incubator for 4 hours with MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
)-2H-tetrazolium, inner salt) and PMS (phenazine methosulfate) at
final concentration of 333 .mu.g/ml MTS and 25 .mu.M PMS,
respectively. In the presence of PMS, MTS is converted to a
water-soluble formazan by a dehydrogenase enzyme found in
metabolically active cells (Cory et al., Cancer Commun. 3 207-212,
1991). The quantity of formazan product was determined by
spectrophotometry (Dynatech microplate reader) at 490 nm.
[0345] After 7 days in vitro (DIV), the cells were washed three
times in calcium- and magnesium-free phosphate-buffered saline
(PBS) and fixed with 2% v/v paraformaldehyde for 10 minutes,
followed by 10 minutes at -20.degree. C. in 95% v/v ethanol/5% v/v
acetic acid. Incubation with primary antibodies against NSE
(neuron-specific enolasecalbindin, from Sigma Chemical Co.), GABA
(from Sigma Chemical Co.), calbindin (from Sigma Chemical Co.), or
glial fibrillary acidic protein (GFAP) was carried out for 60
minutes at room temperature. Antibodies were applied at dilutions
of 1:500-1:5,000 in the presence of 2% v/v normal goat serum and
0.2% v/v BSA. The antibodies were visualized using the ABC system
(from Vector Lab) and diaminobenzidine. At least 20 fields were
counted from 2-3 wells for each experiment. The average number of
cells per field was then calculated to determine the ratio for the
number of cells stained by the other antibodies relative to
NSE-positive cells in control cultures.
[0346] BrdU labeling (BrdU labeling kit was supplied by--Amersham)
was performed by the method described (Gratzner, Science 218
474-475, 1982; Gao et al., Neuron 6, 705-715, 1991) with the
following modifications. The cells were plated in 8-well chamber
slides and PEDF was immediately added. For this experiment, DMEM
rather than DMEM:F12 was used in chemically defined medium (CDM)
and no Ara-C was added to serum-containing medium (SCM). After 24
hours, BrdU (diluted 1:100; Amersham cell proliferation kit) was
added to the culture medium for 24 hours, after which the cells
were fixed in 2% v/v paraformaldehyde for 10 minutes, treated with
95% v/v ethanol, 15% v/v acetic acid for 10 minutes, and incubated
with an anti-BrdU monoclonal antibody, which was diluted 1:20, for
2 hours. The cultures were then incubated with a horseradish
peroxidase-conjugated goat anti-mouse secondary antibody (Vector
Lab) for 60 minutes. After incubation with diaminobenzidine, the
cells were mounted in Gel Mount. The mitotic index was determined
by counting the percentage of labeled cells with microscopy. For
each value, a random sample of 3,000 cells was counted.
[0347] Neurofilament ELISA was performed according to the method of
Doherty et al. (J. Neurochem 42 1116-1122, 1984) with slight
modifications. Cultures grown in 96-well microtiter plates were
fixed with 4% v/v paraformaldehyde in PBS at 4.degree. C. for 2
hours. The fixed cells were permeabilized by treatment for 15
minutes with 0.1% v/v Triton X-100 in PBS, followed by incubation
for 60 minutes with PBS containing 10% v/v goat serum to block
nonspecific binding. The cultures were then incubated with a
monoclonal anti-neurofilament antibody (RMO-42) overnight at
4.degree. C. at a dilution of 1:100 (Lee et al., Proc. Natl. Acad.
Sci. USA 85 7384-7388, 1988). After washing twice with PBS
containing 10% v/v goat serum, cells were incubated with secondary
antibody (horseradish peroxidase-conjugated goat anti-mouse at a
dilution of 1:1,000) for 1 hour. Following sequential washing with
PBS and water, the cultures were incubated with 0.2% v/v
o-phenylenediamine (OPD, from Sigma Chemical Co.) and 0.02% v/v
H.sub.2O.sub.2 in 50 mM citrate buffer, pH 5.0, for 30 minutes. The
reaction was stopped by adding an equal volume of 4.5 M
H.sub.2SO.sub.4. Product formation was quantitated by reading the
optical density (O.D.) of an aliquot of the reaction product at 490
nm using a Dynatech microplate reader.
[0348] The PEDF used in the experiments was a recombinant construct
(Asp.sup.44-Pro.sup.418) as previously described (Becerra et al.,
J. Biol. Chem. 268 23148-23156, 1993) and as described above. The
recombinant expression construct from the human PEDF cDNA was
expressed in Escherichia coli and purified from the bacterial
inclusion bodies. rPEDF was highly purified by gel filtration and
cation exchange chromatography, and demonstrated neurotrophic
activity on human retinoblastoma Y-79 cells, as reported for the
native PEDF (Becerra et al., J. Biol. Chem. 268 23148-23156, 1993)
and as described above. rPEDF was added in urea at a final
concentration of 500 ng/ml urea and 10 mM rPEDF. All controls
contained the concentration of urea corresponding to that present
in the rPEDF added and no dose of urea affected any of the
assays.
[0349] All experiments were replicated twice. The statistical
analyses that were carried out by standard statistical methods.
[0350] Unless indicated otherwise, all experiments were carried out
using CGC prepared from postnatal day 8 (P8) rats. In SCM, optical
density (O.D.) was proportional to the cell number plated over a
range from 1 to 9.times.10.sup.5 cells/cm.sup.2. In contrast, for
cells grown CDM, the linear range covered 1 to 5.times.10.sup.5
cells/cm.sup.2. For all subsequent experiments, cells were plated
at 2.5.times.10.sup.5 cells/cm.sup.2, i.e., within the linear range
for either type of culture medium.
[0351] Exposure of cells to 500 ng/ml (equivalent to 11.68 nM)
rPEDF in SCM resulted in a statistically significant difference in
the O.D. between rPEDF-treated and untreated cultures by two days
in vitro (DIV 2): the difference lasted up to DIV 10. By DIV 4,
there was a 50% increase in cell number in the presence of rPEDF,
with a 30-40% increase maintained through DIV 10. A dose-response
curve demonstrated that the effect of rPEDF was statistically
significant at 500 ng/ml or above, although increasing the
concentration above 500 ng/ml did not produce further increases.
PEDF had a much larger effect on cell number when added to CGC in
chemically defined medium. The time course of the rPEDF effect in
CDM. The time course analysis demonstrates that rPEDF-treated
cultures contain significantly more cells than control cultures by
DIV 4, with even larger differences by DIV 7 and 10. Most of the
2-3 fold difference was the result of large decreases in cell
numbers in the control cultures. The dose-response curve in CDM
shows that there is a statistically significant effect at 20 ng/ml
(equivalent to 0.47 nM) rPEDF, 25-fold lower than the effective
dose in serum-containing medium. Increasing the concentration of
rPEDF above 50 ng/ml did not promote further survival of CGC in
CDM.
[0352] Immunocytochemistry was used to identify the cell types
present in CGC cultures before and after treatment with rPEDF.
Postnatal day 8 CGC cultures grown for 7 days with or without rPEDF
(500 ng/ml) were stained with four different antibodies: 1) a
polyclonal rabbit antibody to neuron-specific enolase (NSE), which
recognizes all differentiated cerebellar neurons, including P8 CGC
which are differentiated both morphologically and pharmacologically
by DIV 7; 2) a polyclonal antibody to GABA, which stains all
cerebellar neurons except cerebellar granule cells; 3) an antibody
to calbindin, which is specific for Purkinje cells; 4) an antibody
to glial fibrillary acidic protein (GFAP), an intermediate filament
protein present only in astrocytes. The results are summarized in
Table IV. TABLE-US-00006 TABLE IV Antigen Treatment SCM CDM NSE
Control 100.0 .+-. 6.2 100.0 .+-. 4.5 PEDF 127.0 .+-. 5.9* 157.2
.+-. 7.4* GABA Control 2.8 .+-. 0.2 1.4 .+-. 0.2 PEDF 3.2 .+-. 0.2
1.8 .+-. 0.2 Calbindin Control 0.06 .+-. 0.01 0.07 .+-. 0.02 PEDF
0.07 .+-. 0.02 0.12 .+-. 0.02 GFAP Control 0.86 .+-. 0.07 0.99 .+-.
0.07 PEDF 0.06 .+-. 0.03* 0.60 .+-. 0.06* *p < 0.005 relative to
the respective control
There were significantly more NSE-positive cells in both SCM (30%
increase) and in CDM (60% increase) in the presence of rPEDF. No
statistically significant increase was observed in the number of
GABA-positive neurons or Purkinje cells (calbindin-positive).
Furthermore, the results support the purity of the CGC cultures,
since only 1-3% of the cells are GABA-positive non-CGC neurons,
less than 0.1 are Purkinje cells and less than 1% are astrocytes.
The increased number of NSE-positive cells in the presence of
rPEDF, therefore, reflects enhanced survival of CGC neurons.
[0353] In order to determine whether the increase in O.D. (MTS
assay) in response to PEDF reflected simply cell, survival or an
increase in proliferation, a BrdU labeling study was performed
using cultures from postnatal day 5 (P5) animals, a time when
cerebellar granule cells are still dividing in vivo. First, the
effect of rPEDF on P5 CGC cultures at DIV 1 and 2 was determined
using the MTS assay. PEDF had no effect at DIV 1 but caused a small
but significant increase in O.D. at DIV 2 in both serum-containing
medium and chemically defined medium. Therefore, BrdU was added on
DIV 1 and cells were fixed on DIV 2. Under control conditions, the
BrdU labeling index was 5% in SCM and 3% in CDM: PEDF did not
increase the BrdU labeling index in either culture medium. The lack
of effect of PEDF on BrdU labeling showed that enhanced survival
rather than increased cell division underlies the, larger cell
number seen with PEDF.
[0354] In order to investigate the effects of rPEDF on neurite
outgrowth from P8 CGC, a neurofilament ELISA assay was used.
Immunocytochemistry had shown that the monoclonal antibody RMO-42,
which recognizes the phosphorylated domain of NF-H (200 kDa) and
NF-M (160 kDa), stained only the neurites of cerebellar granule
cells in culture in comparison to anti-NSE which stained both
neurites and cell bodies. Therefore, this antibody was used as a
direct measure of neurofilament protein present in the neurites and
an indirect measure of number of neurites. Using the neurofilament
ELISA, the O.D. was found to be proportional to the number of cells
originally plated when the assay was carried out on DIV 7, a time
when all cells have developed a full complement of processes. rPEDF
increased neurofilament content, both in SCM (45%) and CDM (43%)
but the increase was directly proportional to the increase in cell
number. When the data are expressed as the increase in
neurofilament relative to the increase in cell number, these ratios
are about 1.0 for both SCM and CDM. These results demonstrated that
PEDF does not promote neurite outgrowth from CGC in culture.
Microscopic observation revealed no morphological change caused by
rPEDF.
[0355] In the present study, we show that PEDF increased the number
of viable cells in cerebellar granule cell cultures, whether the
cells were prepared from postnatal day 5 or postnatal day 8 rats,
and whether the cultures were maintained in serum-containing medium
or chemically defined medium. In SCM, PEDF showed no effect at DIV
1, but by DIV 4, about 50% more cells were present in
PEDF-containing medium, a difference which was maintained through
DIV 10. In CDM, a similar 50% difference was seen by DIV 4, with
the difference becoming larger at DIV 7 and DIV 10 (final 2-3 fold
more cells at these times in the presence of PEDF). The effect of
PEDF showed a dose-response relationship in both SCM and CDM.
However, whereas a significant effect was seen with 500 ng/ml
(equivalent to 11.68 nM) of rPEDF in SCM, only 20 ng/ml (0.47 nM)
of PEDF were required to achieve a significant increase in CDM.
Thus, effects of PEDF were larger and occurred at 25-fold lower
doses in CDM than in SCM. Furthermore, these effects of rPEDF were
long-lasting in that only a single dose of the factor was added to
culture medium at the start of the culture period. The relatively
high potency of PEDF in CDM compared to SCM may be due, at least in
part, to the presence of inhibitors or degradative enzymes in the
fetal calf serum that reduced the bioactivity of PEDF.
Alternatively, another trophic factor, additive in action to PEDF,
may be present in serum, which masks the full biological activity
of PEDF.
[0356] To determine whether this PEDF-induced difference in cell
number reflected an increase in cell survival or an increase in
proliferation, BrdU incorporation was measured in the presence of
PEDF using cells from postnatal day 5 animals, an age when
cerebellar granule cells are still dividing in vivo. PEDF did not
alter BrdU incorporation into cells cultured in either SCM or CDM.
The lack of effect of PEDF on BrdU incorporation indicates that
enhanced survival rather than increased cell division underlies the
larger cell number seen with PEDF. Since the MTS assay only
determines total cell number, immunocytochemistry was used to
identify the general types and relative proportions of cells
present in cultures treated with PEDF. There were significantly
more NSE-positive cells in PEDF-treated cultures. However, no
statistically significant effect of PEDF was found on GABA-positive
cells, which includes all cerebellar neurons except the granule
cells, or on the number of calbindin-positive Purkinje cells. Since
GABA-positive cells represent only 1-3% of the total NSE-positive
neurons in the cultures and even fewer calbindin-positive cells are
present (about 0.1%), it thus appears that PEDF affects only the
CGC neurons. Moreover, the effect seems to be on long-term neuronal
survival since PEDFdoes not promote increased mitotic activity. Our
present results are of particular interest with regard to recent
results on the expression of the PEDF gene in WI-38 fibroblast
cells in culture. In these cells, PEDF (called EPC-1) mRNA
accumulates in young WI-38 cells at G.sub.0 but little or no
transcription is found in senescent cells. No PEDF mRNA has been
detected in P8 CGC neurons, in agreement with their lack of mitosis
by P8. Just what roles PEDF may play in cell cycle or survival
events remain to be determined. In this regard, it will be
interesting in the future to determine if PEDF exerts an
anti-apoptotic effect in promoting the survival of CGC.
[0357] Both purified native PEDF and recombinant PEDF exhibit a
striking neurotrophic effect on cultured retinoblastoma cells as
outlined above. rPEDF had no comparable effect on the morphology of
the CGC, however. To investigate a possible effect of PEDF on
neurite outgrowth, we used a specific neurofilament assay designed
to quantify neurite outgrowth. Although the neurofilament content
was higher at DIV 7 in PEDF-treated cultures (40% in both SCM and
CDM), this simply reflected the fact that there were more cells
present in the PEDF-treated cultures (30% in SCM and 60% in CDM by
immunocytochemistry). The biochemical data are thus in concert with
the morphological data and indicate that PEDF has no effect on
neurite outgrowth in CGC.
[0358] Since PEDF shares considerable sequence homology with
members of the serine protease inhibitor (serpin) supergene family,
PEDF may act by inhibiting protease activity. The glia-derived
nexins, other members of the serpin family, have been proposed to
exert neurotrophic actions by regulating the balance between
protease and protease inhibitor activities. However, PEDF lacks
significant homology to the proposed consensus sequence for the
serpin reactive center region, which itself is heterogeneous in
length and amino acid composition. Furthermore, protease inhibition
assays showed that PEDF did not affect trypsin, chymotrypsin,
elastase, cathepsin G, endoproteinase Lys-C, endoproteinase Glu-C,
or subtilisin activity, suggesting that inhibition of known serine
proteinase may not be the biochemical pathway for the PEDF
neurotrophic activity.
[0359] Aside from a direct action on cerebellar granule cells, it
is also possible that PEDF acts to regulate expression of some
other neurotrophic factor. BDNF and NT-3 are both present in the
immature cerebellum, and Trk B, the BDNF receptor, is also
expressed in the cerebellum early in development. BDNF was shown to
act as a survival factor for embryonic granule cells. It increased
cerebellar granule cell number 50 to 100% at 20 ng/ml, with the
effect occurring after DIV 4, results very comparable to ours with
PEDF. Furthermore, BDNF has no effect on mitosis of cerebellar
granule cells. Since a number of hormones and neurotransmitters are
known to affect the production of neurotrophins by neurons, the
effect of PEDF could be mediated through regulation of one of these
factors. Tri-iodothyronine, for example, enhanced the production of
NT-3 in CGC cultures while neurotransmitters or analogs such as
kainic acid and GABA increased the synthesis of NGF and BDNF in
hippocampal neurons. Thus, PEDF may act directly through its own
receptor and signal transduction pathway, or more indirectly
through regulation of the production of other neurotrophic factors
in the CGC cultures.
[0360] All of the references cited herein are hereby incorporated
in their entireties by reference.
[0361] The above descriptions of exemplary embodiments of retinal
pigmented epithelium derived neurotrophic factor are for
illustrative purposes. Because of variations which will be apparent
to those skilled in the art, the present invention is not intended
to be limited to the particular embodiments described above. The
present invention may also be practiced in the absence of any
element not specifically disclosed. The scope of the invention is
defined by the following claims.
Sequence CWU 0
0
SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 34 <210>
SEQ ID NO 1 <211> LENGTH: 1503 <212> TYPE: DNA
<213> ORGANISM: HUMAN <220> FEATURE: <221>
NAME/KEY: mRNA <222> LOCATION: (1)..(1503) <220>
FEATURE: <221> NAME/KEY: CDS <222> LOCATION:
(117)..(1373) <223> OTHER INFORMATION: PRODUCT = PIGMENT
EPITHELIAL-DERIVED FACTOR GENE = PEDF CODON_START =1 <220>
FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION:
(117)..(170) <223> OTHER INFORMATION: GENE = pedf CODON_START
= 1 <220> FEATURE: <221> NAME/KEY: mat_peptide
<222> LOCATION: (171)..(1370) <223> OTHER INFORMATION:
PRODUCT = PIGMENT EPITHELIAL-DERIVED FACTOR GENE = PEDF CODON_START
= 1 <400> SEQUENCE: 1 ggacgctgga ttagaaggca gcaaaaaaag
atctgtgctg gctggagccc cctcagtgtg 60 caggcttaga gggactaggc
tgggtgtgga gctgcagcgt atccacaggc cccagg atg 119 Met cag gcc ctg gtg
cta ctc ctc tgc att gga gcc ctc ctc ggg cac agc 167 Gln Ala Leu Val
Leu Leu Leu Cys Ile Gly Ala Leu Leu Gly His Ser -15 -10 -5 agg tgc
cag aac cct gcc agc ccc ccg gag gag ggc tcc cca gac ccc 215 Arg Cys
Gln Asn Pro Ala Ser Pro Pro Glu Glu Gly Ser Pro Asp Pro -1 1 5 10
15 gac agc aca ggg gcg ctg gtg gag gag gag gat cct ttc ttc aaa gtc
263 Asp Ser Thr Gly Ala Leu Val Glu Glu Glu Asp Pro Phe Phe Lys Val
20 25 30 ccc gtg aac aag ctg gca gcc gct gtc tcc aac ttc ggc tat
gac ctg 311 Pro Val Asn Lys Leu Ala Ala Ala Val Ser Asn Phe Gly Tyr
Asp Leu 35 40 45 tac cgg gtg cga tcc agg atg agc ccc acg acc aac
gtg ctc ctg tct 359 Tyr Arg Val Arg Ser Arg Met Ser Pro Thr Thr Asn
Val Leu Leu Ser 50 55 60 cct ctc agt gtg gcc acg gcc ctc tcg gcc
ctc tcg ctg gga gcg gag 407 Pro Leu Ser Val Ala Thr Ala Leu Ser Ala
Leu Ser Leu Gly Ala Glu 65 70 75 cag cga aca gaa tcc atc att cac
cgg gct ctc tac tat gac ttg atc 455 Gln Arg Thr Glu Ser Ile Ile His
Arg Ala Leu Tyr Tyr Asp Leu Ile 80 85 90 95 agc agc cca gac atc cat
ggt acc tat aag gag ctc ctt gac acg gtc 503 Ser Ser Pro Asp Ile His
Gly Thr Tyr Lys Glu Leu Leu Asp Thr Val 100 105 110 act gcc ccc cag
aag aac ctc aag agt gcc tcc cgg atc gtc ttt gag 551 Thr Ala Pro Gln
Lys Asn Leu Lys Ser Ala Ser Arg Ile Val Phe Glu 115 120 125 aag aag
cta cgc ata aaa tcc agc ttt gtg gca cct ctg gaa aag tca 599 Lys Lys
Leu Arg Ile Lys Ser Ser Phe Val Ala Pro Leu Glu Lys Ser 130 135 140
tat ggg acc agg ccc aga gtc ctg acg ggc aac cct cgc ttg gac ctg 647
Tyr Gly Thr Arg Pro Arg Val Leu Thr Gly Asn Pro Arg Leu Asp Leu 145
150 155 caa gag atc aac aac tgg gtg cag gcg cag atg aaa ggg aag ctc
gcc 695 Gln Glu Ile Asn Asn Trp Val Gln Ala Gln Met Lys Gly Lys Leu
Ala 160 165 170 175 agg tcc aca aag gaa att ccc gat gag atc agc att
ctc ctt ctc ggt 743 Arg Ser Thr Lys Glu Ile Pro Asp Glu Ile Ser Ile
Leu Leu Leu Gly 180 185 190 gtg gcc cac ttc aag ggg cac tcc gta aca
aag ttt gac tcc aga aag 791 Val Ala His Phe Lys Gly His Ser Val Thr
Lys Phe Asp Ser Arg Lys 195 200 205 act tcc ctc gag gat ttc tac ttg
gat gaa gag agg acc gtg agg gtc 839 Thr Ser Leu Glu Asp Phe Tyr Leu
Asp Glu Glu Arg Thr Val Arg Val 210 215 220 ccc atg atg tcg gac cct
aag gct gtt tta cgc tat ggc ttg gat tca 887 Pro Met Met Ser Asp Pro
Lys Ala Val Leu Arg Tyr Gly Leu Asp Ser 225 230 235 gat ctc agc tgc
aag att gcc cag ctg ccc ttg acc gga agg atg agt 935 Asp Leu Ser Cys
Lys Ile Ala Gln Leu Pro Leu Thr Gly Arg Met Ser 240 245 250 255 atc
atc ttc ttc ctg ccc ctg aaa gtg acc cag aat ttg acc ttg ata 983 Ile
Ile Phe Phe Leu Pro Leu Lys Val Thr Gln Asn Leu Thr Leu Ile 260 265
270 gag gag agc ctc acc tcc gag ttc att cat gac ata gac cga gaa ctg
1031 Glu Glu Ser Leu Thr Ser Glu Phe Ile His Asp Ile Asp Arg Glu
Leu 275 280 285 aag acc gtg cag gcg gtc ctc act gtc ccc aag ctg aag
ctg agt tac 1079 Lys Thr Val Gln Ala Val Leu Thr Val Pro Lys Leu
Lys Leu Ser Tyr 290 295 300 gaa ggc gaa gtc acc aag tcc ctg cag gag
atg aag ctg caa tcc ttg 1127 Glu Gly Glu Val Thr Lys Ser Leu Gln
Glu Met Lys Leu Gln Ser Leu 305 310 315 ttt gat tca cca gac ttt agc
aag atc aca ggc aaa ccc atc aag ctg 1175 Phe Asp Ser Pro Asp Phe
Ser Lys Ile Thr Gly Lys Pro Ile Lys Leu 320 325 330 335 act cag gtg
gaa cac cgg gct ggc ttt gag tgg aac gag gat ggg gcg 1223 Thr Gln
Val Glu His Arg Ala Gly Phe Glu Trp Asn Glu Asp Gly Ala 340 345 350
gga acc acc ccc agc cca ggg ctg cag cct gcc cac ctc acc ttc ccg
1271 Gly Thr Thr Pro Ser Pro Gly Leu Gln Pro Ala His Leu Thr Phe
Pro 355 360 365 ctg gac tat cac ctt aac cag cct ttc atc ttc gta ctg
agg gac aca 1319 Leu Asp Tyr His Leu Asn Gln Pro Phe Ile Phe Val
Leu Arg Asp Thr 370 375 380 gac aca ggg gcc ctt ctc ttc att ggc aag
att ctg gac ccc agg ggc 1367 Asp Thr Gly Ala Leu Leu Phe Ile Gly
Lys Ile Leu Asp Pro Arg Gly 385 390 395 ccc taa tatcccagtt
taatattcca ataccctaga agaaaacccg agggacagca 1423 Pro 400 gattccacag
gacacgaagg ctgcccctgt aaggtttcaa tgcatacaat aaaagagctt 1483
tatccctaaa aaaaaaaaaa 1503 <210> SEQ ID NO 2 <211>
LENGTH: 418 <212> TYPE: PRT <213> ORGANISM: HUMAN
<400> SEQUENCE: 2 Met Gln Ala Leu Val Leu Leu Leu Cys Ile Gly
Ala Leu Leu Gly His 1 5 10 15 Ser Arg Cys Gln Asn Pro Ala Ser Pro
Pro Glu Glu Gly Ser Pro Asp 20 25 30 Pro Asp Ser Thr Gly Ala Leu
Val Glu Glu Glu Asp Pro Phe Phe Lys 35 40 45 Val Pro Val Asn Lys
Leu Ala Ala Ala Val Ser Asn Phe Gly Tyr Asp 50 55 60 Leu Tyr Arg
Val Arg Ser Arg Met Ser Pro Thr Thr Asn Val Leu Leu 65 70 75 80 Ser
Pro Leu Ser Val Ala Thr Ala Leu Ser Ala Leu Ser Leu Gly Ala 85 90
95 Glu Gln Arg Thr Glu Ser Ile Ile His Arg Ala Leu Tyr Tyr Asp Leu
100 105 110 Ile Ser Ser Pro Asp Ile His Gly Thr Tyr Lys Glu Leu Leu
Asp Thr 115 120 125 Val Thr Ala Pro Gln Lys Asn Leu Lys Ser Ala Ser
Arg Ile Val Phe 130 135 140 Glu Lys Lys Leu Arg Ile Lys Ser Ser Phe
Val Ala Pro Leu Glu Lys 145 150 155 160 Ser Tyr Gly Thr Arg Pro Arg
Val Leu Thr Gly Asn Pro Arg Leu Asp 165 170 175 Leu Gln Glu Ile Asn
Asn Trp Val Gln Ala Gln Met Lys Gly Lys Leu 180 185 190 Ala Arg Ser
Thr Lys Glu Ile Pro Asp Glu Ile Ser Ile Leu Leu Leu 195 200 205 Gly
Val Ala His Phe Lys Gly His Ser Val Thr Lys Phe Asp Ser Arg 210 215
220 Lys Thr Ser Leu Glu Asp Phe Tyr Leu Asp Glu Glu Arg Thr Val Arg
225 230 235 240 Val Pro Met Met Ser Asp Pro Lys Ala Val Leu Arg Tyr
Gly Leu Asp 245 250 255 Ser Asp Leu Ser Cys Lys Ile Ala Gln Leu Pro
Leu Thr Gly Arg Met 260 265 270 Ser Ile Ile Phe Phe Leu Pro Leu Lys
Val Thr Gln Asn Leu Thr Leu 275 280 285 Ile Glu Glu Ser Leu Thr Ser
Glu Phe Ile His Asp Ile Asp Arg Glu 290 295 300 Leu Lys Thr Val Gln
Ala Val Leu Thr Val Pro Lys Leu Lys Leu Ser 305 310 315 320 Tyr Glu
Gly Glu Val Thr Lys Ser Leu Gln Glu Met Lys Leu Gln Ser 325 330 335
Leu Phe Asp Ser Pro Asp Phe Ser Lys Ile Thr Gly Lys Pro Ile Lys 340
345 350 Leu Thr Gln Val Glu His Arg Ala Gly Phe Glu Trp Asn Glu Asp
Gly 355 360 365 Ala Gly Thr Thr Pro Ser Pro Gly Leu Gln Pro Ala His
Leu Thr Phe 370 375 380 Pro Leu Asp Tyr His Leu Asn Gln Pro Phe Ile
Phe Val Leu Arg Asp 385 390 395 400 Thr Asp Thr Gly Ala Leu Leu Phe
Ile Gly Lys Ile Leu Asp Pro Arg 405 410 415 Gly Pro <210> SEQ
ID NO 3 <211> LENGTH: 379 <212> TYPE: PRT <213>
ORGANISM: HUMAN <220> FEATURE: <223> OTHER INFORMATION:
/note= Met 1...Ile 4 is an N-terminal fusion to Asp 44...Pro 418 of
SEQ ID No: 2; Met 1...Glu 43 of SEQ ID NO:2 is deleted <400>
SEQUENCE: 3
Met Asn Arg Ile Asp Phe Phe Phe Lys Val Pro Val Asn Lys Leu Ala 1 5
10 15 Ala Ala Val Ser Asn Phe Gly Lys Asp Leu Tyr Arg Val Arg Ser
Ser 20 25 30 Met Ser Pro Thr Thr Asn Val Leu Leu Ser Pro Leu Ser
Val Ala Thr 35 40 45 Ala Leu Ser Ala Leu Ser Ser Gly Ala Glu Gln
Arg Thr Glu Ser Ile 50 55 60 Ile His Arg Ala Leu Tyr Tyr Asp Leu
Ile Ser Ser Pro Asp Ile His 65 70 75 80 Gly Thr Tyr Lys Glu Leu Leu
Asp Thr Val Thr Ala Pro Gln Lys Asn 85 90 95 Leu Lys Ser Ala Ser
Arg Ile Val Phe Glu Lys Lys Leu Arg Ile Lys 100 105 110 Ser Ser Phe
Val Ala Pro Leu Glu Lys Ser Val Gly Thr Arg Pro Arg 115 120 125 Val
Leu Thr Gly Asn Pro Arg Leu Asp Leu Gln Glu Ile Asn Asn Trp 130 135
140 Val Gln Ala Gln Met Lys Gly Lys Leu Ala Arg Ser Thr Lys Gln Ile
145 150 155 160 Pro Asp Glu Ile Ser Ile Leu Leu Leu Gly Val Ala His
Phe Lys Gly 165 170 175 Gln Trp Val Thr Lys Phe Asp Ser Arg Lys Thr
Ser Leu Glu Asp Phe 180 185 190 Tyr Leu Asp Glu Glu Arg Thr Val Arg
Val Pro Met Met Ser Asp Pro 195 200 205 Lys Ala Val Leu Arg Tyr Gly
Leu Asp Ser Asp Leu Ser Cys Lys Ile 210 215 220 Ala Gln Leu Pro Leu
Thr Gly Ser Met Ser Ile Ile Phe Phe Leu Pro 225 230 235 240 Leu Lys
Val Thr Gln Asn Leu Thr Leu Ile Glu Glu Ser Leu Thr Ser 245 250 255
Glu Phe Ile His Asp Ile Asp Arg Glu Leu Lys Thr Val Gln Ala Val 260
265 270 Leu Thr Val Pro Lys Leu Lys Leu Ser Tyr Glu Gly Glu Val Thr
Lys 275 280 285 Ser Leu Gln Glu Met Lys Leu Gln Ser Leu Phe Asp Ser
Pro Asp Phe 290 295 300 Ser Lys Ile Thr Gly Lys Pro Ile Lys Leu Thr
Gln Val Glu His Arg 305 310 315 320 Ala Gly Phe Glu Trp Asn Glu Asp
Gly Ala Gly Thr Thr Pro Ser Pro 325 330 335 Gly Leu Gln Pro Ala His
Leu Thr Phe Pro Leu Asp Tyr His Leu Asn 340 345 350 Gln Pro Phe Ile
Phe Val Leu Arg Asp Thr Asp Thr Gly Ala Leu Leu 355 360 365 Phe Ile
Gly Lys Ile Leu Asp Pro Arg Gly Pro 370 375 <210> SEQ ID NO 4
<211> LENGTH: 14581 <212> TYPE: DNA <213>
ORGANISM: HUMAN <220> FEATURE: <223> OTHER INFORMATION:
mRNA: 6683; EXON: 6683-6790; EXON 11584-11675; EXON: 14539-14581;
INTRON: 6791-11583; INTRON: 11676-14538; CDS: 11584-11675;
14539-14580 <400> SEQUENCE: 4 gatctagagc ggccgcaggg
tggactgtgc tgaggaaccc tgggcccagc agggtggcag 60 cccgcgcagt
gccacgtttg gcctctggcc gctcgccagg catcctccac cccgtggtcc 120
cctctgacct cgccagccct cccccgggac acctccacgc cagcctggct ctgctcctgg
180 cttcttcttc tctctatgcc tcaggcagcc ggcaacaggg cggctcagaa
cagcgccagc 240 ctcctggttt gggagaagaa ctggcaatta gggagtttgt
ggagcttcta attacacacc 300 agcccctctg ccaggagctg gtgcccgcca
gccgggggca ggctgccggg agtacccagc 360 tccagctgga gacagtcagt
gcctgaggat ttgggggaag caggtgggga aaccttggca 420 cagggctgac
accttcctct gtgccagagc ccaggagctg gggcagcgtg ggtgaccatg 480
tgggtgggca cgcttccctg ctgggggtgc agggggtcca cgtggcagcg gccacctgga
540 gccctaatgt gcagcggtta agagcaagcc cctggaagtc agagaggcct
ggcatggagt 600 cttgcttctt gcaaacgagc cgtgtggaga gagagatagt
aaatcaacaa agggaaatac 660 atggtctgtc cgaggatgag ctgccggaga
gcaatggtga aagtgaagtg ggggaggggg 720 cggggctggg aggaaaagcc
ttgtgagaag gtgacacgag agcacggcct tgaaggggaa 780 gaaggagggc
actatggagg tcccggcgaa gcgtggcctg gccgaggaac ggcatgtgca 840
gaggtcctgc cgaggagctc aagacaagta ggggacggtg gggctggagt ggagagagtg
900 agtgggagga ggagtaggag tcagagagga gctcaggaca gatcctttag
gctctaggga 960 cacgataaac acagtgtttt ttgtcttgtc aagtgtgtcc
tttttatttt tttgaaagag 1020 tctcgctctg tagcccaggc tggagtgcag
cggtgcgacc tcggctcagt gcaacctctg 1080 cctcccgggt ccaagcaatt
ctcctgcctc agcctcccga gtagctggga ttacaggcac 1140 ccgccaccac
gcactgctaa tttttgtatt ttagtagaga ccgggttttg ccatgttggt 1200
caggctggtc tcgaactcct gacctcaggt gatccgcccg cctcggcctc ccagagtggt
1260 gtgagccact atgccctgca gcacttgtca agtctttctc agcgttcccc
tcctctccac 1320 tgcagctccc agtgccccag tctgggcctc gtcttcactt
cctgggatcc ctgacattgc 1380 ctgctaggct ctccctgtct ctggtctggc
tgccttcact gtaacctcca cccagcaggt 1440 acctcttcag cacctcccat
gaacccagca gaataccaag ccctggggat gcagcaacga 1500 acaggtagac
gctgcactcc agcctgggcg acagagcaag actccgcctg aagaaaaaaa 1560
aaaggaccag gccgggcgcg gtggctcacg cctgtaatcc cagcactttg ggaggccgag
1620 gtgggtggat catgaggtca ggagttcaag accagcctgg caaaaatggt
gaaaccccgt 1680 ctctactgaa aaatacaaaa attagctggg tgcagtggcg
ggcgcctgta gtctcagcta 1740 ctcaggaggc tgaggcagga taattgcttg
accccaggag gcagaggttg cagtgaaccg 1800 agatcacgcc actgcactcc
agcctgggcg acagagcaag actctgcctc aaaaaaaaga 1860 ataaaaataa
aaaaaaggac cagatacaga aaacagaagg agacgtacta tgaaggaaat 1920
tggagagctt ttgggatact gagtaactca gggtggcctt tcccagggga catttagctg
1980 agagatagac ggtatgaaga cctgaccgtt cagaaacagg ggaagaggca
gcagcccggg 2040 caaaggcctt tggggcagga aagggcttgg atcactggag
aagcagaaag atggccagtg 2100 tgaccagagt gtgacaaagt cagagaaaac
caggaagatg gagctggaga cacaggcggg 2160 gccagatcac gagggtcctc
gcagaccaga gcaagggttt ggattttatt ccaagtatga 2220 agggaagctg
ctgaagtgtg ttttccttta caatttgtag ttgaaatata atatgcaaag 2280
tacacaagtc ttaactatat gtaagcttaa tgaatgtttc catgaaccaa ataccgctgt
2340 gcaaccatca ccagctcaag agacgaaccc ttctccctcc tcctgactgc
cagtaacata 2400 gtggttcagc tcaagaaaca gaactcttct gacttcccct
aacatagcgg gttttctttt 2460 ttgttttgtt ttttgttgtt ttttaagaga
caatgtcttt attattttta ttttttttta 2520 tttttgagac ggagtcttgc
tgtcgcccag gctggagtgc agtggtgcga tctcggctca 2580 ctgcaggctc
tgccccccgg ggttcatgcc attctcctgc ctcagcctcc ctagcagctg 2640
ggactacagg tgcccgccac ctcgcccggc tatttttttg tatttttagt ggagacgggg
2700 tttcaccgtg ttagccagga tggtctcgat ctcctgacct cgtgatccgc
ccacctcggc 2760 ctcccaaagt gctgggatta caggcatgag ccaccgcgcc
cagccaagag acacggtctt 2820 gctctgtcgc ccaggctgga tggagtgccg
tggtgcgatc acagctcgcg gcagccttga 2880 catcctgggc tcaagcaacc
ttcctgcctt ggcctcccaa atgttgggat tataggcatg 2940 agccactgtg
cttggcatct attcatcttt aatgtcaagc aggcaattga atatttgatc 3000
agggatagaa ttgtctattt gggggtatgc agatgtgctt catgtcatgg aactgggccg
3060 ggcgcggtgg ctcatgccta taatcccagc actttgggag gccgaggcag
gcggatcata 3120 aggtcaggag atcgagacca tccgggccaa caggtgaaac
cccgtctctt actaaaaata 3180 caaaaattag gcaggtgtgg tggtgcgtgc
ctgtagtccc agctactcag ggaggctgag 3240 acaggagaat tgattgaacc
tgggaggcag aggttgtagt gagccaagat cgcgccactg 3300 cactccagcc
tgggcgacat gagcgagact ccgtctcaaa aataaacaaa aaaaagtcat 3360
ggaattgatg gaaattgcct aaggggagat gtagaagaaa aggggtctca ggatcaagcc
3420 agcagagaag gcagaaaagg taaggtgtgt gaggtggcag aaaaagggaa
gagtgtggac 3480 agtgagggtt tcaaggagga ggaactgtct actgcctcct
gccaaggacg gaggtgtcca 3540 ctgccagttg acataaggtc acccatgaac
ttggtgacag gaatttcagt ggagaagtgg 3600 ccacagacac aagtctagaa
ttgaaatggg agccgaggca gcgtagacaa aagaggaaac 3660 tgctccttgc
agagcggctc tgagcgagca ccgagaaatg ggcagtggct ttaggggatg 3720
tagcgtcaag gaagtgtctt ttaaagaagt cgggggccgg gcacggtggc tcacgcctgt
3780 agtcccagca ctttgggagg ccgaggcagg cagatcactt gaggtcagga
gttcgagacc 3840 agcctggcta acacgatgaa accccgtctc tactaaaaat
acaaaaaatt agctgggcac 3900 ggtggctcgt gcctgtaatc ccagcacttt
gggaggcaga ggtgggcaga tcacttgagg 3960 tcaggagttt gagaccagcc
tagccaacat ggtgaaaccc catctctact aaaactacaa 4020 aaattagccg
ggagtggtgg cacgtgcctg taatcccagc cagtcaggag gctgaggcag 4080
gagaatcact ggaatcctgg aggtggaggt ggcagtgagc cgagatggta cctctgtact
4140 ccagcctggg ggacagagtg agactccgtc tcaaaaaaaa aagaaggtgg
ggaaggatct 4200 ttgagggccg gacacgctga ccctgcagga gaggacacat
tcttctaaca ggggtcggac 4260 aaaagagaac tcttctgtat aatttatgat
tttaagattt ttatttatta ttatttttta 4320 tagaggcaag catttttcac
cacgtcaccc aggctggtct ccaactcctg ggctcaagtg 4380 tgctgggatt
atagccatga gtcaccacac ctggcccaga aactttacta aggacttatt 4440
taaatgattt gcttatttgt gaataggtat tttgttcacg tggttcacaa ctcaaaagca
4500 acaaaaagca cccagtgaaa agccttcctc tcattctgat ttccagtcac
tggattctac 4560 tcttgggatg cagtgttttt catctctttt ttgtatcctt
ttggaaatag tattctgctt 4620 taaaaagcaa ttacaggcca ggtatggtgg
ctcactcctg taatcccagc actttgggag 4680 gccgaggcag gtgatcacct
aaggtcagga gttcaagacc agcctggcca atatggtgaa 4740 accctgtctg
taccaaaaga caaaaacaaa aacaaaaaca aaaattagcc gggcgtggtg 4800
gcgtgctcct gtaatcccag ctactcagga ggctgaggca ggagaatcgc ttgaacctgg
4860 gaggcagagg ttgcagtgag ccgagattgt gccactgtac tccagcctgg
gccacagagc 4920 aaggttccat ctcaaacaaa acaaaacaaa acaaacaaaa
aaacaaaaca aaagctaata 4980
caaacacata tacaatagac aaaactgtaa atattttatt atttttattt tttttagtag
5040 agacagggtt tcaccatgtt ggccaggatg gtctcaaact cctgacctca
ggtgatccac 5100 ccacctcagc ctcccgatag ttaggattac aggcatgagc
caccacaccc ggcctaaaat 5160 tgtaaacgtt ttagaagaaa gtatagatga
atcccttcgt gatctcgggg aagaagagat 5220 tttttaaaaa agataccaaa
agaagcacaa attataaaag aaaagattga aaatgttggt 5280 gttaaaatta
aaaacttgtt ttaaaacaag cttgtgtaac ccatgaccca caggctgcat 5340
gtggcccaga aaagctttga ctgcagccca acacaaattc gtaaactttc ctaaaacatt
5400 atgagatttt ttttgagatt ttgttttgtt ttgttttttg tttttttagc
tcattcggta 5460 tcattaatgt tagcatattt tacgtggggc ccaagacaat
tcttcttcca atgtgtctca 5520 ggggagccaa aagattggac acccctgcca
taaacatgaa aagacaatgg ccgggcacgg 5580 tggctcacgc ctgtaatccc
agcactttgg gaggctgagg ggggcgggat cacctgaggt 5640 caggagtttg
agacaagcgt gaccaatgtg gtgaaaccct gtctctacta aaaatacaaa 5700
aattagccgg gcatgctcgt gcacacctat agtcccaact actcagcagg gtgaggcagg
5760 agaacctctt gaacccggga agcggaggtt gcagtgagcc gacattgcac
ccctgcactc 5820 gagcctgggt gacagagtga gtctccactg gaaaaaaaaa
aaaaagaaca gtgtgataca 5880 ttgacctaag gtttaagaac atgcaaactg
atactatata tcacttaggg acaaaaactt 5940 acatggtaaa agtaaaaaga
aatgtacgaa aataataaaa atcaaattca agatggtggt 6000 tatggtgacg
ggaaagaact gaggcggaaa tataaggttg tcactatatt gagaaatttt 6060
tctatctttt ttttcttttt tcttttttga gacggggtct cgctctgtcg cccaggatgg
6120 agtgcagtgg tgtgatctca gctcactgca acctccgcct cccaggttta
agtgattctc 6180 ctgcctcaga ctcccaagta gctgggacta caggtgcgcg
ccaacacacc tgggtaattt 6240 tgtttgtatt tttagtagag atggggtttc
accgtgttga ctaggctggt ctcgaactcc 6300 tgacctcagg tgatcccccg
gcctcggtct cccaaagtgc tgggataaca agcgtgagcc 6360 actgcgccca
gctttgtttg catttttagg tgagatgggg tttcaccacg ttggccaggc 6420
tggtcttgaa ctcctgacct caggtgatgc acctgcctca gtctcccaaa gtgctggatt
6480 acaggcgtta gcccctgcgc ccggcccctg aaggaaaatc taaaggaaga
ggaaggtgtg 6540 caaatgtgtg cgccttaggc gtaatggatg gtggtgcagc
agtgggttaa agttaacacg 6600 agacagtgat gcaatcacag aatccaaatt
gagtgcaggt cgctttaaga aaggagtagc 6660 tgtaatctga agcctgctta
tggacgctgg attagaaggc agcaaaaaaa gctctgtgct 6720 ggctggagcc
ccctcagtgt gcaggcttag agggactagg ctgggtgtgg agctgcagcg 6780
tatccacagg taaagcagct ccctggctgc tctgatgcca gggacggcgg gagaggctcc
6840 cctgggctgg ggggacaggg gagaggcagg ggcactccag ggagcagaaa
agaggggtgc 6900 aagggagagg aaatgcgaga cagcagcccc tgcaatttgg
ggcaaaaggg tgagtggatg 6960 agagagggca gagggagctg gggggacaag
gccgaaggcc aggacccagt gatccccaaa 7020 tcccactgca ccgacggaag
aggctggaaa ggcttttgaa tgaagtgagt gggaaacagc 7080 ggagggcggg
tcatggggag gaaaggggag ctaagctgct gggtcgggtc tgagcagcac 7140
cccaagactg gagcccgagg caaggaggct cacgggagct gcttccacca agggcagtca
7200 ggaaggcggc cgccctgcag cccagccctg gcccctgctc cctcggctcc
ctgctacttt 7260 ttcaaaatca gctggtgctg actgttaagg caatttccca
gcaccaccaa accgctggcc 7320 tcggcgccct ggctgagggc tgggatggag
gacagctggg tccttctagc cagcccccac 7380 ccactctctt tggctacatg
agtcaaggct gggcgaccaa tgaggttgtg gcctccggca 7440 aacaatgacc
actatttagg ccggcaggtg tatagggcgt gggggcccag ctgccagtgc 7500
tggagacaag ggctgtccga gatgaaccct ttctgctgcc tgccaagcca ctgggagggg
7560 taggtctcag caggattccc agaaaccccg cccctgtcca gcctaggccc
cccacccggt 7620 gttagctaac ccaacgttag cccccaggtt ccgtggggtt
ggggggcagg gagtcctatt 7680 cttggggctg ctgcttctgg ggtgtgggga
agtgcaactc cacggcaccc tgggctgact 7740 cattcagctt ctaaagcttc
aggaaacatt gtttggggct gggtcaccat gggtgggcca 7800 gagaggaccc
ctcaatcccc tccggagagc caggggaggg ggaggtgccc ttccccatgc 7860
tatctccgag gccactgcca tgtggcctga aggctgtgcg gttctgggaa gagggggagg
7920 tggcggtgga ggctgtttgt ctcctaactg ggcttaatct gaaacacatg
tattggcttg 7980 agttgatccg cctcacgtgg aggcaagatc acaaaagctt
ctgtgtttct tgatgtgggc 8040 aattgtcaga aaataaggcc tgaccttggc
ccagcaggga gggtatctac ctctccctga 8100 gccctccccc gcctgctagg
acgagagcgg ggcttggata ctgccctttg gacaggatgg 8160 catcattgtc
tgtggctgca gccagccagc ggtcgcctgc tcagcccatg agcaaccact 8220
gtggacaggg tattgcgtgt gtgctgaggg gcgtccatgc agacccccac gcttgccctc
8280 tcactgccct tgtagggttt tcaatcatct ctcctcttcc cttatccaga
tggcttgaag 8340 tggaggattc agacttgccg ttaatactct gggtccctgt
gtctagctcg gggccacctt 8400 tggacccatg tcccttccct gccaggctcc
ctcacctcac ctcagcctac ccacattgtg 8460 acaatcatct accacctgat
ctggggtttg ggcttagatt ctgtaggcac caagactaaa 8520 gtcgctcctt
caagtccatt tgaattgtga ctttagtttc cttaaatact atgccaggat 8580
aatggccagg gatggtggct cacgcctgta ctcctggcac tttgggatgc tggtggatca
8640 cctgagatca ggattccagg ccagcctggc caacacggtg aaaccccatc
tctactaaaa 8700 cataaaaatt aaccaggtgt ggtggcgggc acctgtaatc
ccagctactc aggagactga 8760 ggcaggagaa ttgcttgaac ccgggaggtg
gaagttgcac tgagctgaga tcgcgccact 8820 gcactttagc ctgggcgaca
agagtgaaac tctgtctcaa aaacaaaaaa aactatgccg 8880 ggatgagcct
gtctcctccc ttaatttctt acttgggcca gaggaactag aactaacaac 8940
ttctcttcta gccttgcctc ctgtgtacct cactgaattt ttggtctcta ataaaccagt
9000 ctgcagaggc tcaggggagg caggctcctg gcagctgggt ggggctggcc
ccagccgggt 9060 ggagaccagc tgtaggcctg gatggtggtg aggcctctgt
cttgcactgc agaaagcttt 9120 tcctgttgtc tacacgaaag ttttctccct
gcatgtcagg gcagccacgt gcaagagcag 9180 ctggctggga acgcagaggt
ctgcggctcg aggcggggtt tagaaaggaa aaccaggctg 9240 cttcctgctg
cccgtcctgc cttaagctga gtaaactcaa aggcaatctt ctttcatgcc 9300
tcacgatatt gtccagtgga ttatctgatt taatttgaag gacgagagcc aacaatcaca
9360 caacgtcctc ccaaattttc tgatccactt tgttctggga agtcaaaaag
tgcgtgtgct 9420 gtgtgggtgg atgtttgtga tataaatgga taatgaagga
tgatgtgttg gggggccagg 9480 gcaggggaga caacgctgtt cagattctac
attttttttt cctttttttt ttttttttga 9540 gatggagtct tgctctgttg
cccagcctgg agtgcagtgg cgcgatctca gctcactgca 9600 acctccactt
cctggattca agtgattctc ctgccttagc ctcccaagta gctgggatta 9660
caggcatgcg ccaccacacc cggctaattt ttgtattttt agtagagatg gggtttctcc
9720 atgttggcca ggatggtctc aaactcctga cctcaggtga tctacccgcc
tcggcctctc 9780 aaagtgctgg gattacaggt ttgagccact gcgcctggcc
tttttttttt tttttgagat 9840 ggagttttca ctcttgttgc ccaggctgga
gtgcagtggt gcgatcttgg ctcactgcaa 9900 cctccacctc ccaagttcaa
gtgattctcc agccttagcc ctccaagtag ctgggactac 9960 aggtgtgtgc
caccatgcct ggctatttta ttttatttta ttttatttat ttatttttga 10020
gactaagtct tgctctgttg cccaggctgg agtgcagtgg cataatcggc tcactgcaac
10080 ctctgcctcc caggttcaag tgattctcct gcctcagcct cctgagtaac
tgggattaca 10140 ggggcctgcc accacgcctg gctacttttt gtatttttag
tatagatggg gtttcaccat 10200 gttggccagg ctggtctcga actcctgacc
tcaggctatc cgcctgcctc agcctcccaa 10260 aagtgctggg attacaggca
tgagccactg tgctcggtag ttgtttattt taatagtagg 10320 ttattttatt
tccattttac aagagaaaaa atggtgattt aaagagctac taagacacag 10380
cactgagacc atgtgtgatg gcatgcgcct gcagtcccag ctactcacga ggctgaggca
10440 ggaggatcac atgaggtcag gagttccagg ctgtggagtg ctatggttgt
gtagtgaata 10500 gccactacac tccagcctgg gcagcacagc aagatcttgt
ctcccaaaaa aaaaaaaaaa 10560 aaaaaatttc aaatgtgaac ccaggatctc
tgaccgggct aggccctgca ctgctaacca 10620 tgggaggaag agctcttgaa
agggaactgt gggagaaggg aatgagctgc cttgtgaggc 10680 cacagaagtc
caaagacagc ttgagaattt ggaggacagc acgtgccgga ctggggtgcc 10740
tctatgcttg gtatccggtg attccatgga ggagacctgg gttctgcccc attctcctgg
10800 gaggggttgc ccaaagtctt atcaccggag tgggtcagct gcctccagga
caaagcttta 10860 gcatacactt gtgctgggcc atactccacg tggagaagcc
ctgctggggc tggggcccca 10920 ctgctctgga tctttaaaag ctattggttc
aggggccagg tgtaatggct cacacctata 10980 accctagcac tttgggaggc
tgaagcaggt ggatagcctg aggtcaggag tttgagacaa 11040 gcctgatgac
gtggtgaaac cccatcgcta ttaaaaatac aaaaaattag ccgggcatgg 11100
tggcaggtgc ctgtaattcc agctacttgg gaggctgagg cgggagaatc gcttgaaccc
11160 aggaggcgga ggttgcagtg agccaagatc gctccactgt actccagcct
gggcgacaga 11220 gccagactct gtttcaaaaa ataaaatata aataaataaa
taaataaata aataaataaa 11280 taaaagcttt aggcttaaag gagggtcccc
tgacgcagac agtggaacaa aagcacaagc 11340 ttatggtatg actgtgggcc
ctgaggcagg gggaggggcg ggagaacctt gctgggaggg 11400 atgggccatc
aagctgaggg tccacttctg ggggcctgga ggggtgaggg gtggtcgctg 11460
cagggggtgg gggaaagtga ctaacccctg ggtcctggct gggcctggct ggggtggcca
11520 ggaaggggta gcggggcagt gcagtgtcgg gggagagcgg cttgctgcct
cgttcttttc 11580 ttgcaggccc caggatgcag gccctggtgc tactcctctg
cattggagcc ctcctcgggc 11640 acagcagctg ccagaaccct gccagccccc
cggaggtcag taggcaggcg gggagggcgt 11700 ggtcagcatt ccccgcccct
ccttggcagg cagcacggga aacaggacag ggaacccgga 11760 cccaggttcc
aggccaggct tgggccttta tttctctagg gctggagttt ctccagcagc 11820
aaaacagaga gaaaatgtct tgccttgcct ttcaggggat ggagtaggga catgaataag
11880 atcccaaaag agtaaaaatc tgaagcactt ttaacaagtc cagggcaatt
ctcctgcctc 11940 agcttcccaa gcagctggga ttacaggcat gcaccaccaa
gcccggctca ttttgtattt 12000 ttagtagaga cggggtttct ccatgttggt
caggctggtc tcgaactccc gacctcaagt 12060 gattctcctg cctcggcctc
ccaaagtgcc gggatgacag gtgtgagcca ccgcacctgg 12120 ccaggatctt
ttctcattac cttgtcttcc tagtgggggc tccactgagc aggtcatgtt 12180
cccggacatt tgttcggata ctgaccaggc tgtggcaggg agtgagggta tggagtgacc
12240 tctctcctgc ccagaaaggg cgcagctggg ttcccaaggc agatacaggc
acatggaggg 12300 aagcctgggc catatgagtg ttatggggtg agtgttggcg
gaggcccacc cttgagggac 12360 aagagcagct gggcatcttg gcgagagccc
tggactttcg tgaggtcaga gtatgaattc 12420 tgcgtctccc tcttcctagc
tttgtgaccc tagacaaccc ttacctcagt ctttgcttcc 12480
ttgcctatga aatgggataa aaacacccat tctacagggc catgtggcca ctcatttatt
12540 tctcatctac caaacaccta ctcgacaggg gctggcaatg ggcggaaata
aaaactcagt 12600 tctgccgggt gcggtggctc acacctgtaa tcccagcagt
gtgggaggcg gagcaggacg 12660 atcccttgaa tccaggagtt tgagaccagc
ataggcaaca tagtgagacc cctgtctcta 12720 cacaaaagca aaaattacca
ggcgtggtgg caagtgcttg tggtactacc tacttgggaa 12780 gctgaggtgg
gaggatcact tgagcccagg agattaagac tgcagtgagg ggccgggcgc 12840
ggtggctcac gcctgtaatc ccagcacttt gggaggtgga ggtgggtgga tcacgaggtc
12900 aggagatcga gaccatcctg gctaacacgg tgaaaccccg tctctactaa
aaatacaaaa 12960 aattagctgg gtgtggtggg gggcgcctgt agtcccagct
actcgggagg ctgaggcagg 13020 agaatggcgt gaacccggga ggtggaggtt
gcagtgagct gagctcgcac cactgcactc 13080 cagcctgggc gacagagtga
gactccgtct caaaaaaaaa aaaaaaagaa agaaagaaag 13140 aaaaactgag
ttcttttttt taactttctt tttttagaga cagagtctca ctccatcacc 13200
catgctggag tacagtggtg cgatcttggc tcactgcaat cttggcctcc tgagttcaac
13260 caattctcat gcctcagcct cccaaatagc tgggaccaca ggcacgtgcc
accacgccca 13320 gctaattttt tgggtatttt tagtagagat ggggcctcac
catgttgctc aggttggtct 13380 gaaactcctg agctcaagtg atccatcttc
ctcggcctgc caaagtgctg ggattatagg 13440 cataagccac tgcacctagc
tcccaatttt tatatttata tttattttta tttacttatt 13500 tattttttga
gacagggtct cactctgtca cccaggctgg agtacagtgg cactatctca 13560
gctcactgca acctctgcct cctgggttca agcgaatctc gtgcctcagc ctcctgagta
13620 gctgggatta caggcatgca ccaccatgcc ccgttaattt ttttgtattt
ttagtagaga 13680 cgggtttcac cgtgttgccc aggatggtct cgaactcctg
acctcaagtg attcacccac 13740 ctcagcctcc caaagtgctg ggattatagg
tgtgagccac tcggctgatg gtttttaaaa 13800 agtgggtcat ggggctgggc
gcggtggctc atgcctgtaa tcccagcact ttggtagacc 13860 gaggcgggtg
gatcacaagg tcaggagatc gagaccatcc tgcctaacac ggtgaaaccc 13920
cgtctctact aaaaatacaa aaaattaccc aggcatggtg gtgggcgcct gtagtcccag
13980 ctactcggga ggctgaggca ggagaatggc gtgaacctgg gaggcggagc
ttgcagtgag 14040 ccgagatcac gccaccgtac tccagcctga gcgacagagc
gagactccgt ctcaaaaaaa 14100 aaaaaaaaaa gtgggtcata ggtttcggct
tataggtcac aagtgtttaa acctggccat 14160 gaggccaggc gcagtggcgc
atgcctgtaa tcccagccat ttgggaggct aaggcaggaa 14220 aatcgcttga
accggggagg tggaggttgc agtgagctga gatcgcgcca ctgaactcta 14280
gcctgggtga cacagtaaga ctctgtctca aataaaaaaa aaaacagctg atctctcttc
14340 tgcgctgtct ctccacagag agctcatgcg tgatcaggga gtaaaactca
ttcccgtttt 14400 aggccaaaca cagaaaaatt aggaaggaca gccccaaggg
gccagaacca ccaccctaca 14460 caaagccgtg aggagacagt ccctgtgcat
ctctgcgagt ccctgaactc aaacccaaga 14520 cttcctgtct cctgccaggg
ctccccagac cccgacagca caggggcgct ggtggaggag 14580 g 14581
<210> SEQ ID NO 5 <211> LENGTH: 5262 <212> TYPE:
DNA <213> ORGANISM: HUMAN <220> FEATURE: <221>
NAME/KEY: exon <222> LOCATION: (35)..(160) <223> OTHER
INFORMATION: EXON 35-161; EXON 1142-1297; EXON 1984-2187; EXON
5170-5255; INTRON 162-1141; INTRON 1298-1983; INTRON 2188-5169; CDS
35-161; CDS 1142-1297; CDS 1984-2187; CDS 5170-5255 <220>
FEATURE: <221> NAME/KEY: exon <222> LOCATION:
(1142)..(1297) <220> FEATURE: <221> NAME/KEY: exon
<222> LOCATION: (1984)..(2187) <220> FEATURE:
<221> NAME/KEY: exon <222> LOCATION: (5170)..(5256)
<220> FEATURE: <221> NAME/KEY: intron <222>
LOCATION: (162)..(1141) <220> FEATURE: <221> NAME/KEY:
intron <222> LOCATION: (1298)..(1983) <220> FEATURE:
<221> NAME/KEY: intron <222> LOCATION: (2188)..(5169)
<223> OTHER INFORMATION: n = a or g or t or c, any base
<400> SEQUENCE: 5 acaagctggc agcggctgtc tccaacttga atac aag
ctg gca gcg gct gtc tcc 55 aac ttc ggc tat gac ctg tac cgg gtg cga
tcc agc atg agc ccc acg 103 acc aac gtg ctc ctg tct cct ctc agt gtg
gcc acg gcc ctc tcg gcc 151 ctc tcg ctg ggtgagtgct cagatgcagg
aagccccagg cagacctgga 200 gaggccccct gtggcctctg cgtaaacgtg
gctgagttta ttgacatttc agttcagcga 260 ggggtgaagt agcaccaggg
gcctggcctg ggggtcccag ctgtgtaagc aggagctcag 320 gggctgcaca
cacacgattc cccagctccc cgaaaggggc tgggcaccac tgacatggcg 380
cttggcctca gggttcgctt attgacacag tgacttcaag gcacattctt gcattcctta
440 accaagctgg tgctagccta ggttcctggg atgtaactgc aaacaagcag
gtgtgggctt 500 gccctcaccg aggacacagc tgggttcaca ggggaactaa
taccagctca ctacagaata 560 gtcttttttt tttntttttt tnnnctttct
gagacggagt ctcgctttgt cnccaaggct 620 ggagtgcagt ggtgtgatct
cagctcactg caacctctgc ctccctggtt caaggaattc 680 tcctgcctca
gcctccagag tagctgggat tacaggcacc tgccatcatg cccagctaat 740
ttttgtattt ttagtagaga cggggtttca ccatgttgcc taggctggtc tcaaactccc
800 gggctcaagc gatccacccg ccttggcctc ccaaagtgct gggattacag
gcgtgagcca 860 ccgcgcctgg ccagaataat cttaagggct atgatgggag
aagtacaggg actggtacct 920 ctcactccct cactcccacc ttccaggcct
gatgccttta acctacttca ggaaaatctc 980 taaggatgaa nattccttgg
ccacctagat tgtcttgaag atcagcctac ttgggctctc 1040 agcagacaaa
aaagatgagt atagtgtctg tgttctggga gggggcttga tttggggccc 1100
tggtgtgcag ttatcaacgt ccacatcctt gtctctggca g gag cgg agc agc gaa
1156 cag aat cca tca ttc acc ggg ctc tct act atg act tga tca gca
gcc 1204 cag aca tcc atg gta cct ata agg agc tcc ttg aca cgg tca
ctg ccc 1252 ccc aga aga acc tca aga gtg cct ccc gga tcg tct ttg
aga aga 1297 gtgagtcgcc tttgcagccc aagttgcctg aggcatgngg gntccatgct
gcaggctggg 1357 ggggtctttt tttttttttt nnnnagacgg agtctcgctc
tgttgcccag gctggagtgc 1417 agtggcgnga tctcggctca ctgcaacctc
cacctcccgg gttcacacca tcctcctgcc 1477 tcagcctccc gagtagctgg
gactgcaggn gcccagctaa tctttnttgt atttttagca 1537 gagacggggt
ttcaccgtgt ttgccaggat agtctcgatc tcctgacctg gtgttctgcc 1597
cgcctcgacc tcccaaagtg ctgggattac aggtgtgagc caccgcgctc ggcccgtttc
1657 taaacaatag atcatgtgtg cccaggcctg gcctggcact ggtgtggagg
aagggcccgt 1717 gagcccaaag aggctcagaa agaggaagtg ggctgcagga
gacggtggga ggggcnggga 1777 gggcagtggc gcgatgtggg gaaatctgct
gcccccctgg ccagtgcctg gggatgccag 1837 cagaagtcct ggcaagtcac
aggaagatgc tggctgggaa gtcagggcct gctgagcgct 1897 aaaccagaac
ccgagcctgg caggctctca aagacgggat gcttgtcgtn gagtctcata 1957
ngctaacctc tgctccgcct cttctc agc tac gca taa aat cca gct ttg tgg
2010 cac ctc tgg aaa agt cat atg gga cca ggc cca gag tcc tga cgg
gca 2058 acc ctc gct tgg acc tgc aag aga tca aca act ggg tgc agg
cgc aga 2106 tga aag gga agc tcg cca ggt cca caa agg aaa ttc ccg
atg aga tca 2154 gca ttc tcc ttc tcg gtg tgg cgc act tca agg
gtgagcgcgt ctccaattct 2207 ttttcattta ttttactgta ttttaactaa
ttaattaatt cgatggagtc ttactctgta 2267 gccctaactg gagtgcagtg
gtgcgatctc agctcaatgc aacctccgcc tcccaggttc 2327 aagcaattct
tgtgcctcag cctcccgagt agctgggatt acagggatgt accaccactc 2387
ccggctaatt ttttgtattt aatagacatg gggtttcacc atgttggcca ggctggtctc
2447 gaactcctga gctcaggtgg tctgcccgcc tcagcctccc aaagtgctag
gattacaagc 2507 ttgagccacc acgcccagcc ctttttattt ttaaattaag
agacaaggtg ttgccatgat 2567 gcccaggctg gtctcgaact cctgggctca
agtaatcctc ccaccttggc ctcccaaagt 2627 gctgggatta caggcatgag
ccaccgcgcc cggccctttt acatttattt atttattttt 2687 tgagacagag
tcttgctctg tcacccaggc tggagtgcag tggcgcgatc tcggctcact 2747
gcaagctctg ccttccaggt tcacaccatt ctcctgcctc gacctcccga gtagctggga
2807 ctacaggcgc ccgccactgc gccctactaa ttttttgtat ttttagtaga
gacggggttt 2867 caccgtggtc tcgatctcct gacctcgtga tccacccgcc
tcagcctccc aaagtgctgg 2927 gattacaggc gtgagccact gcgcccggcc
cttttacatt tatttttaaa ttaagagaca 2987 gggtgtcact atgatgccga
ggctggtctc gaactcctga gctgaagtga tcctcccacc 3047 tcggcctccc
aaaatgctgg gattaccatg tccaactttc cacttcttgt ttgaccaagg 3107
atggatggca gacatcagaa ggggcttgga aagggaggtg tcaaagacct tgcccagcat
3167 ggagtctggg tcacagctgg gggaggatct gggaactgtg cttgcctgaa
gcttacctgc 3227 ttgtcatcaa atccaaggca aggcgtgaat gtctatagag
tgagagactt gtggagacag 3287 aagagcagag agggaggaag aatgaacact
gggtctgttt ggggctttcc cagcttttga 3347 gtcagacaag atttatttat
ttatttaaga tggagtctca ttctgttgcc caggctggag 3407 tgcagtggtg
ccatcttggc tcactacagc ctccccacct cccaggttca agtgcttctc 3467
ctgcctcagc ctcccgagta gttgggatta caggcgcccg ccaccacacc cagctaattt
3527 ttgtattttc agtagagatg gggtttcgcc atgctggcca ggctgttctc
gaaaactcct 3587 gacctcagat gatccacccg cctcggcctc ccacagtgct
gggattacag gcgtgagcca 3647 ctgcgctggc caaatcagac aaggtttaaa
tcccagctct gcctgtacta gctgaggaac 3707 tctgcacaca tttcataacc
tttctgggcc tacgttctca cctttaacgt gaggataata 3767 tatctacttc
atagacacct ttttatgttg tctccaagtt ttctaacagc tctagttctg 3827
tacccaagac atggcaggtg gccaacgaca tccttctagg ctgtggtgat gtgtttggag
3887 cttgttccac gggtcttgtg tggggccagc cctgttcaga taaggccttg
tggggtggcc 3947 tggggtaggg ggaggggttg ggcaaactct cccttaaaac
gctttgtaac catctgaggc 4007 accagcaaga gcggcccccg agcctggaca
aaatccaaac ggcttcctac ttcaagcact 4067 gatgtctagt gagtgaagga
acagctctgg gtccaggata ttataggtca cattaaacta 4127 aaggggcttg
gccatcagct ggcttccaga gcgtcagcca gttacttcac ctctttggct 4187
ttggcctgtt ttcagctaca agaggactta atccagagga cctcagaggt ccttcccagc
4247 tcagaccttc tttgactgtc tcccagagac actgctgtag gagtgcacac
cagtttactt 4307 ttctttcttt tgtttttgag atggagtttc gctctttttg
cctaggctgg agtgctgtgg 4367 tgtgatctca gctcactgca acctctggct
cccaggttca agtgattctc ctgtctctgc 4427 ctcccgagta gctgggatta
cagacaccca ccactgcacc cggctagttt ttgtattttc 4487 agtagagatg
gggtttcgcc atgctggcca ggctgttctc gaaaactcct gacctcagat 4547
gatccatccg ccttggcctc ccaaagtgct gagattacag atgtgaggca ccacacccgg
4607 ccatttttgt atttttagta gagacggggt tttgccatgt tggccacgct
ggtctcaaac 4667 tcctgacctc aagtgatctg cccaccttgg cctcctgaag
ggctgggact acaggcgtga 4727 gtcaccgtgc ccggccattt ttgtattttt
aggacagcgt tttttcatgt tggccaggct 4787 ggtctcaaac tcctgacctc
aagtgatcca cccaccccgg cctcccaata tgctgggatt 4847 ccaggtgtga
gttaccatgc ccggctacca ctttactttt cctgcaggct atcacagaac 4907
gtgtacaatc tagactctaa tcaaccaaat caacgtcttg ccatcggagt ttgctggtga
4967 agggcacttg gggtcctgga aataactgta ggctccaagc cacacacact
gagataggcc 5027 tattccctga ggcctcagag cccctgacag ctaagctccc
ttgagtcggg caattttcaa 5087 caacgtgctc tggggacaca gcatggcgcc
actgtctttc tggtctcctg gggctcagac 5147 tatgtcatac acttctttcc ag ggc
agt ggg taa caa agt ttg act cca gaa 5199 aga ctt ccc tcg agg att
tct act tgg atg aag aga gga ccg tga ggg 5247 tcc cca tga tgaatc
5262 <210> SEQ ID NO 6 <211> LENGTH: 4421 <212>
TYPE: DNA <213> ORGANISM: HUMAN <220> FEATURE:
<223> OTHER INFORMATION: CDS 66-322 <400> SEQUENCE: 6
ggatcccttg gttggggtgt tggggaaggc agggttttaa cggaaatctc tctccatctc
60 tacagagctg caatccttgt ttgattcacc agactttagc aagatcacag
gcaaacccat 120 caagctgact caggtggaac accgggctgg ctttgagtgg
aacgaggatg gggcgggaac 180 cacccccagc ccagggctgc agcctgccca
cctcaccttc ccgctggact atcaccttaa 240 ccagcctttc atcttcgtac
tgagggacac agacacaggg gcccttctct tcattggcaa 300 gattctggac
cccaggggcc cctaatatcc cagtttaata ttccaatacc ctagaagaaa 360
acccgaggga cagcagattc cacaggacac gaaggctgcc cctgtaaggt ttcaatgcat
420 acaataaaag agctttatcc ctaacttctg ttacttcgtt cctcctccta
ttttgagcta 480 tgcgaaatat catatgaaga gaaacagctc ttgaggaatt
tggtggtcct ctacttctag 540 cctggtttta tctaaacact gcaggaagtc
accgttcata agaactctta gttacctgtg 600 ttggataagg cacggacagc
ttctctgctc tgggggtatt tctgtactag gatcagtgat 660 cctcccggga
ggccatttcc tgcccccata atcagggaag cctgctcgta aacaacacat 720
ggacagatag gagaggccat ttgtaactta aggaaacgga cccgatacgt aaagattctg
780 aacatattct ttgtaaggag gtatgcctat tttacaaagt acagccgggt
gtggtggctc 840 atggctataa tcccagcact ttgggaggcc gaggcgggcg
gatcacctga gatcaggagt 900 ttgagaccag cctgaccaac acggagaaac
cccgtctgta ctaaaaatac aaaattagca 960 gggtgtggtg gtacatgcct
gtaatcccag ctactgggga ggctgaggca ggagaatcac 1020 ttgaacccgg
gaggcggagg ttgcagtgag ccgagatcac gccattgcac tccaatctag 1080
gcaataagag caaaactccg tctcaaacaa caaaaaacca aagtataact gggctttttg
1140 aagaacatga aacatgccca gtgtctgaag tagaataact accgaactgt
ccgtaggact 1200 aaactttttc ttgaaaaagc tctaccaaaa aaagtcaccg
gccactccct tgtcacagtt 1260 attagacagg aggagaaatg ataattctac
tgcccttcat tctacaaatg tttgagtgct 1320 aactgtattc cagattctca
aaaagctatt gccaggtatc tctggggcta ctgatttcct 1380 gatcataatg
caatggcaac caacaggcac ttgggcatgg tgagggtggg caagctttca 1440
aaagcagcgt ggatctggca ttcttttcca cgaatgcacc tcaactactt ggcaccagtg
1500 gtaacacagc aaccagggtt ccgacctaga gaatcccgta accttctgac
tggaacgggg 1560 tctgggctgt cgctacacat cctggtggaa ggcagctatc
atccctacct tctgccttct 1620 gtctcttaaa tctgaaccac aaacagcaac
gtccataccc tcagcattgt tagaatcccc 1680 tgcagcctcc agttctcata
ctgtctgtat tctactcgcc agtttggaga ggtctggtgg 1740 agaaaaggag
tctcttttca ggcttgacaa caaatagaac tcagggccgg gcgcggtggc 1800
tcacgcctgt catcccagca ctgtgggagg ccgaagcggg cggatcacct gaggtcggga
1860 gctcaagacc agcctggcca acatggagaa atcccatctt tactaaaaat
acaaaattag 1920 ccgggcgtac tggcgaatgc ctgtaatgcc agcttctcgg
gaggctgagg caggagaatc 1980 gcttgaacct gggaggcaga ggttgcggtg
agccaagact gtgccactgt actccagcct 2040 tggtgacaga gggagactct
gtcttaagaa aaaaagaaaa aaaaaaaaaa agggccgggc 2100 tcacgcctgt
aatcccagca ctttgggagg ccaaatcacc tgaggccggg agtttgatac 2160
caacctgacc aacatagtga aatcccgtct ctactaaaaa tacaaaatta gccaggcgtg
2220 gtggcgggcg cctgtaatcc cagctactcg ggaggctgaa gcaggagaat
cacttgaacc 2280 cggaaggcgg aggttgccgt aagccaagat cgcgccattg
cgctccagcc tgggcaacaa 2340 gagtgaaact ccatctcaaa aacaaaacaa
aacaaaacaa aaccaacaac tcagaaggag 2400 gcatatgtgt tataaagtct
ttactacaac tttgatttta ttagtggttg gttactgact 2460 ctgccaagag
tacagaatga agggcagaga gtaaggactg gaaaactggc aggaaacaca 2520
ctgacagccg tcatccctgg aggaaactgc tcaataaaac ggctccatat ttacttctct
2580 ggtcacagtt catactccac gattttaaca aaggagtcga ggaagctaga
tactgtaagt 2640 ggaacggtgt gtctctggag gtaagcaggc ttgctgattt
cttgttttat aattcttttt 2700 taattacaat gtaactacta agagcttcag
ttcccactgg agtggtgcac acatctcatt 2760 actactaaaa ccacaggaat
gttccaggga aacagactat catcactgag cgaggtggaa 2820 tccagccaaa
accccaggct aacatccaga tgcctgcata tcagctaaaa tccttttaaa 2880
ggacttggaa tctccagata ctagttttaa gtcttttctg ggaactggga gtttgtactg
2940 gaggccactt aactatttca aaaaatattc accaaaatag gtgtctctct
gactgcaacg 3000 gtttgagtcc tcctcagccc tcatatccta ggcttcggac
tgttgggaaa gtcttatctt 3060 cctgacgaaa gctcagcagc aacagaacct
gttatttttt tgttgagaca gggtcttact 3120 ctgtcaccca ggctggagtg
cagtagtgcg atcttggctc actgcagcct cagcctacca 3180 ggctcaggtg
accctatctc agcttctcga gtaggtggga ctacaggcat gtgccaccat 3240
gctcggtgaa ctaaacaaac ttttttgtag tgatacggtc tcactatatt gcccaggctg
3300 gttttgaact cctgggctca agtgatcctc ccacctcagc gtctcaaagt
actgggatta 3360 caggtgtgag cctctacact gggcctgcag aacctacaca
gaatccgcac ctggtctgca 3420 gaacccacac ccgacccaca gaacccacac
ccgacccaca gaacccacat ctggcagcag 3480 aacctcttag tatttttttt
ttttctttga gatggagtct ggctctgtca cccaggctgg 3540 agtgcagtgg
cgcgatctcg gctcactgca agctcttcct cccgggttca ccccattctc 3600
ctgcctcaac ctcccgagta gctgtgaata caggcgtccg ccaccacgcc cgactaattt
3660 ttttgtattt ttagtagaga cggggtttca ccgtgttagc caggatggtc
tggatctcct 3720 gacctcgtga tctgcctgcc tcggcctccc aaagtgctgg
gattacaggc ttgagccacc 3780 gcacccggcc tcttattttt ttttttgaga
tggagtctca cactgtcacc tgggctggag 3840 tgcagtggag cgatctcggc
tcactgcaac ctccgcctcc tgggttcaag agattctcct 3900 gcctcagcct
cccaagtagc tgggattaca ggtgcccacc accacgcctg gctagttttt 3960
tgtattttta gtaaagatgg ggtttcacca tgttggccag gctggtcttg aactcctgac
4020 atcaggtgat ccgcccacct tagcctccca aagtgctggg attacaggcg
tgagccacca 4080 tacctggcca gcaaaacctc tttaacttgt gttccatggg
ctccttttct gtgggtcaaa 4140 atcctcctgg aaccctacaa tgcaggccct
acaggggtgg gtggtaagtc caacaaacag 4200 gatttcatct tctggagctc
ctggatttca tcgtcccatg ggccacagtg cagcgacaga 4260 acctcctcag
ctttctgtat tgtgctcagg gcttcgggta ctgcaaacct gagccaaggg 4320
aggtaagagg agttagttca ctgattcgtg aggcaaatgt taattgaggg cctactcaca
4380 caccgtgaag aatgtaagat catttctgtc atcaaggatc c 4421 <210>
SEQ ID NO 7 <211> LENGTH: 1153 <212> TYPE: DNA
<213> ORGANISM: MOUSE <220> FEATURE: <223> OTHER
INFORMATION: mRNA: 1-1153 <223> OTHER INFORMATION: CDS
27..1153 "product = "pigment epithelial - derived factor" gene =
"PEDF" codon_start = 1" <223> OTHER INFORMATION: mat_peptide
27-1153 "product = "pigment epithelial-derived factor" gene =
"PEDF" codon_start = 1 <400> SEQUENCE: 7 ggagctgccg
caaccacagt tccgggatgc aggccctggt gctactcctc tggactggag 60
ccctcctggg gcacggcagc agccagaacg tccccagcag ctctgagggc tccccagtcc
120 cggacagcac gggcgagccc gtggaggagg aggacccctt cttcaaggtc
cctgtgaaca 180 agctggcagc agctgtctcc aacttcggct acgatctgta
ccgcctgaga tccggtgcca 240 gcccaacggg caacgtcctg ctgtctccac
tcagcgtggc cacggccctc tcggccctct 300 ctcttggagc tgaacatcga
acagagtctg tcattcaccg ggctctctac tacgacctga 360 tcaccaaccc
tgacatccat agcacctaca aggcgctcct tgcctctgtt actgcccctg 420
agaagaacct caagagtgct tccagaattg tgtttgagag gaaacttcga gtcaaatcca
480 gctttgttgc ccctctggag aagtcctatg ggaccaggcc ccggatcctc
acgggcaacc 540 ctcgagtaga ccttcaggag attaacaact gggtgcaggc
ccagatgaaa gggaagattg 600 cccggtccac gagggaaatg cccagtgccc
tcagcatcct tctccttggc gtggcttact 660 tcaaggggca gtgggtaacc
aagtttgact cgagaaagac caccctccag gattttcatt 720 tggacgagga
caggaccgtg agagtcccca tgatgtcaga tcctaaggcc atcttacgat 780
acggcttgga ctctgatctc aactgcaaga ttgcccagct gcccttgaca ggaagtatga
840 gcatcatctt cttcctgccc ctgaccgtga cccagaactt gaccatgata
gaagagagcc 900 tcacctctga gttcattcat gacatcgacc gagaactgaa
gactatccaa gctgtgctga 960 ctgtccccaa gctgaagctg agcttcgaag
gcgaacttac caagtctctg caggacatga 1020 agctacagtc gttgtttgaa
tcacccgact tcagcaagat tactggcaaa cccgtgaagc 1080 tcacccaagt
ggaacacagg gctgctttcg agtggaatga agagggggca ggaagcagcc 1140
ccagcccagg cct 1153
<210> SEQ ID NO 8 <211> LENGTH: 1490 <212> TYPE:
DNA <213> ORGANISM: HUMAN <220> FEATURE: <223>
OTHER INFORMATION: mRNA: 1-1490 <223> OTHER INFORMATION: CDS:
117-1373; "PRODUCT ="PIGMENT EPITHELIAL-DERIVED FACTOR" GENE =
"PEDF" CODON_START = 1" <223> OTHER INFORMATION: sig_peptide:
117-170; "GENE = "pedf" CODON_START = 1" <223> OTHER
INFORMATION: mat_peptide: 171-1370; "PRODUCT = "PIGMENT
EPITHELIAL-DERIVED FACTOR" GENE = "PEDF" CODON_START = 1"
<400> SEQUENCE: 8 ggacgctgga ttagaaggca gcaaaaaaag atctgtgctg
gctggagccc cctcagtgtg 60 caggcttaga gggactaggc tgggtgtgga
gctgcagcgt atccacaggc cccaggatgc 120 aggccctggt gctactcctc
tgcattggag ccctcctcgg gcacagcagc tgccagaacc 180 ctgccagccc
cccggaggag ggctccccag accccgacag cacaggggcg ctggtggagg 240
aggaggatcc tttcttcaaa gtccccgtga acaagctggc agcggctgtc tccaacttcg
300 gctatgacct gtaccgggtg cgatccagca cgagccccac gaccaacgtg
ctcctgtctc 360 ctctcagtgt ggccacggcg ctctcggccc tctcgctggg
agcggagcag cgaacagaat 420 ccatcattca ccgggctctc tactatgact
tgatcagcag cccagacatc catggtacct 480 ataaggagct ccttgacacg
gtcactgccc cccagaagaa cctcaagagt gcctcccgga 540 tcgtctttga
gaagaagcta cgcataaaat ccagctttgt ggcacctctg gaaaagtcat 600
atgggaccag gcccagagtc ctgacgggca accctcgctt ggacctgcaa gagatcaaca
660 actgggtgca ggcgcagatg aaagggaagc tcgccaggtc cacaaaggaa
attcccgatg 720 agatcagcat tctccttctc ggtgtggcgc acttcaaggg
gcagtgggta acaaagtttg 780 actccagaaa gacttccctc gaggatttct
acttggatga agagaggacc gtgagggtcc 840 ccatgatgtc ggaccctaag
gctgttttac gctatggctt ggattcagat ctcagctgca 900 agattgccca
gctgcccttg accggaagca tgagtatcat cttcttcctg cccctgaaag 960
tgacccagaa tttgaccttg atagaggaga gcctcacctc cgagttcatt catgacatag
1020 accgagaact gaagaccgtg caggcggtcc tcactgtccc caagctgaag
ctgagttacg 1080 aaggcgaagt caccaagtcc ctgcaggaga tgaagctgca
atccttgttt gattcaccag 1140 actttagcaa gatcacaggc aaacccatca
agctgactca ggtggaacac cgggctggct 1200 ttgagtggaa cgaggatggg
gcgggaacca cccccagccc agggctgcag cctgcccacc 1260 tcaccttccc
gctggactat caccttaacc agcctttcat cttcgtactg agggacacag 1320
acacaggggc ccttctcttc attggcaaga ttctggaccc caggggcccc taatatccca
1380 gtttaatatt ccaataccct agaagaaaac ccgagggaca gcagattcca
caggacacga 1440 aggctgcccc tgtaaggttt caatgcatac aataaaagag
ctttatccct 1490 <210> SEQ ID NO 9 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PRIMER <220> FEATURE:
<223> OTHER INFORMATION: PRIMER 603 <400> SEQUENCE: 9
acaagctggc agcggctgtc 20 <210> SEQ ID NO 10 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: SYNTHETIC PRIMER <220>
FEATURE: <223> OTHER INFORMATION: ANTISENSE PRIMER 604
<400> SEQUENCE: 10 cagaggtgcc acaaagctgg 20 <210> SEQ
ID NO 11 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: SYNTHETIC
PRIMER <220> FEATURE: <223> OTHER INFORMATION: PRIMER
605 <400> SEQUENCE: 11 ccagctttgt ggcacctctg 20 <210>
SEQ ID NO 12 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PRIMER <220> FEATURE: <223> OTHER
INFORMATION: ANTISENSE PRIMER 606 <400> SEQUENCE: 12
catcatgggg accctcacgg 20 <210> SEQ ID NO 13 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: SYNTHETIC PRIMER <220>
FEATURE: <223> OTHER INFORMATION: PRIMER 2213 <400>
SEQUENCE: 13 aggatgcagg ccctggtgct 20 <210> SEQ ID NO 14
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PRIMER
<220> FEATURE: <223> OTHER INFORMATION: ANTISENSE
PRIMER 2744 <400> SEQUENCE: 14 cctcctccac cagcgcccct 20
<210> SEQ ID NO 15 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PRIMER <220> FEATURE: <223> OTHER
INFORMATION: PRIMER 2238 <400> SEQUENCE: 15 atgtcggacc
ctaaggctgt t 21 <210> SEQ ID NO 16 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PRIMER <220> FEATURE:
<223> OTHER INFORMATION: ANTISENSE PRIMER 354 <400>
SEQUENCE: 16 tggggacagt gaggaccgcc 20 <210> SEQ ID NO 17
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PRIMER
<220> FEATURE: <223> OTHER INFORMATION: PRIMER
JT10-UP01 <400> SEQUENCE: 17 ggtgtgcaaa tgtgtgcgcc ttag 24
<210> SEQ ID NO 18 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PRIMER <220> FEATURE: <223> OTHER
INFORMATION: PRIMER JT10-DP01 <400> SEQUENCE: 18 gggagctgct
ttacctgtgg atac 24 <210> SEQ ID NO 19 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PRIMER <220> FEATURE:
<223> OTHER INFORMATION: PRIMER 1590 <400> SEQUENCE: 19
ggacgctgga ttagaaggca gcaaa 25 <210> SEQ ID NO 20 <211>
LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PRIMER <220> FEATURE:
<223> OTHER INFORMATION: PRIMER 1591 <400> SEQUENCE: 20
ccacacccag cctagtccc 19 <210> SEQ ID NO 21 <211>
LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: SYNTHETIC PEPTIDE <400>
SEQUENCE: 21 Thr Ser Leu Glu Asp Phe Tyr Leu Asp Glu Glu Arg Thr
Val Arg Val 1 5 10 15 Pro Met Met <210> SEQ ID NO 22
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PEPTIDE
<400> SEQUENCE: 22 Ser Tyr Gly Thr Arg Pro Arg Val Leu Thr
Gly Asn Pro Arg Leu Asp 1 5 10 15 Leu Gln Glu Ile Asn Asn Trp Val
Gln Ala 20 25 <210> SEQ ID NO 23 <211> LENGTH: 14
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PEPTIDE <400> SEQUENCE: 23 Leu
Ala Ala Ala Val Ser Asn Phe Gly Tyr Asp Leu Tyr Arg 1 5 10
<210> SEQ ID NO 24 <211> LENGTH: 29 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PEPTIDE <400> SEQUENCE: 24 Ala Leu Tyr Tyr Asp Leu
Ile Ser Ser Pro Asp Ile His Gly Thr Tyr 1 5 10 15 Lys Glu Leu Leu
Asp Thr Val Thr Ala Pro Gln Lys Asn 20 25 <210> SEQ ID NO 25
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PEPTIDE
<400> SEQUENCE: 25 Thr Val Gln Ala Val Leu Thr Val Pro Lys 1
5 10 <210> SEQ ID NO 26 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: SYNTHETIC PEPTIDE <400> SEQUENCE: 26 Leu Lys Leu
Ser Tyr Glu Gly Glu Val Thr Lys 1 5 10 <210> SEQ ID NO 27
<211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PEPTIDE
<400> SEQUENCE: 27 Ala Gly Phe Glu Trp Asn Glu Asp Gly Ala
Gly Thr Thr Pro Ser Pro 1 5 10 15 Gly Leu Gln Pro Ala His Leu Thr
Phe Pro Leu Asp Tyr His 20 25 30 <210> SEQ ID NO 28
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC
OLIGONUCLEOTIDE <220> FEATURE: <223> OTHER INFORMATION:
Y means T OR C; S means G or C <400> SEQUENCE: 28 agyaayttyt
aygayctsta 20 <210> SEQ ID NO 29 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC OLIGONUCLEOTIDE <220> FEATURE:
<223> OTHER INFORMATION: Y means T OR C; S means G or C; R
means G or A <400> SEQUENCE: 29 ctytcytcrt csagrtaraa 20
<210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PRIMER <220> FEATURE: <223> OTHER
INFORMATION: PRIMER 353 <400> SEQUENCE: 30 ctgggagcgg
acgagcgaac 20 <210> SEQ ID NO 31 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: SYNTHETIC PRIMER <220> FEATURE:
<223> OTHER INFORMATION: PRIMER 1 <400> SEQUENCE: 31
caccttaacc agcctttatt c 21 <210> SEQ ID NO 32 <211>
LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: SYNTHETIC PRIMER <220>
FEATURE: <223> OTHER INFORMATION: PRIMER 2 <400>
SEQUENCE: 32 aaccttacag gggcagcctt cg 22 <210> SEQ ID NO 33
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: SYNTHETIC PRIMER
<400> SEQUENCE: 33 tatcccagtt taatattcca atac 24 <210>
SEQ ID NO 34 <211> LENGTH: 24 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
SYNTHETIC PRIMER <220> FEATURE: <223> OTHER
INFORMATION: ANTISENSE PRIMER 499 <400> SEQUENCE: 34
ttgtatgcat tgaaacctta cagg 24
* * * * *